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ABSTRACT 
Insulin-like growth factor (IGF) -I and -II play a significant role in determining a 
cell's fate, being involved in cellular growth and differentiation, tumourigenesis 
and as survival factors against apoptosis. These diverse biological actions of 
IGFs are mediated by their interaction with the type I IGF receptor (IGF-IR), 
with their availability to this receptor mediated by IGF binding proteins (IGFBPs) 
present within the extracellular compartments. The IGF-I and -II genes 
synthesise multiple mRNAs by alternate promoter usage and alternative splicing. 
This potentially contributes to the diverse biological actions of IGF-I and -II. The 
aim of this doctoral study was to establish whether the differential expression of 
the IGF-I mRNAs, and to a lesser extent IGF-Il mRNAs, is a mechanism which 
determines their particular biological function. 
Using the IGF-I expressing human neuroblastoma cell line SK-N-MC and the 
non-expressing SK-N-SH cell line, I investigated the pattern of mRNA expression 
of IGF-I, IGF-II, the IGF-IR and the six IGFBPs, during growth and 
differentiation in vitro ( +1- foetal+ bovine serum). This study has identified that 
the four major IGF-I mRNAs, the IGF-IR and IGFBP-2, -4, -5 and -6 are 
expressed by the SK-N-MC cells, while IGF-II, its Ser-29 variant and the IGF-IR 
mRNAs were expressed by the SK-N-SH cells. During cell growth, the expression 
of all four IGF-I mRNAs and the IGF-IR increased, with no change in the pattern 
of expression over time, suggesting that these mRNAs each have a consistent and 
coordinate role during cell growth. 
Differentiation of the SK-N-MC cells was stimulated by the removal of exogenous 
growth factors, marked by a change in morphology and a drop in plasminogen 
activator activity. Of the IGF-I mRNAs, only class I Eb was expressed at 
detectable levels and increased with proliferation. IGF-IR mRNA was also 
detected in these cells, as well as an mRNA coding for a potential novel IGF-IR 
mRNA lacking the cysteine binding domain in the a-subunit. A differential 
pattern of IGFBP expression was also observed in SK-N-MC cells grown in either 
a serum-containing or a serum-free environment, with IGFBP-6 expression being 
switched off in a serum-free environment. Surprisingly, the expression of class I 
ii 
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Eb mRNAs and the variant IGF-IR were also detected in the negative control SK-
N-SH cells grown in serum-free medium. These results indicate that class 1 Eb 
mRNAs may have a role in differentiation, and may be regulated by the presence 
or absence of specific serum factor( s ). 
IGF expression during tumourigenesis was examined using the development and 
progression of breast cancer as the model system. The four major IGF-I mRNAs 
were expressed in normal breast tissue with their expression levels increasing in 
breast tumours. The four mRNAs were differentially expressed during the 
development and progression of the disease with class 2 mRNAs increasing 
relative to class 1 and Eb mRNAs increasing relative to Ea. The difference in the 
Class 1/Class 2 and Ea/Eb ratios were highly significant between normal and 
tumourigenic tissues and may provide a possible target for the early detection of 
malignancies. IGF-I mRNAs were found to be stromally expressed in normal 
breast tissue and early stage malignancies, however they were expressed by both 
the stroma and tumour epithelial cells in the more advanced malignancies. Like 
IGF-I, JGF-II was differentially expressed during the development and 
progression of the disease, with Ser-29 IGF-II mRNA levels increasing relative to 
the levels of IGF-II. Of the IGFBPs, a distinct pattern of expression was 
observed between normal, low and high grade ductal carcinomas. The most 
significant difference observed between normal breast and breast tumour 
progression, was the decrease in IGFBP-6 mRNA and the dramatic increase in 
IGFBP-4 expression levels. 
Overall, this doctoral study suggests that Eb mRNA expression, in combination 
with alternate promoter usage, exists in a fine balance. These results suggest that 
an upregulation of class 1 Eb expression contributes to cellular differentiation 
and that an over-expression of Eb mRNAs contributes to a tumourigenic 
phenotype. This study also suggests that there may be a differential role for the 
Ser-29 IGF-II variant in tumourigenesis, and that the deactivation of IGFBP-6 in 
concert with the upregulation of IGFBP-4, may be a precursor of malignancy. 
These hypotheses are discussed in detail. 
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NOTE TO READERS 
• Chapters 4, 6 and 7 have been written in manuscript format with the abstract 
removed. As a result there will be some repetitiveness in these chapters. 
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Chapter 1 
INTRODUCTION 
1.1 Cell Fate 
With development cells can undergo various events (Fig. 1.1 ). These cellular events 
include proliferation, whereby the cell enlarges and divides, generating two daughter 
cells via the process of mitosis (Curtis, 1983). Cells may also differentiate, that is 
their morphology changes and they become specialised for a particular function 
within the organism. A unipotent cell may differentiate to form only fibroblasts, 
which then may differentiate further into adipocytes. If cells are pluripotent, they 
may differentiate into more than one specialised cell type. Alternatively, these 
differentiated cells may de-differentiate back to their ancestral cell type and undergo 
prolific cellular growth generating tumour tissue (Alberts et al., 1989). Finally, 
another pathway available to cells is death, via the physiological process of necrosis 
_Necrosis 
: • ' Apoptosis CJ(f)Daughter Cells 
'fc\ ... h • Qe'l>~ ~\\ GfO"'• 
Differentiation 
Fibroblast 
Tumour 
Figure 1.1- Cell Fate: Through inherent programming and the extracellular milieu, cells will 
grow, differentiate, transform or die by necrosis or apoptosis. 
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or the programmed event of apoptosis (Kerr et a!., 1972). Each of these cellular 
events is complex and consequently must be strictly regulated at many levels. When 
cells are transformed into tumour cells, there is a lack of such regulation at one or 
more of these levels. The interaction of growth factors within various cell types, has 
been identified as a major regulatory mechanism responsible for cell fate. 
1.1.1 Growth Factor Regulation of Cell Fate 
Growth Factors are peptides that regulate hypertrophy (an increase in cell size), 
hyperplasia (an increase in cell number) and differentiation (change in cellular 
morphology and function; Van Wyk, 1984; Froesch et al., 1985). Their presence 
within a multicellular organism was first reported early this century, when Carrel in 
1913 found that connective tissue in embryo extracts could be stimulated to grow in 
culture. Since then many growth factors have been isolated, purified and 
characterised and are now classified into distinct families, mainly determined by 
their structural homology. Examples of these families include the epidermal growth 
factor (EGF) family (Savage et a!., 1973), which includes EGFs and transforming 
growth factor-a (TGF-a; Savage et a!., 1973); the platelet-derived growth factor 
(PDGF; Savage et al., 1973) and fibroblast growth factor (FGF) families (Maciag et 
a!., 1979); and the insulin-like growth factor (IGF) family (Rinderknecht and 
Humbel, 1976). 
Evidence for growth factor interactions regulating cellular fate was present as early 
as 1979, when Stiles and coworkers showed that insulin-like growth factor-! (IGF-I) 
could stimulate cell growth in culture and that this growth could be potentiated by 
PDGF. They proposed that growth factors such as IGF-1, controlled growth by 
progressing the cell through the G1-phase of the cell cycle. While growth factors 
such as PDGF acted as competence factors, making cells competent to enter the S-
phase of the cell cycle (Stiles et a!., 1979; Bockus et al., 1983; Campisi and Pardee, 
1984). Leof et a!., (1982; 1983) showed that a combination of IGF-1, EGF and 
PDGF could replace plasma in stimulating the progression of BALB/c-3T3 
adipocytes through the cell cycle. Clear evidence of growth factor interactions were 
provided in studies of cultured fibroblasts (Clemmons and Van Wyk, 1981; 
Clemmons, 1984), where it was shown that PDGF and EGF induced the production 
of both IGF-I and the type I IGF receptor (IGF-IR). It has since been shown that 3T3 
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cells can not be stimulated to proliferate with IGF-I or EGF unless the competence 
factor PDGF is present (Pietrzkowski et al., 1992). An examination at the 
messenger ribonucleic acid (mRNA) level in these cells, revealed that there was no 
expression for IGF-I or the IGF-IR. When these cells were over-expressed with the 
IGF-IR, EGF alone could stimulate these cells by inducing the production of both 
IGF-I mRNA and protein. There is a wealth of literature to support the interaction of 
growth factors as a regulatory mechanism involved in the stimulation or inhibition of 
cellular events. In concert with other regulatory mechanisms, the interaction of 
growth factors can control the growth and development of a zygote through to a 
multicellular organism. Of interest to this doctoral study has been the role of the 
IGF family in this process, in particular the mechanisms which determine the 
biological actions of IGF-I and to a lesser degree insulin-like growth factor-II (IGF-
II), during cell fate. 
1.2 Insulin-like Growth Factors (IGFs) 
1.2.1 Historical Overview 
Salmon and Daughaday first proposed the presence ofiGFs in 1957, postulating that 
the effects of growth hormone (GH) were mediated by a substrate, which they 
defined as sulfation factor activity (SFA). Salmon and Daughaday (1957) showed 
that sulfate incorporation into cartilage tissue was stimulated by serum from normal 
rats but not by serum from hypophysectomized rats. GH had no direct effect but 
when administered to the hypophysectomized rats, sulfate incorporation was 
stimulated. SFA was found to have other biological activities including stimulating 
the synthesis of ribonucleic acid (RNA), deoxyribonucleic acid (DNA) and specific 
proteins of cartilage tissue (Salmon and Du Vall, 1970). SFA was also shown to 
stimulate amino acid transport (Adamson and Anast, 1966) and glucose transport 
(Daughaday and Mariz, 1962), and was later renamed "somatomedin" to reflect the 
role that these proteins had in mediating the actions of somatotrophin or GH 
(Daughaday et al., 1972). Three forms of somatomedin were isolated and termed 
somatomedin-A, -B and -C. 
In a separate area of research, a group of serum factors were found which had 
significant insulin-like activity that could not be suppressed by antibodies against 
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insulin (Froesch et al., 1963). This activity was identified in muscle and adipose 
tissue, characteristic insulin target tissues, and hence was termed non-suppressible 
insulin-like activities (NSILA). Three components of NSILA were differentiated 
based on their solubility in acid ethanol: NSILA-1, -2 and -P (Zapf et al., 1978). 
Amino acid analysis of NSILA-1 and -2 revealed a strong homology to insulin 
(Rinderknecht and Humbel, 1978a; 1978b; Zapf et al., 1981; Hall and Sara, 1983). 
As well as the insulin-like activities, these factors were also shown to stimulate 
RNA, DNA and protein synthesis (Morel and Froesch, 1973). They were also shown 
to stimulate the incorporation of proline into cartilage (Zingg and Froesch, 1973) and 
to have in vitro mitogenic activity (Rechler et al., 1974). Hence they were re-named 
insulin-like growth factor-! and -II. 
A third IGF-associated activity was multiplication-stimulating activity (MSA) 
proposed by Dulak and Temin in 1973. They identified specific factors within the 
conditioned media of rat liver cells essential for their proliferation. 
Structural analysis of somatomedins, IGFs and MSA resulted in the convergence of 
these three areas of research and a classification based on the structural and 
functional characteristics of these growth factors. Amino acid sequence analysis of 
somatomedin-C (Sm-C) and IGF-I revealed that the first 22 amino acids (aa) of the 
amino terminus (N-terminus) were identical (Svoboda eta!., 1980). In addition, Sm-
C and IGF-I showed identical immunologic determinants, receptor binding and 
biological actions in vitro and consequently were proposed to be identical (Van Wyk 
et al., 1980). Isolation and amino acid sequence analysis of MSA peptides from the 
serum of rat liver cells, revealed that the most potent MSA peptide was 67 residues 
in size. This peptide was shown to be identical to human IGF-II except for 5 
conservative substitutions reflecting species variations (Marquardt et al., 1981 ). 
Immunological characteristics and biological actions confirmed that MSA and IGF-II 
were identical. In 1987, MSA, IGFs and somatomedins officially converged and 
were re-named IGFs (Daughaday et al., 1987) with Sm-C and Sm-A being 
recognised as IGF-I and MSA as IGF-ll. 
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1.2.2 Insulin-like Growth Factor-/ (IGF-1) and IGF-11 Peptide 
and Gene Structures 
A significant advance in IGF research was made when IGF-I and -IT were isolated 
from human plasma and characterised (Rinderknecht and Humbel, 1978a; 1978b). 
IGF-I was described as a 70 residue single chain basic polypeptide with a molecular 
weight 7.6 kilodaltons (kDa), while IGF-IT was described as a 67 residue single chain 
polypeptide, slightly acidic in nature with a molecular weight of 7.5 kDa. IGF-I and 
-IT were found to be homologous, sharing a 62% amino acid sequence identity 
(Froesch et al., 1985). 
The IGFs, like insulin, are translated as prepropeptides that undergo a series of post 
translational proteolytic cleavages to generate their mature forms. The structure of 
mature IGF-I and -IT, like proinsulin, consists of a B-domain and an A-domain, 
surrounding a smaller C-domain. In contrast to proinsulin, mature IGF-I does not 
proteolytically cleave at the C-domain and has an additional carboxyl-terminal (C-
terminal) D-domain (Fig. 1.2). The homology between the IGFs and proinsulin is 
43% in the B- and A-domains, with the C-domain being poorly conserved (Fig. 1.2; 
Rinderknecht and Humbel, 1978a; 1978b ). The homologous regions include the 
amino acids that form the hydrophobic core of insulin and the IGFs, the structurally 
important glycine residues and the three intrachain disulfide bridges within each 
peptide (Blundell et al., 1978; Raschdorf et al., 1988). Based on this amino acid 
conservation between the IGFs and insulin and the known 3-dimensional 
conformation of insulin, it was proposed that the IGFs must have a similar 
conformation to insulin (Fig. 1.3; Blundell et al., 1978; 1980; Dafgard et al., 1985). 
The IGF-I prepropeptide structure determined by amino acid and eDNA sequence 
analysis, consists of a species-dependent N-terminal prepeptide or signal peptide. 
This is followed by a B-domain of 29 aa, a C-domain of 12 aa, an A-domain of 21 
aa, a D-domain of 8 aa and a variable C-terminal E-domain, or extension domain 
(Jansen et al., 1983; Fig. 1.4). The IGF-I signal peptide can consist of 22, 25 or 48 
aa depending on which AUG translation start site is used. There are two common 
forms of IGF-I propeptides, which contain either an Ea or an Eb domain. The first 
16 aa of the E-domain are common to both forms of the propeptide, whereas the C-
terminal portion of the E-domains are quite distinct. The predominant C-terminus of 
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Figure 1.2 -Primary peptide structure of human pro-insulin, IGF-I and IGF-IL Peptide sequences have been aligned. Homologous regions are boxed. Peptide domains 
are indicated (B, C, A and D). Amino acids are numbered according to their position in the peptide chain as well as their position in each of the structural domains (adapted 
from Van den Brande, 1992 ). 
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Figure 1.3 · Diagrammatic representation of the 3-dimensional structure of insulin, determined 
using X-ray analysis of rhombohedral porcine 2-Zn crystals and the proposed conformation of 
proinsulin, IGF-1 and -II determined by model building. The heavy lines represent the A-domains, 
the normal lines the B-domains and double lines represent the D-domains (adaptedfrom Blundell et. 
al., 1980). 
theE domain is termed Ea and is 19 aa in length (Jansen et al., 1983). The alternate 
E-domain is Eb and it is 61 aa in length (Rotwein et al., 1986). The Ea and Eb 
peptides arise by alternative splicing of the IGF-1 pre-mRNA as described in Section 
1.5.4 (Rotwein, 1986; Rotwein et al., 1986). 
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The structure of the IGF-II prepropeptide is similar to IGF-1, consisting of a B-
domain of 32 aa, a C-domain of 7 aa, an A-domain of 20 aa and aD-domain of 6 aa 
(Fig. 1.2; Bell et al., 1984; Jansen et al., 1985). In contrast to IGF-1, IGF-II has one 
signal peptide of 24 aa, as well as a single C-terminal E-domain of 89 aa (Bell et al., 
1984; Jansen et al., 1985). 
48 25 22 
Function? Cleavage Intracellular ? 
Proteases? 
Function? Mature IGF-1 Peptide ~
,......-B-----,-C----,-----A ---rl--,o I _,A  
L...__B_____L__c ..J.....__A__jl...._..jo I ~ 
Function? 
Figure 1.4 - The 1GF-1 Peptide Structure. 1GF-1 is translated as a prepropeptide consisting of 6 
domains; the pre or signal peptide, B-, C-, A-, D- and £-domains. Proteolytic cleavage of the 
signal peptide generates the propeptide; a second proteolytic cleavage of theE domain generates 
mature 1GF-l. The peptide length of each domain is indicated in italics. The different pre- or 
signal peptides are indicated by 22, 25 and 48, representing their lengths in amino acids. 
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The post-translational processing of the IGF-I and -II prepropeptides, involves the 
proteolytic cleavage of the signal peptide at the prepeptide/B junction upon 
translocation to the endoplasmic reticulum (ER; Fig. 1.4). A second cleavage occurs 
during biosynthesis at the DIE junction, generating the mature 70 aa peptide 
consisting of the B-, C-, A- and D-domains, respectively (Fig. 1.4; Jansen et al., 
1983; Rotwein, 1986; Rotwein et al., 1986). It has been hypothesised that the 
event(s) causing cleavage of theE-domains occur late in the biosynthetic pathway or 
following the secretion of pro-IGFs. However, studies by Duguay et al., (1995) 
suggest that the IGF-I propeptide is processed intracellularly, as conditioned media 
from human embryonic kidney 293 cells, as well as serum from mouse, rat and 
foetal bovine, were unable to process an epitope-tagged pro-IGF-I; proiGF-I-FLAG. 
They identified a unique pentabasic prohormone cleavage motif Lysine-XX-Lysine-
XX-Arginine71-X-X-Arginine-X-X-Arginine within the 16 aa homologous region 
between Ea and Eb. This motif is conserved between a range of evolutionary 
divergent species ranging from mammals to teleosts (Duguay et al., 1995). 
Mutational analysis of this basic region revealed that cleavage by an as yet to be 
described convertase, occurs at Arginine71 to generate the mature IGF-I peptide, with 
cleavage depending of the presence of Lysine68 (Duguay et al., 1995). To date theE-
domain of IGF-II has been shown by pulse chase experiments to be cleaved late in 
the secretory pathway and possibly in the extracellular environment (Yang et al., 
1985). It can be hypothesised that the cleavage of the alternate E-domains may be a 
potential mechanism by which the biological activities of each of these growth 
factors are modulated. In addition, the extension domains of IGF-I and -II may have 
independent biological functions. 
1.2.2.1 Domain Functions of IGF-1 
The function of the individual domains that constitute prepro-IGF-I through to 
mature IGF-I, have been proposed using computer generated 3-dimensional protein 
models (Blundell et al., 1980; 1983), studies examining hybrid molecules of insulin 
and IGF-I (Blundell et al., 1980; 1983; Dafgard et al., 1985), the proteolytic products 
of IGF-I including glycyl-propyl-glutamate (GPE; Section 1.4.2.2) and truncated 
IGF-I (des-1-3-IGF-I; Section 1.4.2.1; Sara et al., 1986; 1989), and studies of the 
IGF genes between evolutionary divergent species. 
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The IGF prepeptide appears to function as a co-translationally cleaved signal peptide 
in directing nascent peptides to the secretory pathway. IGF-1 mRNAs from human, 
chicken and Xenopus have been translated in vitro where it has been shown that the 
48 residue signal peptide is synthesised and co-translationally cleaved (Rotwein et 
al., 1987; Kajimoto and Rotwein, 1989; 1990). Human IGF-1 generates multiple 
precursors with a 22, 25 or 48 aa signal peptide giving IGF-1 the potential to effect 
cellular targeting and therefore processing of the nascent IGF-I peptide. The first 19 
residues of the 48 aa signal peptide beginning at the C-terminal end, have a 
positively charged N-terminus, a central hydrophobic core and a polar C-terminus; a 
feature typical of eukaryotic prepeptides (Von Heijne, 1985). The remaining 29 aa 
of theN-terminal signal peptide encode characteristics that are exclusive to the IGF-1 
signal sequence. These include a highly positive charged N-terminus and clustered 
cysteines (Von Heijne, 1985). 
The B-and A-domains of human IGF-1, share 43% sequence homology with insulin 
(Rinderknecht and Humbel, 1978a) and show a high conservation between 
mammalian and non-mammalian species (Rotwein, 1991). When IGF-1 and -II were 
compared to the 3-dimensional model of insulin, a region at the end of the B-domain 
of IGF-1 that was similar in insulin and absent in IGF-11, was proposed to be 
responsible for the binding of IGF-1 to the IGF-IR and the insulin receptor (IR; 
Blundell et al., 1980; 1983; Dafgard et al., 1985). Sheikh et al., (1987) generated 
hybrid IGF-1 and insulin molecules, containing the A-domain of IGF-1 and the B-
domain of insulin. They found that the insulin\IGF-1 hybrid molecules were highly 
mitogenic, suggesting that the A-domain is important for the mitogenic properties of 
IGF-1. This was further supported by the discovery of a proteolytic product of IGF-1 
lacking three N-terminal amino acids (des-1-3-IGF-1; Sara et al., 1986; Francis et al., 
1986). It was proposed that the cleavage of theN-terminal GPE tripeptide of the B-
domain, uncovered an important receptor binding protein site within the A-domain. 
In addition, des-1-3-IGF-1 showed a reduced affinity for insulin-like growth factor 
binding proteins (IGFBPs; Section 1.4.6), emphasising the importance of GPE in 
forming a complex with IGFBPs (Carlsson-Skwirut et al., 1989). GPE itself binds to 
the N-methyl-D-aspartate (NMDA) receptor. The C-terminal glutamate of GPE is 
necessary for binding to this receptor, with the N-terminal glycine providing 
Page 10 
Walker, 1998 
enhancement (Sara et al., 1989). Bayne et al., (1990) and Clemmons et al., (1990a) 
further defined roles for the B-and A-domains of IGF-I. Using site directed 
mutagenesis, they showed that the highly conserved B- and A-domains were 
functionally significant for the binding of IGF-I to the IGF-IR and IGFBP-1 and -3. 
Francis et al., (1994) identified Glu3 of the B-domain as being important for the 
complexing of IGFBPs with IGF-I. Specific biological functions for the C- and D-
domains of IGF-I have not yet been elucidated, however, they have been shown to 
play a role in forming the ternary complex with ALS and IGFBP-3 (Baxter et al., 
1992). 
The Ea and Eb extension peptides ofiGF-I are an interesting phenomenon. They are 
translated and result in two variable pro-IGF-1 peptides, which are proteolytically 
cleaved generating mature IGF-1, Ea and Eb peptides. Two questions have been 
posed: Why would energy be expended in translating two variable E-domains which 
are thought to be subsequently cleaved within the bounds of the ER to generate the 
same mature peptide? Do Ea and Eb peptides have independent biological effects? 
To date little is known regarding the biosynthesis of the two propeptides. Pro-IGF-1 
Eb secretion was detected in the conditioned medium of a human fibroblast cell line 
(Clemmons and Shaw, 1986). This conditioned media was found to be mitogenic 
for BALB/c3T3 cells and it was also found to bind placental IGF-IRs and IGFBPs 
from amniotic fluid. In other studies, patients with renal failure were identified as 
having IGF-I Ea in their serum, detected by immunoblot and radioimmunoassay 
(Powell et al., 1987; Conover et al., 1989). Thus, early experimental data suggests 
that the IGF-I propeptides and/or the Ea and Eb peptides, may have a role in 
regulating the IGF axis or act independently of it. 
Upon translocation of proteins to the ER, one of the major functions ofthis organelle 
is to add sugars to proteins via protein glycosylation. An examination of the amino 
acid sequence of both extension domains have revealed that IGF-1 Ea, but not -Eb, is 
N-glycosylated (Bach et al., 1990). Once translocated to the ER, an asparagine 
within the Ea-domain is enzymatically linked to a sugar complex comprising N-
acetyl-glucosamine, mannose and glucose. In another study using an in vitro 
translation system, Simmons et al., (1993) showed that rat pro-IGF-I can beN-
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glycosylated. The biological significance of glycosylations of the Ea-domain 
remains to be determined; however it has been shown in other systems that 
glycosylation can affect proteolytic processing (Ohuci et al., 1991 ). Possible 
independent effects for the Ea and Eb peptides remain to be shown. As will be 
discussed in detail in Section 1.4.2.3, a study by Siegfried et al., (1992) examining 
the Eb-domain of IGF-I, identified a 22 aa peptide (103-124) referred to as IGF-I-IB-
(103 - 124) E1 amide (IBE1). They showed that IBE1 had growth promoting effects 
in normal and malignant bronchial cells, mediated by a specific receptor. Whether 
IBE1 is physiologically cleaved is unknown, however if so, there are two potential 
peptides of 29 and 14 aa that would result from its cleavage which may also have 
independent activities. A further examination of the 77 aa Eb peptide sequence has 
revealed that it is a highly basic peptide with regions similar in charge to domains 
within IGFBP-3 and -5 (Garcia-Aragon et al., in preparation). These domains in 
IGFBP-3 and -5 are known to be important for binding to the acid labile subunit 
(ALS; Section 1.4.6), binding to the cell surface (Firth et al., 1998; Twigg and 
Baxter, 1998) and nuclear targeting (Radulescu, 1994). Such characteristics strongly 
suggest that this protein may have independent biological effects acting either 
intracellular and/or extracellular via the IGF-IR or independent receptors. 
1.2.2.2 Human IGF-1 and -II Gene Structure 
The human IGF-I gene is a single copy gene, that maps to the long arm of 
chromosome 12 at position 12q 22-24.1 (Brissenden et al., 1984; Tricoli et al., 1984; 
Hoppener et al., 1985). The gene consists of six exons spanning approximately 90 
kilobases (kb) of genomic DNA (gDNA; Rotwein et al., 1986; Steenbergh et al., 
1991). The exact size of the IGF-I gene is unknown, as a 65 kb region between 
exons 3 and 4 still remains to be determined. When the human IGF-I gene was first 
cloned and characterised (Jansen et al., 1983), the now recognised exons 1, 3, 4 and 
6 were identified (Fig. 1.5). Later on an additional 3' exon, now referred to as exon 5 
was found (Rotwein et al., 1986). It was not until 1990 that an additional 5' exon, 
currently referred to as exon 2, was cloned (Tobin et al., 1990). Exon 1 and 2 are 
known to encode a species specific 5' untranslated region (UTR) and the portion of 
the signal or prepeptide sequence. Exon 3 encodes the remainder of the signal 
sequence and the 5' portion of the mature IGF-I B-domain. Exon 4 encodes the 
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Human IGF-1 Gene 
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Figure 1.5 - The structure of the human 1GF-1 gene. Boxes represent exons, which are 
numerically identified in italics; the connecting lines the introns. Boxes shaded in black are the 
coding regions, grey boxes the variable signal sequences and the clear boxes the 5' and 3' UTRs. P 1 
and P2 are the identified promoter regions for human 1GF-1 gene. 
remainder of the mature peptide, including the remaining 3'portion ofB-, C-, A-, D-
and 16 aa of theE-domain common between the Ea and Eb extension domains. The 
remaining exons, 5 and 6, encode the variable E-domains, with Ea being generated 
from exon 6 and Eb from exon 5, along with distinct 3'UTRs. 
The human IGF-ll gene is also a single copy gene, located on the short arm of 
chromosome 11 at position 11p15 (Brissenden et al., 1984; Tricoli et al., 1984; De 
Pagter-Holthuizen et al., 1985). Interestingly on chromosome 11, the IGF-ll gene is 
located in the most downstream position of a gene cluster consisting of tyrosine 
hydroxylase, insulin and IGF-ll (Bell et al., 1985; OMalley and Rotwein, 1988). 
The IGF-ll gene consists of 9 exons, spanning approximately 30kb of gDNA (Fig. 
1.6; Dull et al., 1984; De Pagter-Holthuizen et al., 1986; 1987). Exons 1, 2, 3, 4, 
and 6 encode 5' UTR, with exons 1, 4, 5, and 6 preceded by four distinct promoters, 
Pl to P4 (De Pagter-Holthuizen et al., 1987; 1988; Holthuizen et al., 1990). Exons 
7, 8 and 234 bp of exon 9 encodes the prepropeptide of IGF-ll. Exon 9 is 4.1 kb in 
length, with 3.9 kb of this exon encoding 3UTR. 
1.3 Physiological Actions of IGF-1 and -II 
The IGF family is a key regulator of cellular fate, with important functions from 
early development through to adult life. As will be discussed in the following 
section, IGF-I and -IT have been shown to have very diverse physiological functions 
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Figure 1.6 - The structure of the human 1GF-II gene. Boxes represent exons, which are 
numerically identified in italics; the connecting lines the introns. Boxes shaded in black are the 
coding regions and the clear boxes are the 5' and 3' UTRs. P 1 to P4 indicate the promoter regions 
for the human IGF-II gene. 
with direct roles in cellular growth, differentiation, and tumourigenesis and as 
survival factors against apoptosis. 
1.3.1 Growth 
Although it was previously hypothesised that IGF-II was a growth regulator of foetal 
development, and IGF-I a mediator of postnatal growth, it is now accepted that both 
IGFs play a significant role in early development. IGF-I and -II are expressed by 
pre-implantation embryos and continue to be expressed during foetal development 
(Schultz and Heyner, 1993; Kaye and Harvey, 1995). With birth, IGF-I assumes the 
role as the key regulator of postnatal growth. Transgenic mice overexpressing 
human IGF-I in a range of organs, exhibited enhanced growth in each of these organs 
(Mathews et al., 1988; Behringer et al., 1990; DErcole, 1993). Whereas mice 
overexpressing the human IGF-II transgene did not, despite an elevation of 
circulating IGF-II levels (Rogier et al., 1994; Ward et al., 1994; Wolf et al., 1994; 
Van Buul-Offers et al., 1995). Local growth promoting effects for IGF-II have 
however been observed in the thymus (Van Buul-Offers et al., 1995). This 
demonstrates that IGF-II can effect tissue overgrowth, however IGF-II is not able to 
substitute for IGF-I in maintaining normal somatic growth following birth. 
IGF-II is a key foetal growth factor, as mice with a targeted disruption of the IGF-II 
gene, were 60% the size of their wild type littermates at birth (Dechiara et al., 1990; 
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Liu et al., 1993). Following birth however, these animals exhibited a normal growth 
rate and were fertile (Liu et al., 1993). The decrease in foetal size, was not only 
exhibited by the homozygous mice with the disruption to the IGF-II gene, but also 
heterozygous mice inheriting a paternally derived mutant allele (Dechiara et al., 
1990; 1991). It was established that IGF-II synthesis occurred solely from the 
paternal chromosome, and hence was regulated by parental imprinting (Dechiara et 
al., 1991). Imprinting is a mechanism of regulation that has been observed for a 
small group of genes which have vital growth and developmental roles (Efstratiadis, 
1994). 
IGF-I and -II are mitogenic peptide hormones, expressing growth promoting and 
anabolic or insulin-like properties. In early experiments, IGF-I and -II extracted 
from normal mouse serum and administered to Snell dwarf mice resulted in a 
stimulation of growth, an increase in body weight, length, organ size as well as 
growth in cartilage tissue (Van Buul-Offers and Van den Brande, 1979). This was 
early evidence for the endocrine action of IGF-I and -II. These results were further 
supported by later studies involving the administration of purified IGF-I to 
hypophysectomized rats and Snell dwarf mice (Schoenle et al., 1982; Hizuka et al., 
1986; Van Buul-Offers et al., 1986; 1988; Guier et al., 1988). Studies have also 
been performed utilising a human model system to study the effects of IGFs on 
cellular growth. Laron dwarfism is a condition characterised by severe growth 
retardation (Laron et al., 1966; Rosenbloom et al., 1991 ). This disease has been 
attributed to an inactivation of the GH receptor and a drastic decrease in circulating 
levels of IGF-I. By administering IGF-I to these patients, Laron et al., (1992) 
demonstrated a stimulation of growth. However, Glassock et al., (1992) showed that 
hypophysectomized neonatal rats exhibit negligible growth stimulation when 
administered IGF-I. In a recent study of R- cells (3T3-like fibroblasts isolated from 
mice with a targeted disruption of the IGF-IR) transfected with IGF-II and the IR, 
IGF-II stimulated the cellular proliferation of these cells mediated by the IR. 
Interestingly, the IR is regarded as a mediator of metabolic functions, rather than 
growth and proliferation (Morrione et al., 1997). 
A number of different cell lines, including mammary epithelial cells, chondrocytes, 
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osteoblasts and smooth muscle cells, are stimulated to grow by IGF-I (Jones and 
Clemmons, 1995). For IGF-I to be mitogenic implies that it has the ability to 
stimulate cell division including DNA synthesis (Froesch et al., 1976; Zapf et al., 
1978). Most dividing cells undergo a regular sequence of cellular growth and 
division known as cell cycling (Curtis, 1983). The cell cycle consists of five phases: 
G1, S, G2, mitosis and cytokinesis. Mitosis and cytokinesis together constitute cell 
division, the two processes representing nuclear division and cytoplasmic division 
respectively. G1, S, and G2 are part of the interphase stage of the cell cycle. S is the 
synthesis phase where the chromosomal material is replicated. The G-phases 
separate synthesis and replication in the cell cycle with G1 being a general period of 
cell growth and replication and G2 the assembly of structures associated with mitosis 
(Curtis, 1983). Cells not actively undergoing cell division are said to be in the Go 
phase. As previously described, IGF-I and EGF directly influence cell growth at the 
G1-phase, where they are involved in the progression of the cell through this phase 
(Stiles et al., 1979; Bockus et al., 1983; Baserga and Rubin, 1993). A halting phase 
termed V has been identified within the G1-phase. It has been shown that for the cell 
to pass through the V checkpoint, both amino acids and IGF-I are required (Pardee, 
1989). The function of IGF-I within the cell cycle has been the focus of work by 
Baserga and coworkers (Baserga, 1993). They proposed that in P6 cells, which are 
3T3 fibroblasts overexpressing the IGF-IR, cycling through to the S-phase should be 
rapid. However, it was revealed that pulses of growth factors were required a short 
lag before the P6 cells were stimulated. Subsequently, Baserga (1993) pulsed cells 
with serum and found that serum alone did not stimulate DNA synthesis. However, 
if the serum pulse was followed with IGF-I, the cells proceeded to enter the S-phase. 
They proposed that primary growth factors such as PDGF, prime the receptors of the 
cell for the secondary growth factors such as IGF-I. This highlights the importance 
of the inter-relationship between growth factors and their cell surface receptors, with 
the IGF-IR emerging as a key factor for cell cycle progression (Sell et al., 1994). 
1.3.2 Anabolism 
In early studies, IGF-I mimicked the effect of insulin in insulin responsive cells 
(Zapf et al., 1978; Poggi et al., 1979). The importance of the insulin-like properties 
was confirmed by Kopple et al., (1994) in a clinical study of malnourished patients 
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with chronic peritoneal dialysis (PD). When GH was administered to combat 
malnourishment, it was found that the patients did not always respond anabolically. 
However, when recombinant human IGF-I (rhiGF-I) was administered to continuous 
ambulatory PD (CAPD) patients over a 20 day study, it was found that their protein 
balance increased. The conclusion drawn was that IGF-I was anabolic for patients 
with CAPD. Evidence for the anabolic effects of IGF-II has been seen in a number 
of diseases including patients with haemangiopericytoma, where severe 
hypoglycaemia is a side effect of this disease. Hoog et al., (1997), showed that the 
hypoglycaemic effect was due to the anabolic effects of high molecular weight 
(HMW) IGF-II, mediated by its non-specific binding to theIR. 
The peptide structure of IGF-I and -II provide a partial explanation for their insulin-
like properties. The amino acids that form the hydrophobic core of insulin, namely 
the structurally important glycine residues and the disulfide bridges, are conserved in 
both IGF-I and -II (Blundell et al., 1978; Raschdorf et al., 1988). Based on the 
amino acid conservation and the known tertiary structure of insulin, it was proposed 
that IGF-I, -II and insulin must have a similar tertiary structure (Blundell et al., 1978; 
Dafgard et al., 1985). The anabolic properties of IGF-I and -II are mediated by their 
binding to both the IGF-IR and IR. The IGF-IR and IR are also structurally similar 
and as members of the tyrosine kinase family they share common endogenous 
substrates (Yarden and Ullrich, 1988a; 1988b). These characteristics are responsible 
for the overlapping anabolic functions of the IGFs and insulin. It has been proposed 
in numerous reports, that the anabolic functions of IGFs are the result of their 
binding to the IR (Hoog et al., 1997). In a study where the cytoplasmic portion of 
the beta (~)-subunit of theIR was replaced with the ~-subunit of the IGF-IR, it was 
found that this manipulated receptor mediated the growth promoting effects of 
insulin (Lammers et al., 1989). Indeed, the insulin-like properties of IGF-I and -ll 
are secondary to their growth promoting properties. 
1.3.3 Differentiation 
Cellular differentiation is the morphological and functional change of cells due to 
external stimuli resulting in a range of different cell types. A unipotent cell can only 
differentiate into one cell type, whereas a pluripotent cell can generate several 
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differentially specialised cells. The differentiation and integratation of cells into a 
functioning organ, are regulated by IGFs and their interactions with other growth 
factors. 
In vitro studies have shown that IGF-I participates in the differentiation and 
maturation of a number of cell types including muscle, fat, bone, neurons, 
oligodendrocytes (Barres et al., 1992) and lymphoid progenitors (Landreth et al., 
1992; Rodriguez-Tarduchy et al., 1992). Interestingly, IGF-I and -II stimulate both 
growth and the terminal differentiation of myoblasts to form the contractile 
myotubules that constitute muscle tissue (Ewton and Fiorini, 1981 ). Overexpression 
of IGF-I and -II, as well as the IGF-IR in cultured myoblasts leads to accelerated 
differentiation (Quinn et al., 1994; Coleman et al., 1995; Stewart et al., 1996). 
However, a study by Minniti et al., (1995) showed that the overexpression of IGF-II 
caused de-differentiation and the formation of a malignant phenotype. The role of 
enhanced IGF-II expression in muscle requires further investigation. In further 
studies, Ewton et al., (1994) showed that the greater the proliferative effects of IGF-I 
on cultured L6 muscle cells, the longer the delay in the onset of differentiation. 
Interestingly they found that when IGF-I was present and devoid of IGFBPs, it 
resulted in a 100-fold stimulation of differentiation. It was concluded that muscle 
growth and differentiation is controlled by IGFs in a complex interactive system 
utilising the IGF-IR and IGFBPs but the exact molecular mechanisms remain to be 
elucidated. 
IGF-I also stimulates the proliferation and differentiation of fibroblasts, or 
preadipocytes into adipocytes (Smith et al., 1988). In bone, IGF-I has also been 
shown to be responsible for stimulating collagen synthesis (Fiorini et al., 1991; 
Delany et al., 1994). In neurons, IGF-I shifts from a promoter of cell division to a 
potentiator of neuronal differentiation, with IGF-I being important for myelination 
(McMorris and Dubois-Dalcq, 1988; Pahlman et al., 1991). It appears from a range 
of studies in diverse cellular systems that both IGF-I and -II function as agents for 
cellular differentiation, but in a tissue specific fashion. 
1.3.4 Apoptosis 
The cascades of events to which a cell may be subjected include not only cellular 
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growth and differentiation, but also cell death, which is a critical step in the life cycle 
of a cell and the formation of a multicellular organism (Fig. 1.1 ). For a long time it 
was considered that cell death was the result of necrosis. Necrotic cell death is 
caused by environmental stresses or insults on contiguous groups of cells and is 
associated with an inflammation event due to the release of cellular debris. These 
environmental insults include hypothermia (Buckley, 1972), hypoxia (Laiho et al., 
1983), ischaemia (Borgers et al., 1987), complement attack (Hawkins et al., 1972), 
poisons (Trump et al., 1984) and direct physical cell damage (Trump and Bulger, 
1967). However cell death can also be a programmed event that rapidly affects 
single cells of a cell population with no resulting inflammation in the surrounding 
tissue. This process is known as apoptosis. Apoptosis begins with a loss of cell 
junctions and specialised plasma membranes, with the cytoplasm and chromatin 
condensing (Lockshin and Beaulaton, 1981 ). The ER dilates, forms vesicles and 
fuses with the plasma membrane resulting in a convoluted shape (Morris et al., 
1984; Stacy et al., 1985). The cell then fragments into a number of apoptotic bodies 
that vary in size depending on cell type and size. These bodies are then either 
rapidly phagocytosed by cells such as macrophages, epithelial cells, vascular 
endothelium and tumour cells (Wyllie, 1980), or extruded into an adjacent lumen 
following the degradation of their cytoplasmic contents, referred to as secondary 
necrosis (Searle et al., 1975; Don et al., 1977). The fragmentation of the cellular 
contents is a rapid event (Sanderson, 1976; Matter, 1979) which when combined 
with the lack of observable inflammation, makes apoptosis a difficult process to 
study. Consequently, the current focus in apoptotic research is to establish 
biological markers for cells undergoing this kind of death. 
Apoptosis is now widely recognised as a form of cell death and represents a 
mechanism of cell clearance in many physiological situations, where the removal of 
cells is a critical event (Collins et al., 1993). For example, apoptosis has been 
shown to be a major mechanism of cellular changes in embryogenesis, as observed 
specifically in the regression of female sexual organs in male embryos (Hinchliffe, 
1981). Due to their role in cell growth and differentiation, growth factors, 
particularly IGF-I and -II, have been implicated as important regulators of apoptosis 
by inhibiting cell death. 
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A wide variety of cells in culture undergo apoptosis when they are deprived of 
essential growth factors. Some examples include glial cells, when deprived of IGF-I 
and PDGF (Barres et al., 1992); sympathetic neurons, when deprived of nerve 
growth factor (NGF; Batistatou and Greene, 1991); endothelial cells, when FGF is 
absent (Araki et al., 1990); and differentiating myoblasts, when IGF-II is absent 
(Stewart and Rotwein, 1996a). Thus growth factors can serve as survival factors 
when administered to cells in culture. IGF-I has been shown to act as a survival 
factor for neurally derived cells including glial progenitor cells and primary cultures 
of oligodendrocytes (Barres et al., 1992; Raff et al., 1993). At a physiological level, 
IGF-I has been shown to prevent apoptosis induced by gonadotropins during ovarian 
follicular development (Chun et al., 1994). A mechanism by which the deprivation 
of growth factors trigger apoptosis, or stimulates survival, was proposed by Collins 
et al., (1993). They proposed that a lack of growth factors results in reduced 
receptor signalling, with low to nil response in the signal transduction pathway, 
resulting in low cellular metabolism, a down-regulation of survival genes such as 
p53 and myc and a possible change in cellular gene expression. Furthermore, the 
addition of growth factors results in receptor binding with the stimulation of 
alternate signal transduction pathways, leading to a choice whereby the cell is 
stimulated to either proliferate, or to survive. IGF-I has been implicated as a 
survival factor for glial cells but not as a promoter of cell proliferation (Barres et al., 
1992). Alternatively, there are cases where IGFs cause proliferation, differentiation 
and survival, as seen for IGF-I in primary cultures of bone marrow derived IL3-
dependent cells and IGF-II in skeletal myoblasts (Rodriguez-Tarduchy eta!., 1992; 
Stewart and Rotwein, 1996a). Thus upon binding to its receptor, IGF-I or -II rapidly 
stimulate distinct signal transduction pathways; either for survival against apoptosis 
in certain cells or for proliferation in others. A clear direction for future research in 
this area is to establish the link between IGFs and apoptosis, or how IGF-I and -II 
control the selection of cellular proliferation versus cellular death. 
1.3.5 Tumour Proliferation 
In the formation of tumours, cells transform and proliferate at the expense of 
neighbouring cells, suggesting a breakdown in the regulatory mechanisms that 
maintain the balance between proliferation and cell death within a tissue. It has been 
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suggested that growth factors play a role in the formation and the maintenance of 
tumours. Consequently, knowledge of the involvement of the various growth factors 
in tumour development would be very important for the treatment and prevention of 
cancer. 
IGF-I, -II and insulin have been detected in both transformed and untransformed 
cells. There is also evidence that transformed cells in culture grow in low serum 
culture medium and secrete polypeptide growth factors (Sporn and Roberts, 1985), 
and that the receptors for these growth factors are present. This supports the 
hypothesis that endogenous hormones may be associated with tumour growth and 
propagation (Israel and Band, 1984). Various groups have reported that the IGF 
mode of action in cancer proliferation is either via autocrine or paracrine 
mechanisms (Section 1.4.1; Minuto et al., 1988; Yee et al., 1988; 1989a). In one 
study, IGF-I was shown to behave as an autocrine mitogenic stimulator in a human 
lung cancer cell line (Minuto et al., 1988). In other studies, Yee et al., (1988; 1989a) 
reported that IGF-I and -II acted as autocrine stimulators of stromal cells in breast 
tumours, while IGF-I was a paracrine stimulator of the tumour epithelial cells and 
IGF-II was both an autocrine and paracrine stimulator of the tumour epithelial cells. 
IGF-I has also been reported to be present at the protein and/or message level in 
human small cell lung cancers (Macauly et al., 1987; Nakanishi et al., 1988), the 
human lung cancer cell line CALU-6 (Minuto et al., 1988), T61 human breast cancer 
tumours and established breast cancer cell lines (Yee et al., 1989a; Tobin et al., 
1990), ovarian cancer (Yee et al., 1991b), human colon carcinomas and 
liposarcomas (Tricoli et al., 1986), neuroectodermal tumours (Yee et al., 1990), 
glioblastomas (Trojan et al., 1992; 1993), human hepatomas (Tsai et al., 1988; 
Tsung-Sheng et al., 1989), smooth muscle tumours (Hoppener et al., 1988), the 
human macrophage cell line, U937 (Nagaoka et al., 1990) and the leukemic cell line 
Burkitt type All (Hartmann et al., 1988). The expression of IGF-I within these 
systems implies that an inhibition or complete knock-out of IGF-I would be of 
benefit in cancer therapy. For example, the serum-independent growth of lung 
cancer cells, CALU-6 was abolished by the introduction of an IGF-I antibody (sm-
1.2; Minuto et al., 1988). In addition, pioneering studies by Trojan et al., (1993) 
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utilised an expression vector system encoding antisense IGF-I eDNA, which when 
transfected into C6 glioma cells, resulted in the loss of tumourigenicity. The authors 
then applied these cells to a rat model system and showed that the transfected cells 
expressing antisense IGF-I could prevent glioblastomas and regress established 
tumours. Like IGF-I, the overexpression of IGF-II has been identified in a number 
of tumours including breast tumours (Y ee et al., 1988), lung cancers (Zhan et al., 
1995) and Wilm's tumours (Reeve et al., 1985; Scott et al., 1985). In a number of 
malignancies such as Wilm's tumours, imprinting of the IGF-II gene has been either 
relaxed or lost and has been hypothesised to be the cause of tumourigenesis in these 
tissues (Reeve et al., 1985; Scott et al., 1985; Ogawa et al., 1993). 
In other studies, Yee et al., (1990) examined the message levels of IGF-I, -II and the 
IGF-IR in a number of neuroectodermal tumour cell lines and found that some cell 
lines over-expressed IGF-I mRNA in conjunction with the IGF-IR; those that did not 
express IGF-I, expressed IGF-II. In the same study, a primitive neuroectodermal cell 
line (PNET) with a t(11:22)q(12:24) translocation was described. This cell line 
over-expressed IGF-I, while the same cell line without the translocation expressed 
IGF-II instead of IGF-I, suggesting that the translocation may be involved in the 
control of IGF-I transcription. The study also examined some samples of Ewings 
sarcomas, which expressed low levels of the IGF-IR but no IGF-I or -II mRNA. It 
was implied from these results that tumour proliferation is the result of an interactive 
process among a range of growth factors, of which IGF-I and -II are major 
contenders. 
Although there is a wide cross-section of tumour tissues and cell lines that express 
IGF-I and -II, there are tumour cell lines that express the IGF-IR but no IGF mRNA 
or protein. Numerous studies support the role for the IGF-IR in mediating 
tumourigenesis. When fibroblasts overexpressing the IGF-IR were injected into 
immunodeficient mice, tumours formed (Kaleko et al., 1990). In contrast, when 
fibroblasts lacking the IGF-IR were injected into immunodeficient mice, tumours did 
not form (Long et al., 1995). Studies point to the fact that a functional IGF-IR is 
required for malignant transformation (Li et al., 1994; Hernandez-Sanchez et al., 
1995). 
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Binding proteins (refer to Section 1.4.6) are essential regulators of IGF actions and 
have recently become an important area of investigation with respect to the role of 
IGFs in tumour proliferation. It has been reported recently that the human IGFBP-4 
gene maps to the same chromosome as the gene for hereditary breast-ovarian cancer, 
BRCA1 (Merchav et al., 1994; Ehrenberg et al., 1994). It is possible that the 
BRCA1 gene product influences the expression of IGFBP-4 and consequently the 
tissue distribution of the IGFs. While Merchav and co-workers (1994) reported that 
IGFBP-4 levels are higher in women with breast and ovarian cancer, they were 
unable to correlate the marker for BRCA1 with serum levels of IGFBP-4. 
Ehrenberg et al., (1994) also suggested that IGFBP-4 is associated with breast cancer 
development despite the poor correlation to BRCAl. This proposal was based on 
the close proximity of the IGFBP-4 gene to ERB B2 gene, an oncogene implicated in 
breast tumour proliferation. IGFBPs have also been investigated for their possible 
role in controlling the proliferative effects of IGFs in other cancers, including 
leukemia. Northern analysis and in situ hybridisation histochemistry were used to 
show that IGFBP-2 and -4 were present. It is proposed that the role of IGFBP-2 is 
inhibitory in both the basal and IGF-I stimulated growth of the myelogenous 
leukemic cell line KG-1 (Jaques et al., 1994) 
1.4 Mechanisms of Action 
Both IGF-I and -II are a highly conserved and yet simple in their structure. 
Interestingly however, as discussed in Section 1.3, these proteins have diverse 
biological effects. These diverse actions are achieved by a variety of means, 
occurring both extracellularly and intracellularly, including transmembrane 
receptors, signal transduction pathways and regulation by binding proteins. These 
mechanisms of action will be discussed in the following sections. 
1.4.1 Autocrine, Paracrine, Endocrine 
The largest quantity of IGFs in the human body is found in the serum. It has been 
identified that most of the circulating IGF-I is synthesised in the liver, which is also 
believed to be the main source of IGF-II (Schwander et al., 1983; Scott et al., 1985). 
The IGFs that reach their target cell via the circulation are said to act in an endocrine 
fashion. The detection of IGF-I and -II protein in the culture medium of organ 
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explants and cell culture lines, revealed that IGFs were not only synthesised by the 
liver but also by a variety of other organs and tissues. Thus IGFs not only exert their 
physiological effects in an endocrine fashion, but also in an autocrine and paracrine 
manner (Fig. 1.7; D'Ercole et al., 1980; 1984). 
Autocrine Paracrine Endocrine 
+ 
• IGFBP + 
IGFBP 
~ 
Target Cell R 
Figure 1. 7 - The IGFs are produced as autocrine, paracrine and endocrine hormones. 
Autocrine; IGF synthesis, secretion and action are on the same cell. Paracrine; IGFs produced in 
one cell and act on neighbouring cells. Endocrine; IGFs are produced in one cell and elicit their 
action distally. 
1.4.2 Proteolytic Products of /GF-1 
Structurally distinct variant forms of IGF-I have been identified which play a 
specialised biological role in cellular activities. These variant forms include truncated 
IGF-I (des-1-3-IGF-I; Fig. 1.8), the tripeptide glycyl-propyl-glutamate (GPE; Fig. 
1.8), the IGF-I-IB-(103 - 124) E1 amide (IBE1) and IGF-IB-(129 - 142)E2 amide 
(IBE2; Fig 1.9). 
1.4.2.1 Truncated IGF-1 ( des-1-3-IGF-1) 
It was proposed in the 1970's that GH action on brain growth and development was 
mediated by a brain growth factor that was produced by either placental tissue or the 
foetus (Sara and Lazarus, 1974; Sara et al., 1974). This brain growth factor was 
isolated using a bioassay which measured DNA synthesis in human foetal brain cells 
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Figure 1.8 - GPE and truncated 1GF-l are two identified neuroactive products of IGF-I gene 
expression in the central nervous system (CNS). These peptides result from post-translational 
processing of the IGF-l prohormone via an acid protease (adapted from Sara et al., 1991 ). 
(Sara et al., 1976) and a radioreceptor assay (Sara et al., 1981). Amino acid 
sequence analysis of the product revealed that this putative brain growth factor was 
identical to mature IGF-I, except that it lacked the first three residues of the N-
terminal B-domain (Fig. 1.8; Sara et al., 1986). Des-1-3-IGF-I was also isolated 
from adult and foetal human brain, where it was found to be the exclusive form of 
IGF-I detected (Carlsson-Skwirut et al., 1986). These results suggested a specific 
biological function for des-1-3-IGF-I in brain growth and development. 
Concurrently, des-1-3-IGF-I was isolated from bovine colostrum (Francis et al., 
1986), together with mature IGF-I. Des-1-3-IGF-I has also been isolated from other 
material including porcine uterine extracts, where it was shown to be exclusively 
responsible for mitogenesis within this tissue (Ogasawara et al., 1989). Des-1-3-
IGF-I was also found in human platelets, where it was hypothesised to have wound 
healing properties together with mature IGF-I and IGF-II (Karey et al., 1989). 
During the purification of des-1-3-IGF-I, it became evident that des-1-3-IGF-I had a 
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greater biological activity than mature IGF-I. This was seen in the stimulation of 
growth and differentiation in neuroblasts and glioblasts where des-1-3-IGF-I was 
found to be more potent than IGF-I or IGF-II (Sara and Carlsson-Skwirut, 1990). 
This increased potency was suggested to be a result of poor complexing between 
des-1-3-IGF-I and the IGFBPs (Bagley et al., 1989; Carlsson-Skwirut et al., 1989). 
Using an in vitro foetal brain cell model system, Carlsson-Skwirut et al., (1989) 
showed that if IGFBP-1, a known inhibitor of IGF-I action, was added to the cell 
culture medium, stimulation of brain cell DNA synthesis by mature IGF-I was 
inhibited. In the same experiment using des-1-3-IGF-I in place of IGF-I, there was 
no inhibitory effect of des-1-3-IGF-I's ability to stimulate DNA synthesis within the 
foetal brain cell model system. From these results it was suggested that poor 
complexing of des-1-3-IGF-I with IGFBPs allows des-1-3-IGF-I to be available for 
binding to the IGF-IR by which its enhanced actions are mediated. The increased 
potency of des-1-3-IGF-I is retained when administered in vivo, therefore clinical 
opportunities for des-1-3 IGF-I have been proposed, particularly in relation to 
catabolic states (Ballard et al., 1996). 
An examination of the cleavage point of GPE and des-1-3-IGF-I at the genomic 
level, revealed that this processing is not a result of an exon/intron junction but in 
fact is a result of post-translational modification of pro-IGF-I. An acid protease 
capable of generating des-1-3-IGF-I has been identified and characterised from rat 
serum (Yamamoto and Murphy, 1994). Further investigation revealed that the 
enzymatic activity of this protease is regulated by GH in all tissues except lung and 
in serum, with GH increasing the acid protease activity (Yamamoto and Murphy, 
1995). 
1.4.2.2 The GPE Tripeptide 
With the discovery of the neuropotent des-1-3-IGF-I, questions were raised 
regarding the activity of the GPE tripeptide, which is cleaved from the N-terminus of 
mature IGF-Ito produce des-1-3-IGF-I (Fig. 1.8). 
The biosynthetic pathway and biological function(s) of GPE remam to be 
determined. GPE isolated from foetal brain (Sara et al., 1989) and adult brain 
(Carlsson-Skwirut et al., 1989), was shown to be biologically active. However, 
Page 26 
Walker, 1998 
unlike des-1-3-IGF-I, the activity of GPE is not mediated by the type I or type II IGF 
receptors, nor does it complex with the IGFBPs. It has been demonstrated that GPE 
has no growth promoting effects in vitro or in vivo (Sara et al., 1989). Instead, GPE 
seems to function as a neuromodulator by potentiating the release of dopamine, a 
neurotransmitter (Sara et al., 1989). The neuromodulatory function of GPE is 
mediated by its interaction with the N-methyl-D-aspartate receptor (NMDA receptor; 
Sara et al., 1989), which is a subclass of receptor that binds to the major excitatory 
amino acid neurotransmitter, glutamate. GPE also inhibits the secretion of 
gonadotrophin releasing hormone (GnRH; Bourguignon et al., 1993), via the NMDA 
receptor. It is proposed that GPE also utilises a still undefined receptor system since 
it stimulates the potassium driven release of acetylcholine (ACh) from cortical 
neurons (Sara et al., 1989). A function that is not mediated by the NMDA receptor. 
An example of such a receptor system is the insulin related receptor (IRR), a novel 
member of the insulin receptor family which currently has no ligand specific 
binding. The mechanism for the release of ACh thus remains to be established 
although, work by Nilsson-Hakansson et al., (1993) on the potassium induced 
release of ACh from rat cortex, found that GPE was several hundred fold more 
potent than mature IGF-I and des-1-3-IGF-I showed no effect. This supports the 
hypothesis that GPE is an active site of mature IGF-I, which was first suggested by 
Sara et al., (1989). Thus, to date it appears that GPE is an additional protein product 
of the expression of IGF-I within the central nervous system and may be involved in 
the modulation of neurotransmitter release. 
1.4.2.3 IBE1 and IBE2 
Siegfried et al., (1992) introduced the possibility that the IGF-I Eb could produce 
several peptides with distinct physiological effects in different tissues. They 
identified IGF-I-IB-(103 - 124) E1 amide (IBE1), and the potential IGF-IB-(129 -
142)E2 amide (IBE2) via the presence of a Gly-Lys-Lys-Lys signal sequence for 
proteolytic cleavage and peptidyl C-terminal amidation within the variable Eb 
domain (Fig. 1.9). Using a synthetic analog to the 23 residue IBE1 peptide, they 
showed that IBE1 is a growth factor for human lung cells, and that its actions are 
mediated by a specific receptor. IBE1 may also be a growth factor for other species 
as a molecule containing immunoreactivity to an antibody raised against an IBE1 
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603 aac aag aac acg aag ucu cag aga agg aaa ggu ugg 
93 Asn Lys Asn Thr Lys Ser Gln Arq Arq Lys Gly Trp 
640 cca aag aca cau cca gga ggg gaa cag aag gag ggg 
105 Pro Lys Thr His Pro Gly Gly Glu Gln Lys Glu Gly 
676 aca gaa gca agu cag cag auc aga gga aag aag aaa 
117 Thr Glu Ala Ser Leu Gln Ile Arg Gly Lys Lys Lys 
712 gag cag agg agg gag auu gga agu aga aau gcu gaa 
129 Glu Gln Arg Arq Gl u Ile Gly Ser Arg Asn Ala Glu 
748 ugc aga ggc aaa aaa gga aaa uga 
141 Cys Arg Gly Lys Lys Gly Lys 
Figure 1.9 - eDNA sequence and predicted amino acid sequence of 1GF-1 Eb. Numerical location 
of base pairs is the upper value in the paired lines; the amino acid numerical location is represented 
by the lower value of paired lines. 1BE1 is highlighted in bold. The amino acids underlined represent 
potential cleavage sites Italicised bold amino acids represent a second potential amide IGF-IB-( 129-
142 ), denoted IBE2 (adapted from Siegfried et al., 1992) 
synthetic analog (Y-23-R-NH2), was detected in extracts of liver from a range of 
other species. It was originally suggested that the enzyme responsible for the 
cleavage, is co-localised with IGF-I Eb in secretory granules. However, it has since 
been suggested that IBE1 may be regulated by alternative splicing of the IGF-I gene 
(Section 1.5.4; Chew et al., 1995). Further investigations are required to determine 
whether the proteolytic products of Eb have independent effects. 
1.4.3 /GF-11 Serine-29 and Serine-33 Variants of /GF-11 
Two variant forms of the human IGF-ll prohormone have been isolated and 
identified. The IGF-ll Serine-29 (Ser-29) variant replaces the amino acid Serine at 
residue 29 in the B-domain, with the tetrapeptide Arginine-Leucine-Proline-Glycine 
(Jansen et al., 1985). The corresponding mRNAs arise by alternative splicing of the 
IGF-ll pre-mRNA. The IGF-ll Serine-33 (Ser-33) variant possesses the tripeptide 
Cysteine-Glycine-Aspartic acid in place of the amino acid Serine at position 33 
within the C-domain (Zumstein et al., 1985). The Ser-33 variant was isolated as a 
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larger molecular weight form of IGF-II from human serum and was hypothesised to 
be the result of allelic variation rather that alternative splicing. Each variant results 
in a different IGF-II prohormone with functions potentially independent of IGF-II. 
1.4.4 Receptors 
The IGFs have been identified as having biological roles in cell growth, 
differentiation, tumourigenesis and as survival factors for cells undergoing 
apoptosis. As eluded to in previous sections, these diverse biological functions can 
be largely attributed to their interaction with cell surface receptors. Both IGF-I and-
II bind to the IGF-IR, with IGF-I showing the greatest affinity for this receptor, being 
2 -10-fold greater than IGF-II. Insulin also binds the IGF-IR, but shows the lowest 
affinity being approximately 100-fold less than IGF-I (Steele-Perkins et al., 1988; 
LeRoith et al., 1995). In addition to the IGF-IR, IGF-II also binds with a high 
affinity to the type II IGF/mannose-6-phosphate receptor (IGF-II/M-6-P receptor; 
Morgan et al., 1987; Kiess et al., 1988; MacDonald et al., 1988; Tong et al., 1988). 
Variant receptors have also been described in a number of systems. The molecular 
basis of these receptor subtypes is unknown, however these receptors may differ in 
their ability to regulate the biological effects of IGF-I and -II and their variant forms 
previously described. 
1.4.4.1 Type IIGF receptor (IGF-IR) 
Human IGF-IR mRNA is synthesised from a gene consisting of 21 exons located on 
chromosome 15q25-q26 (Ullrich et al., 1986; Abbott et al., 1992). The IGF-IR 
mRNA is translated into a 1367 aa prepeptide, whereby a 30 aa signal peptide is 
cleaved during post-translational processing. The IGF-IR peptide is then 
glycosylated and cleaved at the tetrapeptide Arginine-Lysine-Arginine-Arginine 
sequence at position 707-710, generating an alpha -(a) and a ~-subunit (Ullrich et 
al., 1986). The a- and ~-subunits then bond through di-sulfide linkages to form an 
a~-hemireceptor, which then binds to a second hemireceptor by disulfide linkages 
resulting in a mature IGF-IR. Thus the mature IGF-IR consists of four glycoprotein 
subunits: two extracellular a-subunits, with a Mr of approximately 135 kDa; and two 
~-subunits which encode an extracellular domain, membrane spanning domain and a 
large intracellular domain, with a Mr of approximately 90 kDa (Fig. 1.1 0; Ullrich et 
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Figure 1.10 - Structure of the JGF receptors and JR. The JGF-JR and JR are heterotetrameric 
protein complexes consisting of extracellular a-subunits containing the cysteine ligand binding 
domain and intracellular /)-subunits, which traverse the plasma membrane and contain the tyrosine 
kinase domain. Hybrid receptors consist of a hemireceptor from the JGF-JR and the JR. The JGF-
11/M-6-P receptor shares no similarities to the JGF-1R or 1R, consisting of a large extracellular 
domain and a short cytoplasmic domain with no tyrosine kinase activity (LeRoith et a/., 1993; 
1995). 
al., 1986). Domain swappmg experiments have shown that the extracellular a-
subunits contain a conserved cysteine-rich region, which is responsible for the ligand 
binding affinity of IGF-I and insulin (Anderson et al., 1990; Gustafson and Rutter, 
1990; Kajeldson et al., 1991). While the transmembrane cytoplasmic ~-subunit 
contains a tyrosine kinase domain and locations for tyrosine and serine 
phosphorylations (Ullrich et al., 1986; LeRoith et al., 1995). 
1.4.4.2 IGF-IR Variants 
Several IGF-IR variants have been described. Like the IGF-IR, theIR is also a ligand 
activated tyrosine-specific protein kinase (Fig.l.1 0). The IGF-IR and IR areencoded 
by two distinct genes yet they share a 60% homology in their aa sequence 
(Chernausek et al., 1981; Ebina et al., 1985; Duronio et al., 1986; Ullrich et al., 
1986). The cysteine residues involved in the linkage between the a~-hemireceptors 
are also conserved between these receptors. This raised the possibility that in cells, 
which express both receptors, hybrid receptors consisting of 
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an a~-hemireceptor of the IGF-IR and an a~-hemireceptor of the IR could form 
(Fig. 1.10). In fact hybrid receptors have been identified in certain tissues, such as 
the placenta (Moxham et al., 1989; Soos and Siddle, 1989; Treadway et al., 1989; 
Soos et al., 1990) Nlli3T3, HepG2 and neuronal cell lines (Chin et al., 1991; 
Garofolo and Barenton, 1992). IGF-I has a higher affinity for the hybrid receptor 
than insulin, equivalent to its affinity for the IGF-IR. It has therefore been proposed 
that the hybrid receptor may predominantly mediate the actions of IGF-I in certain 
tissues and cell types (Moxham et al., 1989; Garofolo and Barenton, 1992; Soos et 
al., 1993). However, it remains to be established whether the hybrid receptors, 
which are activated primarily by IGF-I, can elicit alternate signal transduction 
pathways distinct from those activated by the classic IGF-IIIGF-IR interaction, and 
whether this hybrid receptor also mediates the actions of IGF-II. 
IGF-I receptor variants have also been described which are generated through 
variable RNA processing. In particular, an alternate splice site at the 5' end of exon 
14 leads to the synthesis of isoforms with either a Threonine-Glycine or an Arginine 
located in the extracellular domain of the ~-subunit (Yee et al., 1989b ). Each 
isoform has been overexpressed in Chinese hamster ovary cells (CHO). The 
Threonine-Glycine variant exhibited a lower ligand-induced endocytosis, higher 
levels of autophosphorylation and a higher phosphorylation of the intracellular 
peptide insulin receptor substrate 1 (IRS-1; Condorelli et al., 1994 ). Their role in 
vivo however, remains to be elucidated. 
In addition to IGF-IR variants produced by alternative splicing, receptors with 
variations in the glycosylation of the a- and ~-subunits have also been identified in a 
range of tissues and cell lines. Human neuroblastoma cell lines, leukemic cells, 
human placenta and numerous other tissues and cell lines, have been found to 
contain to two sizes of ~-subunits which have been attributed to differential 
glycosylation (Ota et al., 1988; Kellerer et al., 1990; Alexandrides et al., 1993). A 
separate study characterising IGF-IRs in the human brain, found that the a-subunits 
were 120 kDa in size, approximately 15 kDa smaller than IGF-IRs found in human 
placenta and other tissues. This variation in size was also believed to be due to 
glycosylation (Sasaki et al., 1991). The role of tissue specific glycosylation of the a-
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and ~-subunits of the IGF-IR remain to be elucidated but may provide an additional 
level of IGF regulation. 
1.4.4.3 Type II IGF receptor (IGF-11/M-6-P receptor) 
The IGF-ll receptor differs significantly from the IGF-IR and IR, being a single 
chain membrane-spanning glycoprotein of 260-265 kDa. It is also referred to as the 
cation-independent mannose-6-phosphate (M-6-P) receptor since the eDNA 
sequence from each receptor revealed that the two receptors were identical (Morgan 
et al., 1987; Oshima et al., 1988). This was also confirmed by showing that the IGF-
ll and M-6-P receptors could both bind IGF-ll and peptides containing M-6-P 
recognition sequences (Morgan et al., 1987; Kiess et al., 1988; MacDonald et al., 
1988). 
The human gene for the IGF-II/M-6-P receptor has been mapped to chromosome 
6q25-q27 (Laureys et al., 1988). Like the human IGF-ll gene, the IGF-IIIM-6-P 
receptor gene is also imprinted, expressed only by the maternal allele. The mature 
receptor is 2451 residues in size, consisting of 2264 residue extracellular domain, 23 
residue transmembrane domain and a 164 residue intracellular domain (Fig. 1.1 0; 
Morgan et al., 1987; MacDonald et al., 1988; Oshima et al., 1988). The 
extracellular domain consists of 15 repeated sub-domains with each repeat 
containing eight cysteines in analogous positions as well as other conserved amino 
acids (Morgan et al., 1987; Lobel et al., 1988; MacDonald et al., 1988; Szebenyl and 
Rotwein, 1994). The extracellular domain binds both IGF-ll and peptides containing 
the M-6-P recognition sequences, such as lysosomal peptides (Kornfeld, 1992). The 
intracytoplasmic domain regulates movement between cellular compartments, such 
as the lysosomal enzymes from their sites of synthesis to the lysosomes (Dahms et 
al., 1989). Mouse fibroblasts lacking either the IGF-IIJM-6-P receptor showed a 
50% decrease in lysosomal enzymes and an increase in their secretion (Ludwig et al., 
1994; Pohlmann et al., 1995). In addition to the transportation of proteins, the IGF-
II/M-6-P receptor has also been suggested to act as a tumour suppressor, regulating 
IGF-ll levels by sequestering, internalising and degrading IGF-II, thereby preventing 
its binding to the IGF-IR where it would elicit a biological response (Ellis et al., 
1996). Most of the biological actions of IGF-1 and -ll are mediated by the IGF-IR, 
however it has been proposed that IGF-IIIM-6-P receptor has a role in the signal 
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cascade even though this receptor lacks an intracellular tyrosine kinase domain (refer 
to Section 1.4.5). For example IGF-II stimulated BalbC/3T3 cells to grow and this is 
accompanied by an influx of Ca2+ (Nishimoto et al., 1987). This effect was found to 
be mediated by the IGF-Il/M-6-P receptor, and is related to the activation of GTP-
binding proteins (Okamoto et al., 1990a; 1990b). In addition, a role for the IGF-
Il/M-6-P receptor has been proposed for the differentiation of muscle cells 
(Rosenthal et al., 1994). The intracellular domain of the IGF-Il/M-6-P receptor 
contains amino acids phosphorylated by protein kinases (Meresse et al., 1990; 
Rosorius et al., 1993). It has been shown that IGF-II promotes the exocytosis of 
insulin in pancreatic beta cells via the IGF-Il/M-6-P receptor. This process is 
dependent on the phosphorylation of protein kinase-C (Zhang et al., 1997). The 
signal transducing capabilities of the IGF-Il/M-6-P receptor are still a point of 
discussion. 
1.4.5 Signal Transduction of the IGF-IR 
Upon ligand binding, the IGF-IR is activated intracellularly by intramolecular 
tyrosine autophosphorylation of three tyrosines in the ~-subunit. This results in a 
cascade of protein phosphorylations that constitute the stimulation of the signal 
transduction pathway (Yu et al., 1986; Gronborg et al., 1993; Kato et al., 1993; 
1994). Much of what is known regarding the intracellular events that follow the 
autophosphorylation of the IGF-IR, is a result of advances made in the understanding 
of the signal cascade of the IR. 
Activation of the second messenger system of the IGF-IR can be divided into three 
levels. Level 1 events relate to receptor tyrosine activity; level 2 events refer to 
tyrosine, serine and threonine phosphorylations and dephosphorylations; and level 3 
events refer to the biological effects (Fig. 1.11; reviewed by Kahn, 1994; LeRoith et 
al., 1995; Stewart and Rotwein, 1996b). The importance of level 1, or more 
specifically the role of the tyrosine kinase domain within the signal transduction 
pathway, was elucidated by the work of Kato et al., (1993). These researchers 
constructed mutants of the tyrosine kinase domain of the IGF-IR by substituting the 
essential tyrosines and transfecting them into 3T3 cells. Upon stimulation with IGF-
I they found there was no phosphorylation of the ~-subunit and no DNA synthesis, 
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Figure 1.11 · IGF-1 Action : 1GF-I action is divided into three levels : level 1, initial receptor 
events; level 2, tyrosine phosphorylation and dephosphorylation; level 3, biological effects (adapted 
from Kahn, 1994; LeRoith et al., 1995; Stewart and Rotwein, 1996b). 
demonstrating the importance of the tyrosine kinase domain of the IGF-IR. 
Following autophosphorylation of the IGF-IR, the activated receptor was able to 
phosphorylate other tyrosine containing proteins, predominantly the 185 kDa IRS-1 
(White et al., 1985; Izumi et al., 1987; Beguinot et al., 1989; Sun et al., 1991). IRS-
1 is described as a "docking protein." When it is phosphorylated, IRS-1 binds to src 
homology-2 (SH2) domains in a range of proteins bringing them together. This 
includes proteins such as phophoinositol 3' (PI3)-kinase (Myers et al., 1992), growth 
factor receptor binding protein-2 (Grb-2), Nck (an adaptor protein) and Syp (a 
phosphotyrosine phosphatase also known as PTP1D, PTP2C or SHPTP2; Sun et al., 
1993; Pawson and Schlessinger, 1993; Kuhne et al., 1993). Grb-2 SH2 domains bind 
to a guanine nucleotide release factor (Sos), which exchanges GTP for GDP thereby 
activating the Ras complex. The receptor activated proteins such as the Ras 
complex and proteins bound to IRS-1 activate a cascade of phosphorylations and 
dephosphorylations of proteins such as Raf-1 (a cytoplasmic serine kinase), mitogen-
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activated protein (MAP) kinase, and S6 kinase (Fig. 1.11; Kahn, 1994; LeRoith et 
al., 1995). Thus, IRS-1 plays a central role in the second messenger pathway for 
both IGF-I and insulin. The study of IRS-1 deficient mice however, surprisingly 
resulted in viable mice, although they were impaired in growth and had a reduced 
insulin-stimulated glucose uptake (Araki et al., 1994; Tamemoto et al., 1994). This 
phenotype contradicted the central role of IRS-I, suggesting that there were 
additional signalling pathways activated by the binding of IGFs and insulin to their 
prospective receptors. A newly discovered homologue of IRS-I, IRS-2 has been 
suggested to be the key to this alternate pathway of activation (Sun et al., 1995). 
IGF-I rapidly stimulates the tyrosine phosphorylation of IRS-2, which in turn binds 
and activates the PI3-kinase signaling pathway, but not the Grb-2 pathway (Valverde 
et al., 1998) offering an alternate second messenger pathway for IGF-I activation. 
An early event in the IGF second messenger system that is independent of IRS-I, is 
the activation of src homology domain-containing proteins (She; Prank et al., 1993; 
Sasaoka et al., 1994). The She-family consists of three proteins, one of which 
contains a single SH2 domain (Pelicci et al., 1992). Upon tyrosine phosphorylation, 
the She complex binds to Grb-2-Sos activating the Ras complex. Thus IGF-I is able 
to activate Ras by two distinct pathways; the IRS-1-Grb2-Sos and the Shc-Grb2-Sos 
pathways. The activation of the protein kinases in turn activates other peptides, 
which eventually lead to the biological responses (Fig. 1.11). 
While the endogenous substrates discussed so far are shared between the IGF-IR and 
IR, many which remain to be identified and isolated, are unique to each receptor. An 
overexpression of the IGF-IR was able to protect 32D cells, which lack IRS-1 and 
IRS-2, from apoptosis induced by interleukin -3 (IL-3) withdrawal (Dews et al., 
1997). An overexpression of She and/or IRS-I could not compensate for the IGF-
IR, suggesting that there are important endogenous substrates in the IGF-IR signal 
cascade which remain to be elucidated. 
1.4.6 IGF Binding Proteins (IGFBPs) 
In serum, the 750 flg/L combined concentrations of IGF-I and -II are 1000-fold 
greater than the concentration of insulin. Since unbound IGF-I has 5% the 
hypoglycaemic potency of insulin and can cross-react with the IR, it would be 
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expected that IGFs would cause hypoglycaemia in the normal population (Baxter 
and Martin, 1989). However, this does not occur because a large proportion of the 
IGFs in the circulation and extracellular fluids are associated with binding protein 
complexes. So far six classical IGFBPs have been identified, and have been 
systematically named IGFBP-1 to -6 (Drop, 1989). The majority of IGFBP synthesis 
occurs in the liver however IGFBPs are also produced by a wide variety of other 
tissues, with expression levels regulated by hormonal and metabolic factors 
(reviewed by Chan and Spencer, 1997). Certain IGFBPs can be post-translationally 
modified generating glycosylated, phosphorylated and proteolytically cleaved 
products, which can alter their biological role in the IGF axis (Jones et al., 1991; 
Drop et al., 1992; !washita et al., 1998; Neumann et al., 1998). 
IGFBPs play an important role in the biological actions of IGFs by regulating their 
availability to tissues. The 70 residue mature IGF-1 is associated in a 150 kDa higher 
molecular weight complex with IGFBP-3 and ALS (Baxter and Martin, 1989). This 
150 kDa complex is the predominant circulating protein complex, thus IGFBP-3 is 
the most abundant binding protein in serum and is responsible for the binding of up 
to 95% of the endocrine IGF-1. Like IGFBP-3, IGFBP-5 contains a basic C-terminal 
domain and has been shown to form a 130 kDa ternary complex with ALS and IGF-I 
(Twigg and Baxter, 1998). IGFBP-1, -2, -4, and possibly -5 and -6 each participates 
in the formation of a 40 kDa complex. IGFs bound to IGFBP-1, -2, -3 and -4 can 
cross the endothelium of capillary vessels, while the 150 kDa complex is unable to 
traverse membranes (Bar, 1990; Boes et al., 1992). In addition to transportation, 
when IGFs are bound with IGFBPs in complexes, the half-life of IGFs can be 
increased. The half-life of IGF-1 is up to 12 hours (h) when bound in the 150 kDa 
ternary complex, 30 minutes (min) when bound in the 40 kDa complex and 10 min 
when IGF-1 is uncomplexed, comparable to the half-life of insulin (Guier et 
al., 1989). 
At the cellular level, IGFBPs modulate the bioavailability of IGF-1 and -II by 
controlling their binding to cell surface receptors. IGF-1 mediated proliferation can 
be inhibited by the administration of specific IGFBPs to the culture medium of a 
range of cell lines (Ritvos et al., 1988; Ross et al., 1989; Mohan et al., 1989; LaTour 
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et al., 1990; Cohen et al., 1993; Babajko et al., 1997). IGFBPs prevent IGF-I 
binding to its cognate receptors and therefore inhibit IGF-I's growth promoting 
effects. IGFBPs can also potentiate the biological actions of IGFs (De Mellow and 
Baxter, 1988; Blum et al., 1989). The stimulatory effects are thought to be achieved 
by the binding of IGFBPs to the cell surface or extracellular matrix (ECM) therefore 
positioning the IGFs for ligand binding (De Mellow and Baxter, 1988; Bourner et 
al., 1992; Delhanty and Han, 1993), as well as the proteolysis of selected IGFBPs by 
specific proteases (Cohen et al., 1992; Fowlkes and Freemark, 1992; Fielder et al., 
1990). For example, the potentiating effects of IGFBP-3 are due to its association 
with the cell surface which in turn causes a partial proteolysis resulting in forms 
which have a lower affinity for IGFs, thus allowing for receptor binding (Conover, 
1991). 
Specific IGFBPs, in particular IGFBP-1, -3 and -5 have been shown to have intrinsic 
biological activities which are independent of the IGFs (Cohen eta!., 1993; Oh et 
al., 1993a; Jones et al., 1993). In BalbC/3T3 cells, the reduced proliferation of these 
cells by the expression of IGFBP-3 was overridden by the administration of insulin 
when the IGFBP-3 was exogenously expressed rather than endogenously expressed 
(Cohen et al., 1993). It was postulated that IGFBP-3 had biological effects 
independent of the IGFs, which has since been substantiated by Oh et al., (1993a). 
Oh et al., (1993b) and Andress, (1998) showed that the IGF independent biological 
effects of IGFBP-3 and -5 are mediated by cell surface receptors. It has since been 
shown that IGFBP-3 binds to the type V TGF-P receptor (Leal et al., 1997). 
IGFBP-1 to -6 have been isolated and characterised. A summary of their relevant 
features is presented in Table 1.1 (Rechler and Nissley, 1990; Shimasaki and Ling, 
1991; Krywicki and Yee, 1992; Bach and Rechler, 1995). The IGFBPs have a 
simple conserved structure made up of conserved cysteine rich N- and C-terminal 
domains, with the central domain unique to each IGFBP. TheN-terminal domains 
are thought to be responsible for ligand binding, while the C-terminal domains are 
thought to be important for protein/protein, cell surface or ECM interactions. 
IGFBP-1 and -2 have an arginine-glycine-aspartic acid (RGD) amino acid sequence, 
which enables these proteins to bind to integrin receptors on the cell surface. Each 
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Table 1.1- Characteristics of IGFBPs (Rechler and Nissley, 1990; Shimasaki and Ling,1991; Krywicki and Yee, 1992; Kelley et al., 1996). 
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human IGFBP contains 18 cysteines except for IGFBP-6 (16 cysteines); 12 in theN-
terminal domain and 6 in the C-terminal domain. IGFBP-4 possesses two additional 
cysteines in the central variable domain. Each IGFBP gene is comprised of 4 exons 
(IGFBP-3 has 5 exons) with a single mRNA transcribed from each gene to date 
(Rechler and Nissley, 1990; Shimasaki and Ling, 1991). 
More recently, additional IGFBP-like proteins with IGFBP amino acid sequence 
characteristics have been identified. These include IGFBP-7/mac-25, IGFBP-
8/connective tissue growth factor (CTGF), nov and cyr61 (Murphy et al., 1993; 
Swisshelm et al., 1995; Oh et al., 1996; Kim et al., 1997), which are now referred to 
as IGFBP-related proteins (IGFBP-rPs; Baxter et al., 1998). IGFBP-7 /mac-25 or 
IGFBP-rP1 has a 20-25% identity to the IGFBP family, possessing the common 
IGFBP N-terminal motif GCGCCXXC and 11 of the 12 conserved cysteine residues. 
However, IGFBP-rP1 binds IGF-1 and -II with a 5-6-fold and 20-25-fold lower 
affinity respectively, than IGFBP-3 (Oh et al., 1996). IGFBP-8/CTGF now referred 
to as IGFBP-rP2, IGFBP-rP3 (nov) and IGFBP-rP4 (cyr61) also possess the 
conserved IGFBP sequences in their N-terminus, with IGFBP-rP2, like IGFBP-rP1, 
binding IGFs with a low affinity (Kim et al., 1997). Quite recently, IGFBP-rP1 and 
the amino-terminus of IGFBP-3 were shown to bind insulin with high affinity and 
block its binding to the IR (Yamanaka et al., 1997). This suggests that IGFBP-rP 1 
may be an insulin binding protein, however the exact role of these IGFBP-rPs 
remains to be elucidated. 
1.5 How do IGF-1 and -II Elicit such Diverse 
Biological Actions? 
As discussed in the previous sections, a number of distinct mechanisms contribute to 
the diverse biological actions of IGF-1 and -11. These mechanisms occur via both 
extracellular and intracellular means, including the use of transmembrane receptors, 
distinct signal transduction pathways and regulation by IGFBPs. It is possible that 
the IGF function is determined at the level of the gene where altered transcription 
and post-transcriptional processing of IGF-1 and -11, may contribute to the diversity 
of their actions. This concept is the major focus of this doctoral study. 
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1.5.1 Multiple Promoter Usage 
Promoter function provides an important level of transcriptional regulation. The 
human IGF-1 gene, as in other mammalian species, contains two promoter regions 
that regulate the initiation of transcription. The promoter region P 1 located upstream 
of exon 1 generates class 1 transcripts, whilst P2 upstream of exon 2 generates class 
2 transcripts (Fig. 1.12; Jansen et al., 1991; 1992). Transient expression studies 
have shown positive promoter activity for expression vectors composed of DNA 
flanking sequences of human exon 1 (Kim eta!., 1991; Jansen et al., 1992), and 
ex on 2 (Jansen et a!., 1992). In the rat, ex on 1 lacks the characteristic upstream 
promoter elements such as a TATA or CCAAT box (Adamo eta!., 1991a; 1991b). 
P1 P2 > 65kb 
* 
> 15kb 
* * 
",f n I I ll I i ' i l ~ 'i~SJ ' 'l 
1 2 3 4 5 6 
I __ 7.6/7.4 kb 
I IJ 1.1/0.9 kb 
1.3/1.1 kb 
Figure 1.12 - The human 1GF-1 gene and the derived mRNAs. P 1 - P2 depict the /GF-1 
promoters. Exons are depicted as boxes and are numbered accordingly. Solid boxes are the coding 
regions, the open boxes are the non-coding regions and the grey boxes are the variable signal 
sequences. * indicate the polyadenylation signals. Messager RNAs derived from the human /GF-1 
gene are shown with the corresponding size in kb (Adapted from Rotwein, 1991 ). 
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However, it was found that rat exon 2 has these elements. Human IGF-I exhibits a 
similar pattern, although it has not been as extensively studied (Jansen et al., 1991). 
Nuclear factors responsible for PI promoter function are currently under 
investigation, and the initial 5' UTR of exon 1 is known to be important for activity 
of the P1 promoter (Mittanck et al., 1997). CCAAT/enhancer binding protein alpha 
(C/EBP alpha), liver-enriched activating protein (LAP) and hepatocyte nuclear factor 
1 alpha (HNF-1 alpha), have been shown to transactivate the IGF-I P 1 promoter at 
an overlapping site (Nolten et al., 1994; 1995). Despite the presence of both exon 1 
and 2 within normal tissues, P1 is the stronger promoter generating the major IGF-I 
transcripts of 7.6 kb, 1.3 kb and 1.1 kb. However, in abnormal cellular 
circumstances such as malignancy (Kim et al., 1994) and a range of transformed cell 
lines (reviewed by Jansen et al., 1992 and Steenbergh et al., 1993), P2 appears to be 
the more significant promoter generating the 7.4 kb, 0.9 kb and the 1.1 kb mRNAs. 
The mechanisms by which this occurs remain to be elucidated. 
The human IGF-II gene contains four distinct promoter regions that regulate the 
initiation of transcription. The P1 promoter region is located upstream of exon 1, 
whilst P2 is located upstream of exon 4, P3 is upstream of exon 5 and P4 is upstream 
of exon 6 (Fig. l.I3; De Pagter-Holthuizen et al., 1987; 1988; Holthuizen et al., 
I990). IGF-II is a key regulator of foetal development, with promoters P2, P3 and 
P4 active in a range of tissues generating the 5.0, 6.0 and 4.8 kb mRNAs 
respectively. During foetal development P3 is the most active promoter while PI is 
silent (Fig. 1.13; Jansen et al., 1987). In adults, P2, P3 and P4 are expressed weakly 
only in extrahepatic tissues, while PI is expressed by the liver to generate a 5.3 kb 
mRNA (De-Pagter Holthuizen et al., I987). Consensus sequences and peptides have 
been identified which are important for IGF-II promoter function. The P1 promoter 
is TATA-less but binds the transcription factors C/EBP, LAP and Sp1 which have 
been shown to have a stimulatory effect on transcription (Van Dijk et al., I992; 
Rodenburg et al., I997). The P3 promoter contains a TATA box and is regulated by 
the transacting factors krox20/egr2 and krox24/egr1 which activate promoter 
activity, while the Wilms' tumour locus zinc finger protein WT1 inhibits 
transcription from the P3 promoter (Drummond et al., 1992; Holthuizen et al., 
1993). 
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Figure 1.13 - The human IGF-ll gene and the derived mRNAs. PI - P4 depict the IGF-Il 
promoters. Exons are depicted as boxes and are numbered accordingly. Solid boxes are the coding 
regions, the open boxes are the non-coding regions. * indicate the polyadenylation signals. 
Messager RNAs derived from the IGF-II gene are shown with the corresponding size in kb. (Adapted 
from Rotwein, 1991 ). 
1.5.2 Multiple Transcription Start Sites 
Both exon 1 and 2 of human IGF-I gene have multiple transcription start sites which 
contribute to the array of IGF-I mRNAs transcribed from this gene. The exon 1 
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major start site generates a mRNA of approximately 240 bp of exon 1 with the 
remaining start sites generating mRNAs containing anywhere up to 1150 bp of exon 
1 (Jansen et al., 1991). The dominant start site is thought to be partially regulated by 
a region that shows a strong homology to an initiator sequence identified by Smale 
and Baltimore, (1989). Exon 2 contributes 70 bp of mRNAs from a major 
transcription start site, however multiple transcription start sites generate mRNAs of 
up to 750 bp of exon 2. 
1.5.3 Multiple Polyadenylation Sites 
Both human IGF-I and IGF-II 3' UTRs have multiple polyadenylation signals, which 
can yield mRNAs with differing 3'UTRs and, subsequently, transcripts of differing 
sizes (Lund et al., 1989). Human IGF-I exon 5 derived mRNAs, contain a single 
polyadenylation signal generating a 1.3 kb mRNA. While IGF-I exon 6 derived 
mRNAs are alternatively polyadenylated giving rise to 7.6 and 1.1 kb mRNAs (Fig. 
1.12). Exon 9 of human IGF-II possesses two polyadenylation signals which 
contribute to the diversity ofiGF-II mRNAs (Fig. 1.13). The use ofpolyadenylation 
signals remains to be extensively studied, however there appears to be a pattern of 
tissue specificity in preliminary studies. Liver has a preference for the smaller IGF-I 
mRNAs, with 30% of the total IGF-I mRNA being the 7.6 kb mRNA, while in other 
tissues, the high molecular weight transcripts dominate (Roberts et al., 1987; Lund et 
al., 1989). An examination of the sequence within the 7.6 kb transcripts have 
revealed the presence of multiple AUUUA motifs in both human (Steenbergh et al., 
1991) and rat mRNAs (Hepler et al., 1990; Hoyt et al., 1992). As a result these 
transcripts are degraded more rapidly and are subsequently less stable than the 
shorter transcripts (Hepler et al., 1990; Foyt et al., 1991; Thissen and Underwood, 
1992). 
1.5.4 Alternative Splicing 
The diversity of human IGF-I and -II transcription is further complicated by the 
mechanism of alternative splicing which generates variable mRNAs via regulatory 
mechanisms yet to be described. Alternative splicing generates five variations of 
IGF-I mRNAs (Fig.l.14), and the Ser-29 variant for IGF-II as described in Section 
1.4.3. At the 5' end of the human IGF-I gene, PI promoter generated transcripts 
undergo alternative splicing of their pre-mRNA removing exon 2 sequences, 
generating class 1 mRNAs. Class 2 mRNAs are the result ofP2 promoter usage. At 
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Figure 1.14 - Alternative splicing of the human JGF-1 gene. Prepro-domains and UTRs are 
boxed. Pre = signal peptide with B, C, A, D, E, Ea and Eb the functional peptide domains of 1GF-l. 
Exons are indicated in italics. The 5' and 3' UTRs are labelled. Arrows represent the 1GF-1 
mRNAs with the narrow lines the splicing opportunities. The five variant transcripts are shown. 
the 3' end of the IGF-I gene, exons 5 and 6 are spliced in a mutually exclusive 
fashion, resulting in either Ea or Eb mRNAs, respectively (Jansen et al., 1983; 
Rotwein, 1986). Exon 5 generates approximately 0.5 kb oftranscript and constitutes 
part ofthe 1.3 and 1.1 kb IGF-I mRNA. Exon 6 contributes about 6.7 kb ofmRNA 
to the to the 7.6 and 7.4 kb mRNAs, of which 6.5 kb of this is 3' UTR (Steenbergh et 
al., 1991). More recently an additional human mRNA has been identified, reflecting 
the rat Eb mRNA. The exon 4-5-6 mRNA, consists of 48 bp of exon 5 and the entire 
exon 6 (Chew et al., 1995). This mRNA has only been identified in the liver and 
HepG2 cells at levels equivalent to the expression ofEb mRNAs (Chew et al., 1995). 
Propeptide messages containing exon 5, exon 6 or exon 4-5-6, encode identical 
mature IGF-I peptides followed by distinct C-terminal E-domains; Eb, Ea and exon 
4-5-6 respectively. 
Rat and mice IGF-1 genes have been cloned and characterised and like human IGF-1 
consist of 6 exons (Bell et al., 1986; Shimatsu and Rotwein, 1987a; 1987b; Murphy 
et al., 1987a). Transcription of rat IGF-I generates five variable IGF-I mRNAs via 
two different promoters and alternative splicing. Exon 5 of rat IGF-I is a cassette 
exon encoding E-peptide sequence that can be spliced in or out via alternative 
splicing to produce Eb or Ea mRNAs respectively (Roberts et al., 1987). 
Alternatively, human IGF-I exons 5 and 6 are spliced in a mutually exclusive fashion 
resulting in Ea and Eb prohormones respectively (Rotwein, 1986). At the 5' end of 
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the IGF-I gene, both human and rat have two leader exons, 1 and 2. However, in 
addition to class 1 and 2 mRNAs, a class 1 del mRNA where 186 bp has been 
spliced out of exon 1 is generated by the rat IGF-I gene (Shimatsu and Rotwein, 
1987b ). The existence of the additional splicing in rat ex on 1 was confirmed by 
RNase Protection Assay (Foyt et al., 1991). Interestingly, this splicing pattern does 
not occur in human IGF-I, even though the splice sites are present. 
1.5.5 Endonucleolytic Cleavage of /GF-11 mRNAs 
In addition to the alternative splicing, the IGF-II pre-mRNA is also subjected to site-
specific endonucleolytic cleavage from the 3' end of ex on 9 to yield a 1.8 kb mRNA 
(Fig. 1.13; Meinsma et al., 1991). Two widely separated elements, named element I 
and element II, within the 1.8 kb mRNA were identified. These elements were 
shown to interact to form a stem-loop structure which was identified as being 
necessary for post-transcriptional cleavage of IGF-II mRNAs (Scheper et al., 1995). 
1.6 Expression of IGF-1 mRNAs 
Why IGF-I goes through such complicated mechanisms to generate the same mature 
protein is the current question of interest. Such a question has lead to extensive 
research examining the expression and regulation of IGF-I mRNAs in rodent model 
systems. D'Ercole et al., (1980) was the first to find IGF-I mRNAs expressed in 
multiple rodent tissues. Since these first reports, research from many investigators 
has revealed that IGF-I expression in both rat and human, is tissue specific, 
developmentally regulated and influenced by GH, insulin and other trophic factors. 
These factors have all been shown to influence IGF-I at the level of transcription. 
Liver expresses all the major mRNAs for IGF-I in both rat and human, and to date is 
the only source of the exon 4-5-6 mRNA (Chew et al., 1995). Class 1 mRNAs are 
ubiquitous, being predominant in all tissues, whereas class 2 mRNAs are only 
expressed in the liver, kidneys, stomach, lung, testes and ovaries in rat (Adamo et 
al., 1989; Shemer et al., 1992) and human (Jansen et al., 1991; Hernandez et al., 
1992). The highest levels of class 2 mRNAs can be seen in the liver, composing 
<20% of the total IGF-I mRNA (Lowe et al., 1987). Class 2 derived mRNAs also 
dominate over class 1 mRNAs in human IM-9 lymphocytes (Clayton et al., 1994). 
IGF-I mRNAs encoding Ea, constitute> 95% of the total IGF-I mRNAs in all tissues 
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except for the liver. In liver, mRNAs encoding Eb comprise about 10% of total IGF-
I mRNA (Lowe et al., 1988), while exon 4-5-6 mRNAs also constitute 10% (Chew 
et al., 1995). Consequently, IGF-I mRNAs with alternate leader sequences are 
differentially expressed in a tissue specific manner, with variations in the 3' mRNAs 
being differentially expressed in the liver when compared to the kidney, lung and 
heart. 
Studies by Hoyt et al., (1988) and Adamo et al., (1989) revealed that during rat post-
natal development, IGF-I increases were reflected by increases in IGF-I mRNA in 
the liver. Within extrahepatic tissues, the levels of IGF-I during development are 
high in the perinatal stages but decline until puberty (Hoyt et al., 1988; Adamo et 
al., 1989). Thus, it can be stated that the alternate 5' mRNAs of IGF-I are 
differentially expressed not only in a tissue specific fashion, but also 
developmentally. 
GH and insulin are the major regulators of IGF-I synthesis, with part of their control 
occurring at the level of transcription (Mathews et al., 1986; Roberts et al., 1986). 
An examination of the class 1 and 2 mRNAs in rat liver during development 
revealed that class 2 mRNAs are expressed simultaneously with GH, whereas class 1 
mRNAs appear prior to GH. This suggests that class 2 mRNAs are more GH-
sensitive. Lowe et al., (1987; 1988) used hypophysectomized rats treated with GH 
to examine the presence of the 5' and 3' mRNAs. In a host of tissues there was a 2-
or 3-fold induction of class 1 and Ea mRNAs in response to GH. However, only in 
the liver did class 2 and Eb mRNAs respond with a 7- to 8-fold induction, in 
response to GH treatment. In other tissues known to express class 2 mRNAs there 
was no significant response to GH treatment. In heart tissue GH induced a 3-fold 
response in Eb mRNAs. These studies support the proposal that liver-specific class 
2 and Eb-specific mRNAs are GH responsive, with the ubiquitous class 1 and Ea 
mRNAs being less sensitive to GH. LeRoith et al., (1993) proposed that because 
class 1 and Ea mRNAs are ubiquitous and potentially sensitive to factors other than 
GH, these mRNAs must encode the autocrine/paracrine forms of IGF-I. Conversely, 
since the class 2 and Eb mRNAs are responsive to GH and predominate in the liver, 
they must encode the endocrine, or circulating forms of IGF-I. 
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The major 5' variant mRNAs in extrahepatic tissues are the class 1 mRNAs, which 
show low responsiveness to GH (Lowe et al., 1987). Therefore, within these tissues 
the primary regulators must be factors other than GH (Murphy et al., 1987b; 
Hernandez et al., 1989). Estradiol and insulin have been shown to regulate the 
expression of IGF-I with control occurring at the level of transcription (Ernst and 
Rodan, 1991; Pao et al., 1992). AP-1-mediated transcriptional regulation of IGF-I 
upon tetradecanoyl 12, 13 phorbol acetate (TPA) stimulation in the chicken has been 
described (Kajimoto et al., 1993). Kikuchi et al., (1992) have shown that changes in 
chromatin occur with the developmental activation of IGF-I gene transcription. The 
effects of fasting, diabetes and dexamethasone treatment, established that the percent 
reductions between rat exon 1 or 2, or Ea and Eb mRNAs were coordinately altered 
(Hoyt et al., 1988; Adamo et al., 1988; 1989; Fagin et al. 1989; Lowe et al., 1989). 
Adamo et al., (1991b) proposed that coordinate changes in the mRNAs reflect the 
possibility that both promoters Pl and P2 share the same regulatory mechanisms. 
However, Zhang et al., (1997) have shown that liver derived Eb mRNAs decrease 
with fasting in the rat, while both pro-IGF-I Ea and pro-IGF-I Eb peptides decrease 
with fasting. This differential expression is also observed in a range of tissues 
(Adamo et al., 1989), during development (Adamo et al., 1988; 1991b), and with 
GH availability, (Lowe et al., 1987; 1988; Saunders et al., 1991; Foyt et al., 1992; 
Pell et al., 1993). These findings have led these authors to conclude that there are 
promoter-specific regulatory elements involved. 
An examination of IGF-I message in tumour tissue and cultured cell lines has 
revealed variable patterns of expression. For example, human colon carcinomas and 
liposarcomas were shown to express variations in size and abundance of IGF-I 
mRNAs, when compared to normal tissue (Tricoli et al., 1986). Studies in ovarian 
cancer revealed a dominance of class 1 mRNAs (Yee et al., 1991b), and 
neuroblastoma cell lines have been shown to utilise the P2 promoter preferentially 
over the P1 promoter (Jansen et al., 1992). Exon 2, which encodes class 2 mRNAs, 
was originally cloned from human breast cancer cells (Tobin et al., 1990). An 
examination of the variable IGF-I mRNAs in these cases compared to normal tissue, 
revealed another possible level of regulation for IGF-I during tumour proliferation 
and will be one of the areas of focus in the present doctoral study. 
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1. 7 Aims of the Doctoral Study 
During the different stages of development, IGFs have been associated with cellular 
growth and differentiation, as survival factors protecting cells from apoptosis as well 
as being mitogens in tumourigenic cells. In light of this, how is it that both IGF-I 
and -II achieve such diverse biological functions? Research has shown that IGFs are 
regulated by ligand/receptor interactions and subsequent post-receptor signalling. 
Ligand/receptor interactions are also regulated by a large family of IGFBPs and 
IGFBP-rps. Both IGF-I and -II transcribe multiple mRNAs by alternate promoter 
usage, multiple transcription start sites, multiple polyadenylation signals and 
alternative splicing. The studies covered in this PhD stem from the hypothesis that 
these variable mRNAs may represent another mechanism intrinsic in the regulation 
of the biological effects of IGF-I and -II. With this in mind, the specific aims of this 
thesis were to: 
• investigate the expression pattern of the multiple mRNAs of IGF-I and -II during 
cellular growth, differentiation and tumourigenesis, specifically class 1, class 2, 
Ea and Eb mRNAs as well as IGF-II and its alternatively spliced Ser-29 variant. 
• investigate the relationship of the IGF-I and -II mRNAs to other members of the 
IGF axis (IGF-IR and IGFBP-1 to -6) during cellular growth, differentiation and 
tumourigenesis. 
In order to achieve these aims the human neuroblastoma cell lines SK-N-MC and 
SK-N-SH were used to examine the expression of the IGF axis during cellular 
growth and differentiation. These cell lines were selected because SK-N-MC cells 
have previously be shown to express IGF-I mRNAs while SK-N-SH cells express 
IGF-II mRNAs but not IGF-I. The expression of the IGF axis in tumourigenesis 
was examined using a series of pathologically grouped breast tumours and normal 
breast tissue samples. The development and progression of breast carcinogenesis 
was chosen as a tumourigenesis model because both IGF-I and -II have been shown 
to be expressed by both normal and malignant breast tissues and are integral 
components for breast tissue etiology. 
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Chapter 2 
GENERAL MATERIAL AND METHODS 
2.1 Cell Culture 
2.1.1 Neuroblastoma Cell Lines 
The neuroblastoma cell lines SK-N-MC passage 42 (P42) and SK-N-SH passage 34 
(p 34), were obtained from the American Type Tissue Collection (ATTC; Rockville, 
MD, USA). The SK-N-MC cell line was isolated from a metastasis of the supra-
orbital area of a 14 year old girl. The cells are classified as primitive 
neuroectodermal tumour (PNET) cells as they originate from the primitive 
neuroectoderm (Dehner, 1986). Their karyotype indicate hypodiploidy to 
pseudodiploidy. The SK-N-SH cell line was established from a bone marrow 
aspirate of a thoracic catecholamine secreting neuroblastoma of a 4 year old girl 
(Biedler et al., 1973). The cells are near diploid and switch between a neuronal (N) 
and surface adherent (S) epithelioid phenotype (Ross et al., 1983). 
2.1.1.1 Culture Conditions 
Both SK-N-MC and SK-N-SH cell lines were grown in Eagle's minimum essential 
medium (MEM; Gibco BRL, Life Technologies, Grand Island, NY, USA) 
supplemented with 10% heat-inactivated foetal bovine serum (FBS; Commonwealth 
serum laboratory (CSL), Parkville, Victoria, Australia), in the presence of 50U/ml of 
penicillin G and 50!-Lg/ml of streptomycin sulphate (CSL), 1mM sodium pyruvate 
(Gibco BRL), 2.2g!L sodium bicarbonate (Gibco BRL) and 20mM glutamine 
(GlutaMax II; Gibco, BRL). The preparation of heat inactivated FBS is described in 
Section 2.1.1.1.1. Media was filter sterilised through a 0.22!-lm filter unit (Millipore 
Corporation, Bedford, MA, USA) and stored at 4°C for up to 2-3 weeks. Cell 
cultures were grown in a humidified incubator (Forma Scientific, Marietta, OH, 
USA) at 37°C with a 5% carbon dioxide (C02) atmosphere. 
2. 1.1.1.1 Buffers and Reagents 
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Heat-Inactivated FBS involved the heat treatment of FBS for 30min at 60°C to 
destroy complement activity. Following treatment, it was made into aliquots 
and stored at -20°C until required. 
2.1.2 CHO and CHO-K1 Transfected Cell Lines 
Wild type Chinese hamster ovary-K1 (CHO-K1) cells were obtained from ATCC. 
CHO-K1 cells were sub-cultured from a parental CHO cell line isolated from a 
biopsy of the ovary of an adult Chinese hamster (Puck et al., 1958). Their karyotype 
indicates hypodiploidy. Two stably transfected CHO-K1 cell lines expressing pro-
IGF-I Ea (11-1A) or pro-IGF-I Eb (21-IB), were generously provided by Dr. P-A 
Stahlbom (Queensland University of Technology, Brisbane, Qld, Australia). 
2.1.2.1 Culture Conditions 
Wild type CHO-K1 cells and the transfected lines were cultured in Ham's Fl2: 
Dulbecco's modified eagle's medium (1: 1; DMEM; Trace Biosciences, Sydney, 
NSW, Australia) supplemented with 10% heat inactivated FBS (Section 2.1.1.1.1) in 
the presence of 50U/ml of penicillin G, 50!lg/ml of streptomycin sulphate and 1.2g/L 
sodium bicarbonate at 3rc with a 5% C02 atmosphere. 
2.2 Cell Growth : SK-N-MC and SK-N-SH 
Cells were plated at either 4.0 x 106 or 1.0 x 107 cells per 150cm2 plate (Nalge Nunc 
International, Denmark) and grown over a seven day time course. For each 24h time 
point, a 150cm2 plate of cells was taken for a viable and dead cell count (refer to 
Section 2.2.1) and 4 (times) X 150cm2 plates of cells were taken for a total RNA 
extraction (refer to Section 2.5.1). The experimental procedure was performed as 
follows: 
a) SK-N-MC and SK-N-SH cells were progressively grown up into 3 X 225 cm2 
(Costar, Cambridge, MA, USA), flasks containing 30ml of culture medium to 
increase cell number for plating. 
b) At 70-80% confluency, cells were treated with trypsin-versene (CSL), pooled and 
concentrated into a final volume of 1 Oml of culture medium. 
c) A 1 I 100 dilution was made and taken for cell counting using a Neubauer 
haemocytometer as described in Section 2.2.1. Cell number/ml was established 
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and appropriate dilution's made so 4.0 x 106 or 1.0 x 107 cells were seeded per 
150cm2 plate, in a volume of 20ml of culture medium containing 10% FBS. 
d) Cells were allowed to plate for 24h upon which 1 plate designated "Day 1 " was 
taken for cell counting and 4 plates for total RNA extraction (Section 2.5.1 ). 
e) Step d was repeated for day 2-7. At day 5, substantial cell death of SK-N-MC 
cells was apparent, substantiated by a change in the pH of the media. Day 5 was 
designated the point to change to fresh culture media. 
2.2.1 Cell Counting 
The number of viable and dead cells was estimated using a dye exclusion method. 
The dye of choice was trypan-blue and the methodology as follows: 
a) Conditioned media were removed from the cells and collected in a 50ml tube. 
b) Cells were washed with 10ml sterile phosphate buffered saline (PBS; Oxoid Ltd., 
Hampshire, UK) and pooled together with the conditioned media. 
c) Trypsin-versene (2ml) was added to the cells and incubated at 37°C, 5% C02 for 
2-5min or until cells were lifting off the plastic. The cells were washed and 
recovered using the pooled conditioned media/PBS mix. This was done to ensure 
that all cells, floating and adherent, were included in the harvest. Plates were 
examined to ensure that 95-100% of cells was harvested. 
d) Harvested cells were centrifuged at 2000 revolutions per minute (rpm) for I Omin 
at room temperature (RT). The supernatant was discarded and the cells re-
suspended in 1ml PBS. 
e) Cell suspensions were diluted 1/ 20, 1/ 40 or 1/ 100, depending on the cell density, in 
0.4% trypan blue (Sigma Chemical Co., St. Louis, MO, USA) dissolved in PBS. 
f) Samples of 1 0~-tl were applied to the Neubauer haemocytometer, where viable and 
dead cell counts were determined and averaged from 10 squares over two separate 
chambers. Cells excluding trypan blue dye were classified as viable. Pale blue 
cells exhibiting a partial dye uptake with an enlarged morphology, were mitotic 
cells and were also classified as viable cells. Dark blue cells, which had failed to 
exclude trypan blue, were classified as dead cells. Cell counts were determined 
using the following formula: mean x dilution factor x 104 to give cell number/ml 
and hence the cell number/150cm2 plate. 
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2.3 Differentiation : SK-N-MC and SK-N-SH 
The experimental procedure to induce differentiation was performed as follows: 
a) Cells were prepared as per step a to c in Section 2.2 with 4.0 x 106 cells seeded 
per 150cm2 plate. 
b) Six plates of cells for each time point were allowed to plate for 24 - 48h after 
which 5 X 150cm2 plates of cells were washed twice with PBS at RT and 
replaced with SFM (SFM media was prepared as described in Section 2.1.1.1, 
however 10% heat inactivated FBS was not included). The remaining 1 X 
150cm2 plate of cells were also washed with PBS at RT but replaced with fresh 
culture medium containing 10% FBS. 
c) Following 24h SFM conditions, cells were harvested for a cell count as described 
in Section 2.2.1 and total RNA extraction (Section 2.5.1). 
d) This procedure was repeated for 48h and 72h time points. 
2.3. 1 Chromogenic Assay for Plasminogen Activator Activity 
In SK-N-SH cells, an increase in tissue-type plasminogen activator (t-PA) activity is 
representative of lack of terminal differentiation and an increase in cell invasion into 
reconstituted basement membrane (Tiberio et al., 1997). In the present study it was 
hypothesised that the cessation of growth and/or the initiation of differentiation, 
would result in a decrease of plasminogen activator activity in the neuroblastoma 
model systems. 
At 80-90% confluency, the SK-N-MC and SK-N-SH cells were harvested. The cells 
were plated at a density of 3.0 x 104 cells per cm2 into a 6 well plate (Nalge Nunc) 
containing 3ml of phenol red free culture medium (Gibco BRL) containing I 0% 
FBS. Cells were allowed to plate for 48h, after which each well was washed with 
sterile PBS. Time 0 was commenced with 3 of the 6 wells receiving phenol red free 
SFM and the remaining 3 wells receiving fresh phenol red free culture medium, 
containing 10% FBS. At 24, 48 and 72h, the media was collected, centrifuged at 
1000rpm for 5min at RT to remove cell debris, lyophilised and assayed for 
plasminogen activator activity, as described by Zhang et al., (1996). The 
methodology for the assay was as follows: 
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a) In a 96 well microtitre plate (Flow Laboratories, The Netherlands), 25~-tl of 
plasminogen (0.4U/ml; Sigma) was combined with 25~-tl of urokinase 
plasminogen activator (uPA) concentration standards (O.OlU-lU; Sigma), or 
with lyophilised conditioned phenol-red-free medium resuspended in 25~-tl of 
water. 
b) The reaction was incubated at 37°C in 5%C02 atmosphere for 90min. 
c) At the end of the incubation, 200~-tl of colour detection buffer was added to each 
reaction where the incubation at 37°C was continued until a yellow colour 
developed. 
d) The absorbance at 410nm (A410) was determined on a plate reader (Murex, 
Diagnostic Australia Pty. Ltd., North Ryde, NSW, Australia). 
2.3.1.1 Buffers and Reagents 
Phosphate Buffer was made with 42mM Na2HP04 (BDH, MERCK Pty. Ltd., 
Kilsyth, Victoria, Australia), 42mM K2HP04 (BDH) and 80mM KH2P04 
(BDH) in ddH20. The solution was autoclaved for lh at 15lb/in2. 
Phosphate-Tween-Gelatin (P-T -G) contained 1.25g gelatin (Sigma), 50~-tl of Tween 
20 (polyoxyethylene-sorbitan monoleate; Sigma) in 500ml of phosphate buffer, 
which was autoclaved for 1h at 15lb/in2and stored at 4°C. 
Plasminogen 0.4U/ml was prepared in P-T-G. 
DTNB contains 87.2mg of DTNB (5,4'-dithiobis-2-nitrobenzoic acid; Sigma) m 
1 Oml of 50mM Na2HP04 (BDH). 
ZLS contains 36.6mg of ZLS (thiobenzyl benzyloxycarbonyl-L-lysinate; Sigma) in 
5ml of acidified ddH20 (20ml of ddH20 with 2 drops of 1 OmM hydrochloric 
acid (HCl; Ajax Laboratory Supplies, Auburn, NSW, Australia), which is filter 
sterilised and stored at -20°C. 
Colour Detection Buffer was made just prior to use and contained 200~-tl DTNB, 
200~-tl ZLS, 9.6ml ddH20 and lOml of 2X assay buffer (0.4M NaCl, 0.4M 
Na2HP04, 0.2% Triton-X 100 in lL ddH20; autoclaved). 
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2.3.2 Morphological Examination for Apoptosis 
The withdrawal of 1 0% PBS is a known cause of apoptosis in a number of cell lines. 
To determine whether serum-withdrawal would induce apoptosis in either of the 
neuroblastoma cell lines, the following protocol was performed: 
a) Cells were plated into 6 X 150cm2 plates as described in Section 2.3. The cells 
were allowed to plate for 48h, upon which the culture medium was removed. 
The cells were washed with 1X PBS then three plates received serum-free 
medium while the other three received fresh culture medium. 
b) At 24, 48 and 72h, the media was collected from one serum-containing and one 
serum-free plate of cells and the cells were harvested. The cells were pooled 
with the culture medium and 1X PBS wash and spun at 1 OOOrpm for 15min. 
c) The media was discarded and the cells were resuspended in 500~-tl of neutral 
buffered formalin (NBF; BDH) and left to fix over night (0/N) at 4°C. 
d) Cells were spun at 1 OOOrpm for 1 Omin. The supernatant was discarded and the 
cells were resuspended in 500~-tl of analytical reagent (AR) grade alcohol for 
1min. 
e) Cells were spun at 1 OOOrpm for 1 Omin and the alcohol was carefully removed. A 
few drops of heated 3% agarose was added, mixed with the cells, given a quick 
pulse spin and allowed to set. 
f) Five to 6 drops ofNBF was added to the agarose blocks and left for lOmin. 
g) The formalin was removed and the blocks dislodged and cut in half. The agarose 
blocks were then placed into embedding baskets and stored in IX PBS until 
ready for embedding using the automatic processor. The embedding process was 
provided by Joseph Kahn, Histology Lab, QUT, Brisbane, Qld, Australia. 
h) Slides were examined for apoptotic bodies as described by Harmon, 1987. 
2.4 Breast Tissue Samples 
Breast tumours and normal breast tissue from reduction surgery were obtained post 
surgery from Dr. Colin M. Furnival (Wesley Breast Clinic) and Dr. Michael 
Lanigan, respectively. Tissues were immediately frozen in liquid nitrogen and stored 
at -70°C until required. Formaldehyde fixed and paraffin embedded tissue blocks 
were provided following histopathological examination through Michael Doyle 
(Sullivan and Nicolaides). 
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2.4.1 Histochemical Staining 
In order to verify the morphology of the normal breast tissue and tumour tissue 
samples and to establish the tumour/normal breast tissue boundaries, sections of the 
tissue were histochemically stained with Haematoxylin and Eosin (H&E) to visualise 
cell types using brightfield microscopy. The methodology was as follows: 
a) Tissue sections of 3-4!-lm sections were cut on a Spencer microtome 820 
(American Optical Corporation) using disposable microtome blades (Feather, 
LabTech). Sections were mounted on aminopropyltriethoxy-silane (APES; 
Sigma) coated slides (Section 2.4.1.1). 
b) Sections were de-waxed in 3 changes of xylene (BDH) and hydrated in graded 
alcohol's 3min each, followed by a rinse in dH20 for 3min. 
c) Staining was performed in Mayer's haematoxylin for 1-5min (Section 2.4.1.1 ), a 
progressive stain. 
d) Sections were rinsed in running dH20 for up to 5min, to blue the haematoxylin. 
One section was examined to ensure that the nuclei had stained blue and the 
surrounding tissue was clear. 
e) Sections were rinsed in 90% EtOH and stained in Eosin (Section 2.4.1.1) for 1-
5min, a stain for cytoplasmic material and connective tissue. 
f) The sections were quickly dipped in 90% EtOH, dipped in two changes of 100% 
EtOH and transferred straight into xylene for 2min then a second change of 
xylene. 
g) Slides were mounted with DEPEX resin (BDH), left to set over 0/N and viewed 
by light microscopy. 
2.4.1.1 Buffers and Reagents 
APES coating of slides, creates a charged surface from which tissue sections are 
difficult to remove. The slides were prepared as follows: 
a) Slides were washed and left to soak 0/N in detergent. Slides were rinsed 
3 X with tap H20 and 2 X with ddH20 and dried 0/N at 60°C. 
b) In the fume hood, 8ml of APES was combined with 400ml acetone 
(BDH). Slides were dipped in this solution for 2min and then rinsed 2 X 
in ddH20, dried 0/N at 60°C and aseptically repacked until required. 
Page 55 
Walker, 1998 
Mayer's Haematoxylin was prepared by dissolving 0.5g of haematoxylin, 25g potash 
alum and O.lg sodium iodate in ddH20 by standing 0/N at RT. To this 
solution 25g chloral hydrate was dissolved, then 0.5g citric acid and the entire 
solution boiled for 5min. The stain was filtered and stored at RT. This 
solution was kindly provided by Joseph Kahn, Histology Lab, QUT, Brisbane, 
Qld, Australia. 
Eosin Solution was made with 444ml 100% AR grade EtOH, 24ml ddH20, 60ml 1% 
aqueous Eosin Y, 1.5ml 1% aqueous phloxine and 2.4ml acetic acid. This 
solution was kindly provided by Joseph Kahn, Histology Lab, QUT, Qld, 
Brisbane, Australia. 
2.5 Extraction of Nucleic Acids 
2.5.1 Total RNA Extraction 
Total cellular RNA was extracted from frozen tissue and cells grown in culture using 
the acid guanidinium thiocyanate (GTC)/phenol chloroform method of Chomczynski 
and Sacchi, (1987), with some modifications as follows: 
a) Frozen tissues of approximately 0.1g were fractured on dry ice, followed 
immediately by homogenisation for 2min in 1ml solution D (Section 2.5.1.1) 
using a polytron (P-3000, Kinematica AG, Switzerland) set to operate at 18000-
20000rpm. Samples were stored at -70°C for further processing. 
b) For cells grown in culture, the 150cm2 plates were placed on ice, the medium 
discarded and 4ml of solution D applied. Solution D was left on the cells for 
1 min, the cells harvested using a cell scraper (Starstedt Australia, Ingle Farm, 
SA, Australia) and transferred to the next plate of the same treatment. This 
procedure was continued until all plates had been harvested. The pooled cell 
suspension was transferred to a 50ml tube and homogenised as described in step 
a. 
c) To the homogenised samples, lOOf..Ll 2M sodium acetate pH 4.0 (NaAc; Ajax), 
200f..Ll of chloroform (BDH) I isoamylalcohol (BDH; 49: 1) and lml of DEPC 
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(diethyl pyrocarbonate)-ddH20 saturated phenol (Gibco BRL) were combined, 
mixed vigorously for 10sec and left to separate on ice for 15min. 
d) Samples were centrifuged at 10000 x gravity (g) for 20min at 4°C to complete 
separation. 
e) The aqueous phase was removed and re-centrifuged at 2000rpm for 1 Omin at 4 °C 
to remove any carry over from the inversion layer. 
f) The supernatant was collected and precipitated with an equal volume of 100% 
AR grade EtOH stored at -20°C. Samples were left at -20°C for lh and 
centrifuged as described in step d. 
g) Each pellet was recovered and re-suspended in 100)11 solution D. Samples were 
re-precipitated with 250)11 of -20°C 100% AR grade EtOH and incubated for 
30min at -20°C. 
h) Samples were centrifuged at 14000rpm for 25min at 4°C. Pellets were re-
suspended in sterile 100)11 1M ammonium acetate (NH4Ac; BDH) and 
precipitated as described in step g. 
i) Precipitation steps were performed 3-5 times to remove GTC, an RNase 
inhibitor, from the RNA pellets. Following the last precipitation, RNA pellets 
were washed in -20°C 75% AR grade EtOH, centrifuged at 14000rpm for lOmin 
at 4°C. Resulting RNA pellets were air dried and re-suspended in 100)11 DEPC-
ddH20 (Section 2.5.1.1). 
j) The concentration of RNA was determined from A260 reading. RNA purity was 
determined using an A26ot280 ratio with an acceptable range of 1.7-2.0. The 
presence of the RN ase inhibitor GTC, was determined by an A2601230 ratio, with 
the acceptable values > 2. If the A2601230 ratio were < 2, RNA samples were re-
preci pi tate d. 
2.5.1.1 Buffers and Reagents 
Solution D contained 4M GTC (Sigma), 0.5% N-lauryl sarcosine (Sigma), 25mM 
sodium citrate pH 7.0 (BDH) and O.lM ~-mercaptoethanol (BDH). Solution D 
was prepared by combining the components described, without the O.lM ~­
mercaptoethanol. Once the GTC was dissolved, the solution was filtered 
through a 0.45)-lm filter unit (Millipore) and the O.lM ~-mercaptoethanol was 
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incorporated. Without the O.lM ~-mercaptoethanol, the solution is stable for 4 
months at RT, with O.lM ~-mercaptoethanol included, 1 month at RT. 
DEPC-ddH20 contained 0.1% DEPC (BDH) combined with ddH20, vigorously 
shaken and left to sit 0/N in a fume hood with a loosened cap. Solutions were 
autoclaved 2 X 60min at 15lb/in2 or until the odour was gone. 
2.5.1.2 Denaturing Gel Electrophoresis 
To establish the integrity of the RNA extracted from tissue and cultured cells and to 
verify the concentration determined by spectrophotometry, 2j.lg of total RNA from 
each sample was analysed by denaturing gel electrophoresis, along with 2j.lg of RNA 
marker (Promega, Madison, WI, USA). The methodology was as follows: 
a) A 200ml volume of gel was prepared, using 4g agarose LE (low 
electroendosmosis; AGP Technologies, Mt. Gravatt, Qld, Australia), with 20ml 
lOX MOPS (Section 2.5.1.2.1) and 176ml DEPC-ddH20 (Section 2.5.1.1). The 
solution was heated by microwave until the agarose powder dissolved, and 
cooled to 60°C. In a fume hood 4ml formaldehyde (FSE, Homebush, NSW, 
Australia) and lj.ll 10mg/ml ethidium bromide (EtBr; ICN Biomedicals Inc., 
Aurora, OH, USA) were added. The gel was cast and left to set in an apparatus 
that had previously been soaked in 4% HCl and rinsed with DEPC-ddH20 and 
100% EtOH. 
b) RNA (2j.lg) and RNA marker (2j.lg), were made up to a volume of 4.5j.ll with 
DEPC-ddH20. To this lj.ll lOX MOPS, 3.5j.ll formaldehyde and lOj.ll AR grade 
formamide (BDH) were added. The samples were heated to 60°C for 5min and 
quenched on ice. 
c) RNA loading buffer (2j.ll) was added to each sample, gels were loaded and run in 
a running buffer of 1X MOPS at 100volts (V) or 30V 0/N. 
d) Gels were exposed to ultra violet light (UV) and photographed usmg 
Photometries cooled CCD video camera (Fuji Photo Film Co., Ltd., Tokyo, 
Japan). 
2.5.1.2.1 Buffers and Reagents 
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lOX MOPS contained 200mM MOPS (3-(N-morpholino)propane-sulphonic acid; 
Boehringer, Mannheim, Germany), 1 OmM EDT A ( ethylenediamininetetra-
acetic-acid di-sodium salt; Ajax) and 50mM NaAc adjusted to pH 7 .0. 
RNA Loading Buffer contained 50% glycerol (BPH), lmM EDTA and 0.4% 
bromophenol blue (BPB; Bio-Rad Laboratories, Hercules, CA, USA). 
2.5.2 Genomic DNA (gDNA) Extraction 
The isolation of human genomic deoxyribonucleic acid (gDNA) from blood was 
performed by Dr. Juanita Garcfa-Arag6n as follows: 
a) A 500f..Ll aliquot of blood was mixed with 5ml Tris-EDTA (TE). 
b) Tubes were spun at 13000 x g for 1 Osee and the supernatant discarded. 
c) Cells were vortexed in 5ml TE. 
d) Steps band c were repeated twice more. 
e) Pellets were re-suspended in 100111 proteinase K buffer and incubated 56°C for 
45min to digest the red blood cells. 
f) Samples were inactivated by incubating at 95°C. 
g) 5f..Ll of sample was taken for polymerase chain reactions (PCR; 2.8.13) 
2.5.2.1 Buffers and Reagents 
TE was prepared by combining lOmM Tris-Cl pH 8.0 with lmM EDTA pH 8.0. 
PK Buffer contained 50mM potassium chloride (KCL; BDH), 10-20mM Tris-Cl, 
2.5mM magnesium chloride pH 8.3 (MgCh; BDH), 0.5% Tween 20 and 
100f.1g/ml of fresh proteinase K (PK; Boehringer). 
2.6 Reverse Transcription (RT) 
To amplify mRNA by PCR for expression vector construction and expression 
studies it was necessary to perform reverse transcription, which synthesises from 
mRNA first strand eDNA providing a template for PCR amplification. The 
methodology was as follows: 
a) RNA samples (2.5f.1g) were combined with 0.5f.1g of oligo d(T) 18 primer and 
made up to an ll.5f..Ll volume with ddH20. To remove secondary structures, the 
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samples were heated to 70°C for 1 Omin and then quenched on ice. 
b) To each sample a 1X final concentration of optimised RT buffer (Boehringer), 
O.OlM DTT (Promega), 20U RNasin (Boehringer) and 0.5mM deoxy nucleotide 
triphosphates (dNTPs) were added. Samples were incubated at RT for 10min, 
with a second incubation at 42°C for 1 Omin. 
c) AMV RT (20U) were added to each sample and incubated at 42°C for 60min. 
d) The reactions were stopped with incubation at 70°C for 1 Omin. 
2.6.1 Polymerase Chain Reaction (PCR) 
Human eDNA fragments were amplified from either RT reactions (Section 2.6) or 
linearised plasmids using PCR technology. The PCR reactions consisted of 1 OOflM 
of a 5' primer and 100flM of a 3' primer complementary to the gene of interest, a 
template, 10mM dNTPs and 0.5U Taq Polymerase (Boehringer). The cycling 
conditions and concentrations required for each PCR reaction are described in the 
appropriate Sections. All PCR components were obtained from Perkin Elmer. 
2. 7 Construction of Expression Vectors 
In order to quantify and localise mRNA synthesis for IGF-I and the remaining 
members of the IGF family, expression vectors for IGF-1, -II, the IGF-IR, IGFBP-1 
to -6 and the "house keeper" 18S rRNA, were constructed. These expression vectors 
were designed to enable the generation of radioactively labelled or unlabelled 
antisense RNA, also known as complementary RNA (cRNA), or sense RNA probes. 
Antisense RNA probes were used to detect the mRNA of interest and the sense RNA 
probes were used as controls in both the quantitative RNase Protection Assay (RPA) 
analysis and the qualitative in situ hybridisation histochemical analyses. 
The various cDNAs of the IGF family needed for construction of expression vectors, 
were obtained as gifts, through ATCC, or were generated via PCR. These cDNAs 
were cloned directly into pBluescript II SK + (Stratagene, La Jolla, CA, USA) or 
pGEM-T (Promega) expression vectors. The pBluescript II SK + is an expression 
vector that possesses the promoter for T3 and T7 RNA polymerases on either side of 
the multiple cloning site (MCS), along with an ampicillin (amp) resistance gene. 
The pGEM-T expression vector possesses the T7 and SP6 promoter sites and an amp 
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resistance gene. The methodology for the preparation of the expression vectors used 
to generate both sense and antisense RNA probes, is described in the following 
Sections. 
2.7.1 Vector and Insert Preparation 
Vectors and inserts were prepared for ligation. The vector pGEM-T required no 
preparation as it utilises the thymidine (T) incorporated on the ends of PCR products 
by Taq polymerase for cloning. The pBluescript II SK+ vector was linearised by 
restriction enzyme digestion. The various IGF and the 18S rRNA inserts, were 
prepared either by PCR (Section 2.6.1) or restriction enzyme digestion. 
2.7.1.1 Restriction Enzyme Digestion 
a) Both vectors and inserts were digested with 10-50U of the appropriate restriction 
enzyme in IX final concentration of the accompanying enzyme buffer, at 37°C 
for 2h. 
b) The pBluescript II SK+ vectors digested with a single enzyme were treated with 
0.1 U of calf intestinal alkaline phosphatase (Pharmacia) at 37°C for 30min to 
prevent religation. 
c) The total sample volume was run on a 1 - 1.5% low melting point (LMP) agarose 
gel, made as described in Section 2.7.4.1, except the LMP gels were run at 70 -
lOOV and at 4°C. 
d) The concentration of the expected fragments were estimated and excised under 
minimal exposures to UV light (as UV nicks DNA). Gel slices were melted at 
65°C in 5 X the total volume of gel elution buffer (20mM Tris-Cl pH 8.0, 1mM 
EDTApH 8.0). 
e) Samples were extracted with 200f.ll with a 1: 1 solution of Tris-saturated phenol 
(Section 2.7 .1.1.1; Fisons, Lough borough, UK)/ chloroform and centrifuged at 
14000rpm for 5min at RT. 
f) The aqueous layer was treated as in step e, but with 200f.ll of chloroform. 
g) The aqueous layer was precipitated at -20°C for 30min with a 1/ 10 volume 5M 
NH4Ac and 2 Yz volume of -20°C 100% AR EtOH. 
h) Samples were centrifuged at 4°C 14000rpm for 25min. 
i) The pellets were washed with -20°C 70% AR EtOH and centrifuged as in step e 
for IOmin. 
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j) Samples were re-suspended in 10-50!11 of autoclaved ddH20. 
k) One microlitre of sample was run on a 1% agarose gel (Section 2.7.4.1) along 
with a molecular weight (MW) marker to ensure a successful isolation, and to 
estimate the concentration (!lgl!ll) of prospective vectors and inserts for ligation. 
2.7.1.1.1 Buffers and Reagents 
Tris Saturated Phenol was prepared by dissolving 500g of phenol and 0.7g 8-
hydroxyquinoline in 200ml ddH20. To pH the phenol to 7.8, an equal volume 
of 0.1M Tris-Cl pH 8.0 was combined with the phenol. The phases were 
mixed and allowed to separate with the aqueous phase removed and replaced. 
These steps were repeated until the aqueous layer was pH 7.8. The phenol was 
made into aliquots and stored at -20°C or 4°C for 1 month. 
2.7.2 Ligation 
The molar quantity of vectors and inserts was calculated and each ligation reaction 
was set up in a 1: 1, 1:3 and 1:10 vector to insert molar ratio. The volumes required 
were determined and heated to 65°C for 20min prior to ligation to reduce secondary 
structure. To this, a 1X final concentration of optimised ligase buffer (Promega), 
ddH20 and 3U of ligase (Promega) were mixed in a final volume of 30!11. A 10111 
sample was removed from each ligation mix and labelled "pre-ligation". Ligation 
reactions were then incubated 0/N at 16°C for pGEM-T reactions, or 0/N at RT for 
pBluescript IT SK+ reactions. Another 10111 sample was removed from each ligation 
mix and labelled "post-ligation". Samples were run on a 1% agarose gel, as 
described in Section 2.7 .4.1, to establish the success of the ligation. 
2.7.3 Transformation of Bacteria 
E. Coli cells (DH5a strain) were made electro-competent for transformation, as 
follows: 
a) One litre ofLuriaBertani (LB; Section 2.7.3.1) broth was inoculated with 1/ 100 of 
an 0/N culture of DH5a cells. 
b) Cells were grown in an incubator at 37°C shaking at 300rpm, until an appropriate 
cell density was reached (optical density600 [OD6oo] = 0.5 to 0.8). 
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c) Cells were then chilled on ice for 15-30min and centrifuged at 4000 x g for 
15min at 4°C. 
d) Cells were re-suspended in 1L of cold autoclaved ddH20 and centrifuged as in 
step c. 
e) Pellets were re-suspended in 0.5L of cold autoclaved ddH20 and centrifuged as 
in step c. 
f) Cells were re-suspended in 20ml of 10% glycerol and centrifuged as in step c. 
g) Pellets were re-suspended in 2-3ml of 10% glycerol. At this stage the cell 
density was expected to be approximately 3 x 1010 cells/mi. 
h) Cells were made into aliquots of 40~1, frozen in liquid nitrogen and stored at -
70°C. These cells were electro-competent for up to 6 months. 
The competent cells were transformed with 2~1 of ligation reaction as follows: 
a) The 40~1 aliquots of electro-competent cells were thawed on ice and 2~1 of 
ligation reaction was added and gently combined. 
b) The cell/ligation mix was transferred to a Gene Pulser/E.Coli Pulser cuvette 
(Bio-Rad) and electroporated with 2.5kV using a Gene Pulser (Bio-Rad) set to 
25~F and 2000. 
c) The cells were immediately re-suspended in 1ml SOC solution (lg bacto-
tryptone, 0.25g bacto-yeast extract, 0.025gm NaCl, 20mM D-glucose), 
transferred to a 15ml round bottom polycarbonate tube (Starstedt) and incubated 
at 37°C shaking at 200rpm for 1h, to allow the E. Coli cells to undergo two 
rounds of selection. 
d) Agar plates (Section 2.7.3.1) were covered with 100~1 of amp (25mg/ml) and 
50~1 of 5-Bromo-4-chloro-3-indolyl ~-D-galactopyranoside (X-Gal; Sigma) I 
isopropylthio-~-D-galactoside (IPTG; Sigma) solution (Section 2.7.3.1). 
e) A 1 00~1 of the transformed cell suspension from each sample was spread onto 
each prepared agar plate and incubated 0/N at 37°C. 
f) The remaining 900~1 of transformed cells were pelleted at 1500rpm, re-
suspended in 100~1 LB (Section 2.7.3.1) and plated as in step e. 
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g) White colonies were the first sign of a successfully transformed plasmid with a 
ligated insert 1. These were picked and cultured in 5ml LB containing 20~1 amp 
(lOOmg/ml) while shaking at 200rpm ON at 37°C. 
h) Miniplasmid extractions were performed as per Section 2.7.4, digested with the 
appropriate enzymes (Step a Section 2. 7 .1.1) and analysed by gel electrophoresis 
for identification (Section 2.7.4.1). 
2.7.3.1 Buffers and Reagents 
LB Medium was prepared with lOg bacto-tryptone (Oxoid), 5g bacto-yeast extract 
(Oxoid) and lOg sodium chloride (NaCI; Ajax) in 950ml ddH20. The solution 
was stirred until dissolved, adjusted to pH 7.0 with 5M NaOH and the volume 
adjusted to lL. The medium was autoclaved for lh at 15lb/in2. 
Agar Plates were prepared by making IL LB broth to which 15g of Bacto-Agar 
(Oxoid) was added. The agar solution was autoclaved at 15lb/in2 for lh, 
allowed to cool to 50°C and then poured into sterile 92mm plates. 
X-Gal/IPTG was prepared by combining 0.04g X-Gal and 0.0116g IPTG in 2ml of 
formamide. 
2.7.4 Miniplasmid Extraction 
This is a crude yet rapid technique using acid/alkali to extract plasmid DNA from 
Eschericia Coli (E.Coli) strain DH5a. This technique was used during the 
preparation of constructs, to assess transformations and to provide plasmid DNA 
templates for plasmid linearisations. The methodology for miniplasmid extraction 
was as follows: 
a) (LB; Section 2.7.3.1) containing IOO~g/ml ampicillin (Boehringer) grown 0/N. 
b) 2ml of the 0/N cultures were pelleted by centrifugation for 5min at 3000 rpm. 
The supernatant was discarded and the cells re-suspended in 200~1 of lysis buffer 
(50rnM D-glucose (BDH), 25rnM Tris-Cl pH 8.0, lOmM EDTA), a buffer used 
1 In the presence of X-gal/IPTG, the plasmids that do not contain any inserts produce blue bacterial 
colonies. However, if the plasmids contain inserted DNA in the MCS, transcription of the Lac-Z gene 
is interrupted and a white colony will be produced. 
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to permeabolise the cells. 
c) Cells were lysed with 200111 of sodium dodecyl sulfate (SDS; Bio-Rad)/sodium 
hydroxide (NaOH; BDH) buffer (0.5% SDS, 0.2M NaOH). 
d) Proteins and cell debris were precipitated with the addition of 150!11 of 3M 
NH4Ac pH 4.7. To assist in the separation, 150!11 of chloroform were added and 
the samples were centrifuged at 14000rpm for 5min. 
e) The pellet was removed and 1ml of 100% AR grade EtOH at RT was combined 
with the supernatant to precipitate the nucleic acids. 
f) Samples were centrifuged at 14000rpm for 5min, the supernatant discarded and 
the pellet washed with 100111 70% AR grade EtOH at RT. 
g) Samples were re-centrifuged at 14000rpm for 5min at RT, the supernatant 
discarded and the pellets left to air dry for 15min. 
h) The final pellets were re-suspended in 50!11 of autoclaved ddH20, ready for 
restriction enzyme digestion or sequencing. 
2.7.4.1 Gel Electrophoresis 
The methodology was as follows: 
a) A 1% w/v solution of agarose was prepared in a IX concentration of Tris-acetate 
EDTA (TAE; Section 2.7.4.1.1) buffer. The solution was heated by microwave 
to dissolve the agarose, cooled to 60°C and 1111 of EtBr (lOmg/ml) combined. 
The gel was cast and allowed to set. 
b) Samples were prepared 1/ 6 with 6X loading dye (Section 2.7.4.1.1), loaded along 
with 200ng <j>X-174 Haeiii MW marker (Boehringer) and run in IX TAE buffer 
at 300V. 
c) Gels were photographed under UV using Photometries cooled CCD video 
camera. 
2. 7.4. 1.1 Buffers and Reagents 
SOX TAE Buffer was prepared by combining 242g Tris-base, 57.lml of glacial 
acetic acid, lOOml 0.5M EDTA pH 8.0 in 1L ddH20. 
6X Loading Dye was prepared from two solutions designated A and B stored at RT. 
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2.7.5 
a) Solution A contains 50% glycerol (BDH), 0.25% BPB, 0.25% xylene 
cyanol (XC; BDH). 
b) Solution B contains 5% SDS and 50mM EDTA. 
c) As required, A and B were mixed 1: 1 and added to the sample in a 1 X 
final concentration. 
Sequencing 
Sequencing was performed to confirm the identity of the eDNA ligated into the 
designated expression vectors, to establish the orientation of the insert and to detect 
any sequence variations that may have been introduced by PCR. It is important to 
identify any sequence variations, because they may provide cleavage sites for RNase 
during the RNase digestion step in the RPA analysis (Section 2.10). The sequencing 
methodologies used are as follows: 
2.7.5.1 Manual Sequencing 
Manual sequencing was performed as per the manufacturer instructions for the 
Sequenase Version 2.0 T7 DNA Polymerase Kit (United States Biochemical (USB), 
Cleveland, OH, USA). The protocol was as follows: 
a) For each plasmid sample, 0.5-1 pmol of template was combined with 0.5pmol of 
universal primer and 2~1 of 5X optimised sequenase buffer in a total volume 
b) Samples were incubated at 65°C for 2min and cooled to RT over a 30min period. 
c) To the annealed template/primer samples, 5~1 of labelling mix was added (0.1M 
DTT, 2~1 labelling nucleotide mix, 5~Ci [a35S] dATP [Bresatec]). To this, 
3.25U of a 1:8 dilution of sequenase was added and incubated at RT for 2-Smin. 
d) In four separate tubes, 2.5~1 of dideoxy termination mix (ddGTP, ddCTP, 
ddATP or ddTTP) were aliquoted and incubated to 37°C. To each tube, 3.5M-l of 
labelling mix was added and incubated for 2-Smin at 37°C. The reactions were 
stopped with 4~1 of termination reaction and stored at -20°C until run on a 8M 
urea, 5% denaturing gel as described in Section 2.10.1. 
2.7.5.2 Automated Sequencing 
Double stranded DNA plasmid (0.3-0.S~g) was combined with 0.8pm of single 
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stranded universal primer in a final volume of 12J.1l. Automated sequencing was 
performed by Cynthia Cooper using ABI Prism ™ dye terminator cycle sequencing 
ready reaction kit (Perkin Elmer, Norwalk, CT, USA) on a 373A DNA sequencer 
(Applied Biosystems (ABI), Perkin Elmer). 
2.8 Expression Vectors 
The design and methodology used to create each expression vector used in this 
doctoral study are as follows: 
2.8.1 IGF-1 Multiple mRNA Construct (pGW21) 
As described the overall aim of this thesis was to analyse the expression of the 
variable IGF-I mRNAs in relation to cellular growth, differentiation and 
tumourigenesis. To address this major aim, an IGF-I expression vector "IGF-I 
multiple mRNA construct," was designed enabling the detection and comparison of 
the variable mRNAs within the same sample, via RPA analysis (Section 3.3.1). An 
853 bp human eDNA clone encompassing a portion of exon 1 that encodes the 5' 
UTR and the very 5' aa of the signal peptide, as well as the exons encoding the B, C, 
A, D, E common, the Eb domains and a portion of the 3'UTR of IGF-I, was obtained 
from Dr Peter Rotwein (Oregon Health Sciences University, Portland, OR, USA; 
Rotwein, 1986). A 698 bp EcoRI and Pstl fragment of this clone was subcloned into 
pBluescript II SK + vector (Fig. 2.1 ), as described in Section 2. 7. 
Exon5 
Eb 
.............. _ 
------------698 bp ~~~~~ 
EcoRI Pstl 
Figure 2.1 ·Diagrammatic representation of the "IGF-1 multiple mRNA construct" (pGW21). The 
698 bp insert is shown, matched to the peptide domains (boxes), UTR (shaded boxes) and exons 
(italics). The cloning sites are shown, the bold dotted lines represent the MCS, and the ellipses the 
location of the RNA polymerase promoters. 
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2.8.2 Mature IGF-1 Construct (pGW44, pGW45) 
To examine the cellular sites of IGF-I synthesis using in situ hybridisation 
histochemistry, a "Mature IGF-I" probe was designed to collectively localise the 
variable precursor IGF-I mRNAs. The decision to collectively localise IGF-I 
expression was made based on the low expression of IGF-I in most tissues and to 
provide a baseline for IGF-I mRNA specific RNA probes. A probe design 
recognising homologous sequence from the four major mRNAs, was anticipated to 
improve the sensitivity of this assay. 
A human eDNA fragment of 408 bp was amplified using PCR (Section 2.6.1), which 
incorporated 383 bp of mature IGF-I, with EcoRI and Ncol restriction enzyme sites 
shown in lowercase in the primer sequence (Fig. 2.2). The PCR reaction consisted 
of lOO~M 5' primer (atatgaattccATGGGAAAAATCAGCATGC) and lOOJ.!M 3' 
primer (GTTCGGACGGTTCAGTCGATAGccatggtcgactta) provided by Dr P-A 
Stahlbom, combined with lJ.lg of linearised pGW21 IGF-I plasmid (Section 2.8.1 ), 
10mM dNTPs and 0.5U Taq Polymerase (Boehringer). The cycling conditions were 
1 X [94°C, 4.5min]; 11 X [94°C, 45sec; 57°C, lmin; 72°C, lmin]; 1 X [72°C, 7min]. 
The PCR fragment was cloned directly into pGEM-T vector, utilising the T addition 
provided by Taq Polymerase 
EcoRI Not I 
Figure 2.2 - Diagrammatic representation of the "Mature JGF-1 construct" (pGW44, pGW45). 
The 383 bp of the 408 bp insert is shown, matched to the peptide domains (boxes) and exons (italics). 
Restriction enzyme sites introduced by the primers are shown, the bold dotted lines represent the 
MCS, and the ellipses, the location of the RNA polymerase promoters. 
2.8.3 IGF-1 Ea Expression Vector (pGW19, pGW20) 
To examine the cellular sites of synthesis for mRNAs encoding the Ea domain of 
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IGF-I, an expression vector incorporating 254 bp of exon 6, was constructed (Fig. 
2.3). The design of the probe was such that it could be utilised for in situ 
hybridisation histochemistry or in situ PCR. The 853 bp human eDNA clone 
obtained from Dr Peter Rotwein (Rotwein, 1986; described in Section 2.8.1), was 
digested with BamHI to remove the sequence from the 5' end up to the BamHI site 
within the Ea domain. The remaining fragment containing the Ea domain was re-
ligated as described in Section 2. 7 .2. 
"--cw-- .-Ex_.__on_6_E_a_a_n_d_3-'U_T_R-----. -~rip! II SK+ 
Bam HI EcoRI 
Figure 2.3 -Diagrammatic representation of the "Ea construct" (pGWJ9, pGW20). The 254 bp 
insert is shown, matched to the peptide domain (box) and exons (italics). The cloning sites are 
shown, the bold dotted lines represent the MCS, and the ellipses the location of the RNA polymerase 
promoters. 
2.8.4 IGF-1 Eb Expression Vector (pGW23, pGW24) 
To examine the cellular sites of synthesis for mRNAs encoding the Eb domain of 
IGF-I, an expression vector incorporating 460 bp of exon 5, was constructed (Fig. 
2.4). The 853 bp human eDNA clone obtained from Dr Peter Rotwein (Rotwein, 
pBiuescript II SK + 
\ _ Exon 5 
'--GD-- Eb -~ 
,____ ,~ 
-------460 bp.~~~~~~~ 
Pstl EcoRI 
Figure 2.4 -Diagrammatic representation of the "Eb construct" (pGW23, pGW24). The 460 bp 
insert is shown, matched to the peptide domain (box), numeric position and exons (italics). The 
cloning sites are shown, the bold dotted lines represent the MCS and the ellipses represent the 
location of the RNA polymerase promoters. 
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1986; described in Section 2.8.1) was digested with Pstl to remove the sequence 
from the 5' end up to the Pstl site within the Eb domain. The remaining fragment 
containing the Eb domain was re-ligated, as described in Section 2.7.2. 
2.8.5 IGF-11 Expression Vector (pGW42) 
An IGF-II expression vector was designed to detect and distinguish the multiple 
IGF-II mRNAs from the Ser-29 counterpart (IGF-II mRNA lacking Ser-29) 
generated by alternative splicing. A eDNA encoding the human prepro-IGF-II was 
obtained from Dr Holgar Luthman (Karolinska Institution, Stockholm, Sweden; Bell 
et al., 1984), which included the 5'UTR, the signal peptide, the B, C, A, D and E 
domains and part of the 3 'UTR. An 815 bp Pstl fragment was cloned into 
pBluescript II SK + vector (Stratagene) digested with Psti as per the methodology 
described in Section 2.7 (Fig. 2.5). 
pBiuescript II SK+ 
E -~ 
-.... ___ _ 
---
--
---
-------815 bp _____ / 
Pstl Pstl 
Figure 2.5- Diagrammatic representation of the "IGF-II construct" (pGW42). The 815 bp insert 
is shown, matched to the pro peptide domains (boxes), UTRs (shaded boxes) and exons (italics). The 
Pstl cloning sites are shown, with the bold dotted lines represent the MCS and the ellipses the 
location of the RNA polymerase promoters. 
2.8.6 Type IIGF Receptor Expression Vector (pGW27) 
A 700 bp eDNA covering exon 1, 2 and 3 encoding the a-chain of the IGF-IR 
originally developed by Dr Axel Ullrich (Max-Planck-Institut Fur Biochemie, 
Martinsried, Germany; Ullrich et al., 1986), was obtained from ATCC. The IGF-IR 
expression vector (pGW27; Fig. 2.6) was prepared by cloning an EcoRI fragment 
into pBluescript II SK + expression vector, which had previously been digested with 
EcoRI, as described in Section 2.7. 
2.8.7 IGFBP-1 Expression Vector (pGW32) 
A 350 bp eDNA encoding the human IGFBP-1 mature peptide from position 415 to 
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pBiuescript II SK+ 
\.T? -- Exon 2 * Exon·3T
3 
} 
'--CTI) a-Subunit IGF-IR CITY 
~L---------------------------~ 
EcoRI EcoRI 
Figure 2.6- Diagrammatic representation of the "IGF-IR construct" (pGW27). The 700 bp insert 
is shown, matched to the peptide (box), UTR (shaded box) and exons (italics). The cloning sites are 
shown with the dotted lines representing the MCS, the * the Pvull restriction site used for 
linearisation for antisense probe generation and the ellipses, the location of the RNA polymerase 
promoters. 
766 bp cloned into pBluescript SK+ vector, was provided by Dr Charles T. Roberts 
Jr (Department of Paediatrics, Oregon Health Sciences University, Portland, OR, 
USA). Due to a PCR artefact, a cytosine is absent in a cluster of cytosines at 
position 711 - 712 in this clone (Fig. 2.7a; Brinkman et al., 1988). This expression 
vector was transformed (Section 2.7.3), and its sequence confirmed by restriction 
enzyme digestion (Section Step a Section 2.7.1.1) and sequencing as per Section 
2.7.5.2. 
2.8.8 IGFBP-2 Expression Vector (pGW33) 
A eDNA for human IGFBP-2 covering 446 bp coding for the mature peptide from 
position 493 to 939 bp cloned into pBluescript SK+, was provided by Dr Charles T. 
Roberts Jr. This clone is missing a guanine in a stretch of guanines at position 615 -
617, due to a PCR error (Fig. 2.7b; Binkert et al., 1989). This plasmid was 
transformed, examined by restriction enzyme digestion and sequenced . 
2.8.9 IGFBP-3 Expression Vector (pGW34) 
A clone containing a 475 bp eDNA encompassing two thirds of the mature peptide 
from position 398 to 874 bp for IGFBP-3 cloned into pBluescript SK+, was obtained 
from Dr Charles T. Roberts Jr. (Figure 2.7c; Wood et al., 1988). This plasmid was 
transformed, examined by restriction enzyme digestion and sequenced. 
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Figure 2.7 - Diagrammatic representation of the "IGFBP-1 to -6 constructs". The inserts are 
shown, matched to the peptides (box) and numeric positions based on the nucleotide sequences from 
cited references. The cloning sites are shown with the bold dotted lines representing the MCS, the 
ellipses the location of the RNA polymerase promoters and * the location of PCR errors. A. 
IGFBP-1 construct (pGW32) containing a 350 bp insert with a PCR error at position 711-712. B. 
IGFBP-2 construct (pGW33) containing a 446 bp insert with a PCR error at position 615-617. C. 
IGFBP-3 construct (pGW34), 475 bp insert. D. IGFBP-4 construct (pGW35), 505 bp insert. E. 
IGFBP-5 (pGW36) construct, 317 bp insert. F. IGFBP-6 construct (pGW37), 267 bp insert 
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A. 
pBiuescript SK + 
~ .~ 415 
'-<TI)--
297 711-712 cw-J *-766 
Mature Protein IGFBP-1 f-- T3 
',,, ~·'',~ 
........ ---
EcoRV ---------- ... 350 bp_ ............... EcoRV 
B. 
~ ---4~93...==1~23===61~5~~61=7 ======~3~23======~":.pBTiu7escri .P Jt SK+ 
'--CID Mature Protein IGFBP-2 Cf.r>-/ 
EcoRV 
c. 
~--3r=99:.__ __ M_a_t_u_re_P_r_o-te-in-l G_F_B_P---3--~·~~:J SK + 
........ , ,,' 
-- .... _ ,~ '',,,'~475 bp-~~~~~~~~ 
EcoRV EcoRV 
D. 
~-- r-14_4 ___________ ___::6....:..:,49--pBTiu
7
escrip Jt SK + 
'--CID Mature Protein IGFBP-4 Cf.r>-/ 
EcoRI Hind Ill 
E. 
pBiuescript SK+ 
~ .... 415 
'-<TI)-- Mature Protein IGFBP-5 
732 J 
-CITY 
Sa ell Sacl 
F. 
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2.8.1 0 /GFBP-4 Expression Vector (pGW35) 
A 505 bp eDNA fragment from position 144 to 649 bp of mature IGFBP-4 cloned 
into pBluescript SK+ vector, was provided by Dr Charles T. Roberts Jr. (Fig. 2.7d; 
Shimasaki et al., 1990). This plasmid was transformed, examined by restriction 
enzyme digestion and sequenced. 
2.8.11 /GFBP-5 Expression Vector (pGW36) 
A 317 bp eDNA fragment from position 415 to 732 bp of IGFBP-5 covering a 
portion of the signal sequence and most of the mature peptide cloned into 
pBluescript SK+ vector, was obtained from Dr Charles T. Roberts Jr. (Fig. 2.7e; 
Shimasaki et al., 1991a). This plasmid was transformed, examined by restriction 
enzyme digestion and sequenced. 
2.8.12 /GFBP-6 Expression Vector (pGW37) 
A 267 bp IGFBP-6 eDNA from position 99 to 366 bp cloned into pBluescript SK+ 
vector, was provided by Dr Charles T. Roberts Jr. (Fig. 2.7f; Shimasaki et al., 
1991b). This plasmid was transformed, examined by restriction enzyme digestion 
and sequenced. 
2.8. 13 185 rRNA Probe 
To control for concentration variations between the samples examined by RP A 
analysis and to verify the quality of fixation of paraffin embedded tissues to be used 
for in situ hybridisation, a "house keeping" gene was selected to generate an 
expression vector. 18S rRNA was selected over ~-actin as the house keeping gene 
because ~-actin expression is altered with cellular differentiation. 
PCR was performed using human gDNA (isolated as per Section 2.5.2) to generate a 
eDNA fragment containing 262 bp of a conserved region at the 5' end of 18S rRNA 
with restriction enzyme sites for Sail and EcoRI indicated in lowercase in the primer 
sequence (Fig. 2.8). The following primers were used in the PCR reaction: 1 OO!lM 
5' primer (gcgtcgacGAGGGAGCCTGAGAAACGGCTA) and 100!-LM 3' primer 
(GCATCAACCTAGAACCCTCGCcttaagcg) derived from the human sequence 
(McCallum and Maden, 1985). The cycle conditions used were 1 X [94°C, 4min]; 
40 X [94°C, lmin; 55°C, 2min; 72°C, 2min]; 1 X [72°C, 6min]. The fragment was 
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pBiuescript II SK + 
\ 434 
'--CID-- 188 rRNA 
696 J 
··CfL>/ 
........................ ,. ... "" 
- / 
------262 bp// 
EcoRI Sail 
Figure 2.8 • Diagrammatic representation of the "18S rRNA construct" (pGW45). The insert is 
shown, matched to the peptide (box) and numeric position. The cloning sites are shown with the bold 
dotted lines representing the MCS, and the ellipses represent the location of the RNA polymerase 
promoters. 
cloned directly into pBluescript II SK+ expression vector as described in Section 2.7. 
2.9 Labelling Probes and Markers 
2.9.1 Plasmid Linearisation 
Plasmids containing the appropriate complementary DNA (eDNA) sequences 
(Section 2.8), were linearised with specific restriction enzymes that cut at a single 
site in the plasmid, generating eDNA templates for RNA probe synthesis. The 
procedure was as follows: 
a) Plasmids (10f.1l of miniplasmid extraction; Section 2.7.4) were digested with 20-
30units (U) of restriction enzyme with appropriate buffers and lfll RNase A 
(lOmg/ml; Boehringer; for more detail refer to Section 2.9.1.1) in a 50f.1l volume 
for 2h at 37°C. 
b) Linearised plasmids were digested with lfll proteinase K (20mg/ml) in a IX final 
concentration of proteinase K buffer (Section 2.9.1.1) made up to a volume of 
200111 with ddH20. The digestion was incubated at 37°C for 2h. 
c) Samples were extracted as described in steps e- i in Section 2.7.1.1. 
d) Pellets were air dried and re-suspended in l5fll DEPC-ddH20. 
e) lfll of the linearised plasmid was run on a 1% agarose gel to establish if the 
Iinearisation was complete, as described in Section 2. 7 .4.1. 
Page 75 
Walker, 1998 
2.9.1.1 Buffers and Reagents 
RNase A was prepared by dissolving lOmg/ml RNase A in ddH20 and boiling for 
15min. 
lOX PK Buffer contains O.lM Tris-Cl pH 7.8, 0.05M EDTA and 5% SDS in ddH20. 
2.9.2 RNA Probe Synthesis 
RNA probes used to detect specific messenger RNAs (mRNAs) by RPA or in situ 
hybridisation histochemical techniques were labelled with [a 32P-UTP] or [a 35S-
UTP] (Bresatec Pty Ltd, Adelaide, SA, Australia). Antisense RNA probes which 
bind to complementary mRNA and sense RNA probes, which serve as a negative 
control, were generated using specific eDNA templates (Section 2.8). RNA probes 
were synthesised using the Riboprobe Combination System Kit (Promega) according 
to the manufacturer's procedure with some modifications for the incorporation of [a 
32P-UTP] or [a 35S-UTP] as described below. 
2.9.2.1 [a 32P-UTP] Labelled RNA Probes 
[a 32P-UTP] labelled RNA probes were generated in an antisense direction for RPA 
analysis, with unlabelled sense probes used to generate a standard concentration 
curve, described Section 3.4. 
a) The linearised eDNA (0.5-l.O~g) template (Section 2.9.1), was heated to 65°C 
for 15min to reduce secondary structure and re-annealing of the ends. 
b) To the template, a IX final concentration of optimised transcription buffer, 
200mM dithiothreitol (DTT), 17U RNasin (Promega), IOmM each of adenosine 
tri-phosphate (ATP), guanidine tri-phosphate (GTP), cytosine tri-phosphate 
(CTP) and IO~Ci of [a 32P-UTP], were combined with the appropriate RNA 
polymerase (T3, T7 or SP6) and incubated 37°C for I h. 
c) The transcription reaction was inactivated by the addition of 1 U RNase-free 
DNase (Promega), incubated at 37°C for 20min. 
d) The total volume of the transcription reaction was made up to 1 00~1 with DEPC-
ddH20 and cleaned with 1 00~1 of a 1: 1 solution of Tris-buffered 
phenol/chloroform. The solution was vortexed and centrifuged at 14000rpm for 
5min at RT. 
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e) The aqueous layer was transferred and step d repeated using chloroform. 
f) The aqueous layer was again transferred and precipitated using 1/ 10 volume of 
sterile 7.5M NH4Ac and 2 1/ 2 volume of -20°C AR grade ethanol. 
g) The probes were then centrifuged at 14000rpm for 25min at 4°C, air dried andre-
suspended in 5fll of DEPC-ddHzO and 5fll gel loading dye (RPA II Kit, Ambion 
Inc., Austin, TX, USA). 
h) The probes were heat denatured at 95°C for 4-5min, quenched on ice for 2-3min 
and run at 300V on a pre-heated 8M 5% denaturing polyacrylamide gel, as 
described in Section 2.1 0.1. 
i) Following electrophoresis, the gel was left on a casting plate and exposed to X-
OMAT film (Eastman Kodak Company, Rochester, NY, USA) for lOsec. This 
film was used to locate the RNA probe band in the gel. The probe band was 
excised from the gel to reduce incomplete RNA probes. 
j) The gel slice was re-suspended in a sterile probe elution solution (0.5M NH4Ac, 
1mM EDTA, 0.2% SDS) and incubated at 37°C 0/N. The counts per minute 
(cpm) value of the probe was determined using a LS 5000 TA liquid scintillation 
system (Beckman, Fullerton, CA, USA) and the probe stored at -20°C until 
required. 
2.9.2.2 [a 35S-UTP] Labelled RNA Probes 
[a 35S-UTP] labelled RNA probes were generated in an antisense and sense direction 
for in situ hybridisation analysis as described in Section 2.11. 
a) [a 35S-UTP] labelled RNA probes were prepared as per step a and b in Section 
2.9.2.1 except 28U RNasin and 80flCi [a 35S-UTP] were utilised in the 
transcription reaction. After a 45min incubation with the appropriate RNA 
polymerase, an additional 1111 of polymerase was added to the labelling reaction. 
b) RNA probe preparation was as per step c and d of Section 2.9.2.1, however 1fll 
of the probe was removed after making the volume to 1 OOfll, to determine the 
"Total" cpm prior to cleaning up the probe. 
c) The probe was treated as per step e, f and g of Section 2.9.2.1 however the RNA 
probe pellets were re-suspended in 100111 of O.lM DTT, with lfll of the probe 
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removed to determine the "Incorporated" cpm. The probe was stored at -70°C 
until required. 
2.9.3 Labelling Molecular Weight Markers 
This procedure involved labelling the 3' terminus of double stranded-DNA (ds-
DNA) with bacteriophage T4 DNA polymerase (Boehringer). T4 DNA polymerase, 
in the presence of deoxy nucleotide tri-phosphates (dNTPs), will end-label 3' sticky 
ends containing guanines. The methodology is as follows: 
a) 1flg of pGW27 plasmid (Section 2.8.6), was cut with Sau3A1 (NEB, Beverly, 
MA, USA). The volume was increased to 50fll with autoclaved ddH20. 
b) The digest was extracted with 50f1l of Tris-buffered phenol/chloroform mix ( 1: 1) 
and then as per steps e- i in Section 2.7.1.1. 
c) Pellets were air dried and re-suspended in 15fll of autoclaved ddH20. 
d) To the digested plasmid, a IX final concentration of optimised T4 transcription 
buffer, 2mM final concentration of dATP, dGTP and dTTP, 10f1Ci [a 32P] dCTP 
(Bresatec) and 1 U T4 DNA polymerase were added to a final volume of 25fll. 
e) The reaction was incubated for 10min at 37°C, after which a 2mM final 
concentration of unlabelled dCTP was added and incubated for a further 1 Omin. 
f) The enzyme was heat inactivated for 1 Omin at 70°C. 
g) Unincorporated dNTPs were removed with two EtOH precipitation steps. 
h) The labelled markers were re-suspended in 20fll autoclaved ddH20 and 20fll of 
sequencing loading dye (T7 Sequencing Kit, Pharmacia, Stockholm, Sweden). 
2.10 RNase Protection Assay (RPA) 
RPAs were performed as per the manufacturer's protocol (Ambion Inc.) with some 
modifications. 
a) Antisense [a32P] labelled RNA probes for IGF-I, -II, IGF-IR, IGFBP-1 to -6, 18S 
rRNA and an unlabelled sense RNA probe for IGF-I, were synthesised by means 
of in vitro transcription using T3 or T7 RNA polymerases, according to the 
manufacturer's protocol (Promega; Section 2.9.2.1). 
b) Total cellular RNA (100pg-30flg) was hybridised with 1.0 x 105 cpm of RNA 
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probe at 42°C for 20h. 
c) Samples were treated with 6f..Lg/ml RNase A and 120U of RNase Tl at 37°C for 
1h. 
d) The RNase digestion was inactivated and precipitated with a patented kit 
component and incubated at -20°C for 30min. Each precipitation was 
centrifuged at 14000rpm at 4°C for 25min. 
e) The supernatant was removed and the resulting pellets consisting of RNA:RNA 
hybrids were subjected to electrophoresis on a 5% polyacrylamide gel containing 
8M urea (Section 2.10.1). Size markers were prepared by end-labelling the type 
IGF-IR construct, digested with Sau3Al, with [a32P] dCTP and T4 DNA 
polymerase (Section 2.9.3). 
f) Gels were dried, exposed to phosphoimager screens (BAS-IllS, Fuji Photo Film 
Co., Ltd., Tokyo, Japan) for 48h, followed by X-OMAT autoradiography 
(Eastman Kodak Company). 
Images scanned using phosphoimaging technology (Fujifilm BAS-1500 
phosphoimager, Fuji) were used to quantify the amounts of mRNNf..Lg RNA as 
described in Chapter 3.3.1. Representative autoradiographs were scanned using 
Deskscan software and imported into Corel Draw 7 graphical software (Corel 
Corporation, Ottawa, Ontario, Canada). 
2. 10. 1 Denaturing Gel Electrophoresis 
Large format denaturing polyacrylamide gels were prepared as follows: 
a) Eight molar (8M) urea (BDH) was combined with 5% polyacrylamide (National 
Diagnotics, Atlanta, GE, USA) and DEPC-ddH20 and dissolved stirring over a 
low heat. 
b) The solution was filtered through a 0.45f..Lm filter and made up to a 50ml volume 
with DEPC-ddH20. 
c) To 50ml of gel mix, 100!-ll 10% ammonium persulfate (Bio-Rad) and 75f..Ll of 
N,N,N' ,N' -Tetra methylethylendiamin (TEMED; MERCK) were combined and 
the gel immediately cast. 
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d) The gel was pre-heated at 60 watts (W) to 40-45 °C prior to loading to contribute 
to the denaturing characteristics of this gel type. The gel was run at 40W ranging 
from 1-4h depending on the expected size of protected fragments in each RP A 
experiment. 
2.11 In Situ Hybridisation Histochemistry 
High and low grade ductal carcinomas and normal breast tissue samples, were 
analysed by in situ hybridisation histochemistry as described by Angerer et al., 
(1987). 
a) Tissues were formalin-fixed and embedded in paraffin (performed by Sullivan 
and Nicolaides). 
b) Sections of 3-4f..tm were cut and mounted on APES coated slides (Section 
2.4.1.1) as described in step a of Section 2.4.1. Sections were de-waxed in three 
changes of xylene 5min each and hydrated by washes in graded alcohol's for 
3min each. 
c) Sections were de-proteinated with proteinase-K at 50-100~-tg/ml in P buffer 
(Section 2.9.1) at 37°C for lOmin. Sections were immediately washed 2 X with 
IX PBS for 3min each. 
d) Post-fixation was done in 4% paraformaldehyde dissolved in PBS (Section 2.9.1; 
Probing & Structure, Thuringowa, QLD, Australia) for lOmin at RT. Sections 
were then washed 2 X with IX PBS for 3min each. 
e) To reduce non-specific binding, sections were acetylated in acetylation buffer 
(Section 2.9.1) for lOmin at RT, washed 2 X in 2X SSC (Section 2.9.1) for 2min 
each, dehydrated through graded alcohol's and left to air dry for 30min. 
f) Sense and antisense [ a 35S] labelled RNA probes were previously synthesised via 
in vitro transcription (Riboprobe Combination System, Promega) as described in 
Section 2.9.2.2, with the sense RNA probe serving as a negative control. 
g) Sections were immersed in a hybridisation cocktail (Section 2.11.1) along with 
1.0 x 105 cpm of RNA probe, 0.5mg/ml transfer-RNA (tRNA; Boehringer) and 
0.2mM DTT and coverslipped. Hybridisation was in a 1: 1 2X SSC/Formamide 
humidified environment for 18h at 60°C. 
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h) Slides were then treated with 20J.!g/ml RNase A (Section 2.9.1.1; Boehringer) in 
RNase buffer (Section 2.11.1) at 37°C for 1h to digest free RNA probe and 
washed in 1-2 X SSC (Section 2.11.1) at 60°C for 45min to remove the 
unincorporated probe. 
i) Sections were dehydrated in graded alcohol's, mr dried and exposed to 
Hyperfilm-~max (Amersham International plc, Buckinghmnshire, England) for 
48h. 
j) Slides were coated with LM-1 emulsion (Amersham) and exposed at 4°C for 10 
days. 
k) Slides were then developed (D-19, Kodak, Eastman Kodak Company, Rochester, 
NY) for 2min, stopped in 1% acetic acid (BDH) for 1min and fixed (Hypam 
Rapid Fixer, Ilford Pty. Ltd., Vic, Australia) for 5min. Following 5min of dH20 
washes, the sections were counterstained in Mayer's haematoxylin (Section 
2.4.1.1). Representative photomicrographs were prepared using Ilford PANF 50 
black and white film (Ilford Photo Corporation, NJ). 
2. 11. 1 Buffers and Reagents 
P Buffer contained 50mM Tris-Cl pH 7.5, 5mM EDTA pH 8.0. 
Paraformaldehyde 4% was made by dissolving 8g ofparaformaldehyde in sterile lX 
PBS by heating to 60°C in a fume hood and adding a few pearls ofNaOH until 
transparent. 
IX PBS contains 80g NaCl, 11.5g di-sodium hydrogen orthophosphate (Na2HP04; 
BDH), 2g sodium dihydrogen orthophosphate monohydrate (NaH2P04.H20; 
BDH), and KCl (BDH) in IL ddH20 at pH 7.4. 
Acetylation Buffer was made with 2.66ml triethanolamine (Ajax), 36ml 5M NaCl, in 
DEPC-ddH20 (Section 2.5.1.1) with the pH adjusted to 8.0 and the total 
volume made to 200ml. Immediately prior to use, 0.5ml of acetic anhydride 
(Sigma) was added in a fume hood. 
Hybridisation Cocktail contained 50% v/v formamide, 4X final concentration of 
SSC, 30mM di-potassium hydrogen orthophosphate pH 7.0, a IX final 
concentration of Denhardt' s solution and 1 0% dextran sulfate (Pharmacia) 
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dissolved at 37°C in ddH20. The solution was filter sterilised through a 
0.45J..LM filter and stored at -20°C. 
SOX Denhardt's Solution was made with 0.01% w/v bovine serum albumin (BSA; 
Sigma), 0.01% w/v Fico11400 (Pharmacia) and 0.01% w/v poly vinyl 
pyrollidone (Pharmacia) dissolved with heat in ddH20. The solution was filter 
sterilised through a 0.45J..LM filter and stored at -20°C. 
RNase Buffer was made with O.OlM Tris-HCI pH 7.5, 2mM EDTA pH 8.0 and 
0.5M NaCI. 
20X SSC was made with 3M NaCl and 0.3M sodium citrate (Na3C6Hs07; BDH) 
dissolved in ddH20. The pH of the solution was adjusted to 7.0 and 
autoclaved at 15lb/in2. 
2.12 Statistical Analysis. 
Student's t test was used for analysing differences between means of two variables. 
The differences between means of more than two variables was tested by analysis of 
variance CANOVA) and Duncan's multiple range test. Results were considered to be 
statistically significant when p < 0.05. 
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Chapter 3 
THE DEVELOPMENT AND VALl DATION OF 
RNase PROTECTION ASSAYS (RPAS) FOR 
THE DETECTION AND QUANTIFICATION OF 
IGF-1 AND IGF-11 MULTIPLE mRNAs 
3.1 Introduction 
The major aim of this doctoral study was to establish the pattern of expression of the 
multiple mRNAs for IGF-I as well as IGF-II and its Ser-29 variant during cellular 
growth, differentiation and tumourigenesis. It was therefore necessary to develop an 
assay which could detect, distinguish and quantify the variable IGF mRNAs in 
individual samples and enable a comparison of their levels of expression between 
the different samples. To do this, an RNase protection assay (RPA) was selected, as 
this technique is sensitive, specific and quantifiable. The assay involves the 
hybridisation of a 32P-radioactvely labelled antisense RNA probe (specific for the 
mRNA of interest) to total cellular RNA isolated from tissue or cell lines. The 
hybridisation reaction is then treated with RNase. In this step, the RNA:RNA 
hybrids are protected from the RNase digestion while unprotected mRNA and single 
stranded (ss) RNA probes are digested, leaving only the specific protected 
fragments. 
Using the property that RNase digests any ssRNA not protected by hybridisation, 
expression vectors for the generation of antisense RNA probes for IGF-I (Section 
2.8.1) and IGF-II (Section 2.8.5) were designed to enable the detection, comparison 
and quantification of the multiple mRNAs in an RPA. The principals of the probes 
designed for IGF-I and -II and the validation of the quantification assay will be the 
focus of this chapter. 
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3.2 Materials and Methods 
The expression vectors used for the generation of radioactively labelled or 
unlabelled probes for IGF-I and -II are described in Section 2.8.1 and Section 2.8.5 
respectively. 
3.2.1 Total RNA Extraction 
Total cellular RNA was extracted from 4 normal breast tissue specimens and from 
CHO cell lines stably transfected with either pro-IGF-I Ea or pro-IGF-I Eb by the 
method of Chomczynski and Sacchi, (1987) as described in Section 2.5.1. 
3.2.2 [ a-32 P-UTP] Labelled RNA Probes 
[a 32P-UTP] labelled RNA probes were generated in the antisense direction for RPA 
analysis. Unlabelled sense RNA probes were generated for use in a standard 
concentration curve. RNA probes were synthesised using the Riboprobe 
Combination System Kit (Promega) according to the manufacturer's procedure with 
some modifications as described in Section 2.9 .2.1. 
3.2.3 RNase Protection Assays (RPAs) 
RPAs were performed as per the manufacturer's protocol (Ambion Inc.) with some 
modifications as described in Section 2.1 0. 
3.3 Results 
3.3.1 /GF-1 Multiple mRNA Expression Vector (pGW21) 
An IGF-I expression vector "IGF-I multiple mRNA construct," was designed 
enabling the detection and comparison of the variable mRNAs within the same 
sample, via RPA analysis (Fig.3.1a). An 853 bp human eDNA clone encompassing 
a portion of exon 1 that encodes the 5' UTR and the very 5' aa of the signal peptide, 
as well as the exons encoding the B, C, A, D, E common, the Eb domains and a 
portion of the 3'UTR of IGF-I, was obtained from Dr Peter Rotwein (Oregon Health 
Sciences University, Portland, OR, USA; Rotwein, 1986). A 698 bp EcoRI and Pstl 
fragment of this clone was subcloned into pBluescript II SK+ vector as described in 
Section 2.7. 
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Figure 3.1 - A. Human IGF-I multiple mRNA probe design. ?repro-domains are boxed, Pre = 
signal peptide with associated exons in italics. Symbols * and # represent the EcoRI and Pstl 
restriction enzyme sites respectively. Arrows indicate the IGF-l mRNAs with the narrow lines, the 
splicing opportunities. The expected protected fragments for the major IGF-I mRNAs and the minor 
hepatic specific exon 4-5-6 mRNA are illustrated. B. Representative autoradiograph of IGF-l 
multiple mRNA probe test on CHO transfected pro-IGF-I Ea, pro-IGF-I Eb and wild type (WT) CHO 
cells. (M): MW marker; (P): IGF-I multiple mRNA probe; (R): RNase digestion of the IGF-I 
multiple mRNA probe; (I): lOJLg CHO RNA hybridised with IGF-multiple mRNA probe: (2): JOpg 
CHO-pro-IGF-I Ea RNA hybridised with IGF-multiple mRNA probe; (3): IOpg CHO-pro-IGF-I Eb 
RNA hybridised with IGF-multiple mRNA probe. Identified protected fragments are indicated in 
bold, the full-length probe in normal text, with * indicating unidentified protected fragments. 
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3.3.2 Detection of the Multiple mRNAs for IGF-1 
To establish whether the IGF-I multiple mRNA probe was able to distinguish the 
four different precursor IGF-I mRNAs, wild type CHO cells, with undetectable 
levels of IGF-I mRNA, and two CHO cell lines stably expressing either human pro-
IGF-I Ea or human pro-IGF- I Eb kindly provided by Dr P-A Stahlbom (Stahlbom, 
1996), were grown to confluency and analysed for pro-IGF-I Ea and pro-IGF-I Eb 
mRNAs via an RPA (Section 2.10). The IGF-I multiple mRNA probe was able to 
distinguish between pro-IGF-I Ea and pro-IGF-I Eb mRNAs, with no hybridising 
bands detected in untransfected CHO cells (n=3; Fig. 3.1b). The additional 
hybridising bands in each CHO transfected clone shown in Figure 3.1 b, are proposed 
to be due to mismatches introduced by the PCR cloning method used to generate the 
constructs (Stahlbom, 1996). 
3.3.3 IGF-11 Expression Vector 
To address whether there is differential expression between IGF-II and its Ser-29 
variant form, an IGF-II expression vector was designed enabling the detection and 
comparison of the IGF-II mRNA from the Ser-29 mRNA within the same sample, 
via RPA analysis (Fig.3.2a). An 815bp Pstl IGF-II eDNA was subcloned into 
pBluescript SK+ as described in Section 2.7. This IGF-II eDNA lacks the 
tetrapeptide substitution of Arg-Leu-Pro-Gly at Ser-29 (Section 1.4.3), therefore was 
anticipated to give multiple protected fragments when used in an RP A. 
3.3.4 Detection of the Multiple mRNAs for IGF-11 
The IGF-II RNA probe was tested on four normal breast tissue samples, as breast 
tissue has previously been reported to express IGF-II mRNA (Yee et al., 1988). The 
IGF-II RNA probe was able to distinguish between IGF-II and its Ser-29 counterpart 
with protected fragments at 565 bp specific for IGF-II and 4211159 bp specific for 
Ser-29 variant mRNAs (Fig. 3.2b). 
3.4 Quantification of mRNA 
To quantify the amount of mRNA detected per microgram of total cellular RNA 
from the RP A experiments, a density calibration was established to generate a 
standard curve that relates to the amount of mRNA present in each sample. 
Unlabelled sense IGF-I multiple mRNA probe (Section 3.3.1) at concentrations of 
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Figure 3.2 • A. Human 1GF-ll probe design. Domains of the prepro-peptide are boxed with 
associated exons in italics. Location of the Ser-29 and Ser-33 variants are illustrated. The * 
represent the Pstl restriction enzyme sites used for sub-cloning. The region encoding the probe is 
shown along with the protected fragments expected in an RPA analysis. B. Representative 
autoradiograph of the IGF-11 probe tested on normal breast tissue in an RPA analysis. (M): MW 
marker; (P): IGF-II probe; (R): RNase digested 1GF-II probe; (Nl) and (N2): 10j.Lg of RNA 
hybridised with the 1GF-1I probe. The full length IGF-11 probe is in normal text with protected 
fragments indicated in bold. *Represent unidentified protected fragments. 
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0.1, 1, 10, 20 and lOOpg (in triplicate2), was hybridised with 1.0 x 105 cpm of 
[a32P]labelled antisense IGF-I multiple mRNA probe, as described in Section 2.10. 
Results from one of the density calibration experiments is shown in Figure 3.3a. 
The protected 794 bp fragment specific for sense/antisense hybridisation was 
quantified by phosphoimaging technology (Fujifilm BAS-1500 Phosphoimager, 
A 
8 250 
200 
N 150 
E 
E 
:::J 
en 
a. 100 
~IGF-1 
794 
c 
341 
315 
258 
350 18S rRNAProbe 
~ 264 185 rRNA 
1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97 101 
pg Sense IGF-1 RNA Probe 
Figure 3.3 · A. Representative RPA of sense/antisense hybridisation of IGF-1 RNA probes to 
establish the standard concentration curve. (0. I - I 00 ): Amount of sense RNA probe hybridised to the 
32P labelled RNA probe. B. Standard concentration curve showing pg mRNA established from 
density calibrations (PSUmm2) of triplicate experiments. Note that error bars are too small to be 
observed. C. Representative RPA depicting the /8S rRNA "house keeping gene" used for 
concentration adjustments between samples. (M): MW marker; (P): /8S rRNA probe; (R): RNase 
digestion of P; (/, 2, 3): Three independent samples hybridised to the /8S rRNA probe in triplicate. 
Samples selected show the concentration variations observed between samples. 
2 The RPAs for the standard curve were performed on three separate occasions, with three different 
probes to establish consistency. 
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Fuji) and Analytical Imaging Station software (Imaging Research Inc., Ontario, 
Canada) to give the images density units (refered to as PSL!mm2) for each protected 
fragment. A standard concentration curve was then generated from this data as 
shown in Figure 3.3b. All quantitative RP A experiments utilised the same standard 
concentration curve to establish the amount of mRNA present per J..Lg total cellular 
RNA. To allow comparisons between mRNAs within the same sample and between 
samples, values were adjusted for the number of 32P-UTPs present in each identified 
mRNA, and for concentration variations, using ISS rRNA as an internal standard 
(Figure 3.3c). The levels of each mRNA were given as pg mRNA I J..Lg RNA. 
3.5 Discussion 
The human IGF-I gene generates four major mRNAs, referred to as class 1, class 2, 
Ea and Eb, via the use of alternate promoters and alternative splicing (Sections 1.5.1 
and 1.5.4), while the human IGF-II gene generates two variant prohormones, Ser-29 
created by alternative splicing and the Ser-33 variant caused by allelic variation 
(Section 1.4.3). The IGF-I mRNAs have been shown to be tissue specific as well as 
developmentally regulated while differential patterns of expression have not been 
identified for the Ser-29 variant of IGF-II. The overall aim of this thesis was to 
analyse the expression pattern of the variable IGF-I mRNAs and to a lesser degree 
IGF-II and its Ser-29 variant, and their relationship to other members of the IGF axis 
during growth, differentiation and tumourigenesis. 
To establish the pattern of expression of the multiple mRNAs for IGF-I as well as 
IGF-II and its Ser-29 it was necessary to first develop an assay which could detect, 
distinguish and quantify the variable IGF mRNAs in a single sample and enable a 
comparison of their levels of expression between different samples. As described in 
this chapter, an RP A was established to detect, distinguish and quantify the multiple 
mRNAs for IGF-I as well as IGF-II and its Ser-29 counterpart in a single sample. 
The probes designed for the detection of the multiple IGF-I mRNAs and IGF-II 
mRNAs were trialed on tissues and cell lines known to express the variable IGF-I 
and IGF-II mRNAs. The quantitative RPA described in this chapter is based on the 
use of a single standard curve, repeated in triplicate with independent probes and 
sense IGF-I. This procedure was tried and tested in triplicate independent RPAs for 
the IGF-IR using the IGF-I standard curve, and was found to be consistent. This 
methodology is the basis for the quantitative results in the remaining chapters. 
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Chapter 4 
THE VARIANT mRNAs OF HUMAN INSULIN-
LIKE GROWTH FACTOR-I {IGF-1) AND THE 
TYPE I RECEPTOR {IGF-IR), EXHIBIT A 
DISTINCT AND NOVEL PATTERN OF 
EXPRESSION IN THE NEUROBLASTOMA 
CELL LINE SK-N-MC WHEN INDUCED TO 
DIFFERENTIATE BY SERUM-WITHDRAWAL 
4.1 Introduction 
Gene silencing studies have shown that insulin-like growth factors (IGFs), IGF-I 
and -II are essential for normal cellular growth, development and metabolism 
(Baker et al., 1993; Liu et al., 1993; Powell-Braxton et al., 1993). IGF-I and IGF-
IR gene knockouts and an IGF-IIIIGF-IR double mutant in mice, result in severely 
dwarfed homozygous phenotypes, with retarded organ formation and a high 
mortality (Liu et al., 1993). In contrast, transgenic mice expressing high levels of 
IGF-I were 30% larger than their non-transgenic littermates, with enlarged organs at 
8 weeks (Mathews et al., 1988). In vitro experimental models from hematopoietic 
development to tumourigenesis, have demonstrated that IGFs are key regulators of 
cell growth (Pahlman et al., 1991; Cohick and Clemmons, 1993; Li et al., 1997), 
differentiation (Pahlman et al., 1991; Cohick and Clemmons, 1993; Lavenius et al., 
1994; Li et al., 1997), act as survival factors against apoptosis (Barres et al., 1992; 
Babajko and Binoux, 1996; Matthews and Feldman, 1996) and have key functions 
in malignant transformation and tumour cell proliferation (Quinn et al., 1996; 
Silberstein et al., 1997). For a family of peptides to have such diverse biological 
functions, it is expected that they would be tightly regulated, both intracellularly and 
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extracellularly. In the case of malignant transformation and the resulting tumour 
cell growth, there is a lack of or breakdown in regulation. 
IGF-I and -II are regulated extracellularly by their interaction with six classical IGF 
binding proteins (IGFBP-1 to -6). These IGFBPs serve to prolong IGF half-lives as 
well as alter their ability to interact with transmembrane IGF receptors, thereby 
serving to either potentiate or inhibit their biological actions (DeMellow and Baxter, 
1988; Blum et al., 1989; Liu et al., 1991). It has also been identified that some 
IGFBPs have ligand (IGF) independent effects interacting with their own cell 
surface receptor (Jones et al., 1993; Oh et al., 1993a; 1993b; Leal et al., 1997). The 
biological actions of IGF-I and -II are initiated by their binding to the 
transmembrane type I IGF receptor (IGF-IR; Ullrich et al., 1986), which they do 
with roughly equal affinity. This binding triggers the activation of the intracellular 
tyrosine kinases leading to the autophosphorylation of the receptor, which in turn 
activates the second messenger system and ultimately leads to the biological 
response (Frattali and Pessin, 1993; Kato et al., 1993; Stewart and Rotwein, 1996b). 
IGF-II also binds the type II IGF/mannose-6-phosphate receptor (IGF-IIIM-6-PR), 
whose function is to target lysosomal enzymes (Ludwig et al., 1994; Pohlmann et 
al., 1995). The IGF-IIIM-6-PR has also been hypothesised to act as a tumour 
suppressor for IGF-II, whereby it sequesters, internalises and degrades IGF-II, 
preventing its binding to the IGF-IR (Ellis et al., 1996). 
Another potential mechanism that may regulate IGF action is that the IGF-I and 
IGF-II genes transcribe more than one type of mRNA. The human IGF-I gene 
generates four major mRNAs by alternate promoter usage and alternative splicing of 
its 5' and 3' exons. These mRNAs are referred to as class 1, class 2 and Ea, Eb 
respectively (Fig. 4.1a; Jansen et al., 1983; Rotwein, 1986; Tobin et al., 1990). 
Class 1 and 2 mRNAs code for slightly different signal peptides, 21 aa for class 1 
and 5 aa for class 2 (Jansen et al., 1983; Rotwein, 1986; Tobin et al., 1990). Ea and 
Eb mRNAs encode variant C terminal E domains, 19 aa for Ea (Jansen et al., 1983) 
and 61 aa for Eb (Rotwein, 1986). Studies in rat model systems have shown these 
variant IGF-I mRNAs to be tissue specific as well as developmentally and 
hormonally regulated (Adamo et al., 1989; 199lb). In addition to the 3' mRNA 
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variants of human IGF-I, an exon 4-5-6 mRNA which uses an alternative 5' -donor 
splice site in exon 5, has recently been identified and shown to be liver specific with 
equivalent expression levels to Eb mRNAs (Chew et al., 1995). Following 
translation and post-translational modifications of the different IGF-I mRNAs, the 
same mature 70 aa IGF-I protein is found in the human serum (Rinderknecht and 
Humbel, 1978a). The human IGF-II gene generates variant mRNAs primarily by 
alternate promoter usage and alternative splicing. When translated, most of these 
mRNAs encode the same mature IGF-II protein, however, one of these mRNAs 
encodes a Ser-29 variant of IGF-II which consists of a tetrapeptide substitution at 
Ser-29 in the B-domain (Jansen et al., 1985). 
It is unclear as to why variable IGF-I mRNAs are transcribed to ultimately generate 
the same mature protein. It is possible that the IGF-I prohormones or their 
proteolytically cleaved products may have additional biological functions. For 
example, pro-IGF-I Ea and pro-IGF-I Eb secretion has been detected in human 
fibroblast cell lines (Clemmons and Shaw, 1986), while Ea peptides have been 
identified in the serum of patients with renal failure, detected by immunoblot and 
radioimmunoassay (Powell et al., 1987). In a parallel study (Chapter 6), a 
significant increase of class 1 relative to class 2 and Eb relative toEa mRNAs, was 
observed between normal breast tissue and ductal breast tumours (Walker et al., 
1998). Overall, the detection of IGF-I proteolytic products and the differential 
expression of IGF-I mRNAs in the breast model system, suggests that the 
differential expression of IGF-I may be one mechanism contributing to breast 
tumourigenesis and possibly other forms of cancer. 
The aim of the present investigation was to examine whether an altered expression 
pattern of the variant IGF-I mRNAs, and to a lessor degree IGF-II and its Ser-29 
counterpart can be related to the biological role of IGF-I and -II in growth and 
differentiation. This study was performed using the human neuroblastoma cell lines 
SK-N-MC and SK-N-SH. The SK-N-MC cell line is derived from a primitive 
neuroectodermal tumour (PNET) and has previously been shown to express and be 
regulated in an autocrine fashion by IGF-I (Yee et al., 1990; Kiess et al., 1997), 
while the SK-N-SH cell line expresses only IGF-II (Yee et al., 1990). Both cell 
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lines were grown under normal culture conditions and were induced to differentiate 
by the withdrawal of serum, marked by morphological changes and a decrease in 
plasminogen activator activity. Total cellular RNA extracted during both the 
growth and differentiation profiles, was examined for the expression pattern of IGF-
I, -II and the IGF-IR by quantitative RPA (Chapter 3). 
4.2 Material and Methods 
4.2.1 Cell Culture 
Neuroblastoma cell lines SK-N-MC (P42) and SK-N-SH (P34) were grown in 
MEM supplemented with 10% heat-inactivated FBS and glutamine in the presence 
of penicillin G and streptomycin sulphate, sodium pyruvate and sodium bicarbonate 
as described in Section 2.1.1.1. 
4.2.2 Cell Growth 
At 80-90% confluency, both SK-N-MC and SK-N-SH cells were harvested using 
trypsin-versene and plated at a density of 3.0 - 6.0 x 104 cells per cm2 onto 35 X 
150cm2 plates (Section 2.2). Every 24h, 1 plate was harvested for a viable and dead 
cell count (Section 2.2.1) and the remaining 4 plates were collected for total cellular 
RNA extraction (Section 2.5.1). When the SK-N-MC cells reached approximately 
100% confluency (Day 5), the culture medium was replaced. Cell growth 
experiments were performed a minimum of three times for each cell line. 
4.2.3 Differentiation 
At 80-90% confluency, both SK-N-MC and SK-N-SH cells were harvested using 
trypsin-versene and plated at a cell density of 3.0 x 104 cells per cm2 onto 18 X 
150cm2 plates (Section 2.3). Cells were allowed to plate for 48h, following which 
the culture medium was removed and the cells washed with PBS. Fifteen plates 
were given serum-free medium while the remaining 3 plates receiving fresh culture 
medium containing 10% FBS as before. This was taken as time 0. At 24h, 48 and 
72h time points, 1 serum-free plate and 1 culture medium plate were photographed 
and harvested for cell counts (Section 2.2.1), while the remaining 6 plates were 
harvested for total cellular RNA (Section 2.5.1). Experiments were performed a 
minimum of three times for each cell line. Representative photomicrographs were 
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prepared using llford PANF 50 black and white film (llford Photo Corporation, NJ, 
USA). 
4.2.4 Morphological Evaluation for Apoptosis 
In independent serum-free and serum-containing experiments, SK-N-MC and SK-
N-SH cells at 24,48 and 72h were harvested, fixed and embedded in paraffin as 
described in Section 2.3.2. The blocks were cut in 5)lm sections and stained with 
H&E as described in Section 2.4.1, to evaluate whether serum-withdrawal induced 
programmed cell death (apoptosis; n=3). 
4.2.5 Plasminogen Activator (PA) Activity 
An increase in plasminogen activator activity, particularly t-PA, has previously been 
used as a marker for a lack of terminal differentiation and cell invasion in SK-N-SH 
cells (Tiberio et al., 1997). In light of this, we expected the plasminogen activator 
activity to decrease with a cessation of growth or differentiation. Hence the 
following plasminogen activator assay was used as a biochemical marker for 
differentiation. At 80-90% confluency, both the SK-N-MC and SK-N-SH cells 
were harvested and plated at a cell density of 3.0 x 104 cells per cm2 onto 1 X 6 well 
plate in phenol red-free culture medium (Section 2.3.1). Cells were allowed to plate 
for 48h. Time 0 was commenced with 3 of the 6 wells receiving serum-free and the 
remaining 3 wells receiving fresh culture medium containing 10% FBS. At 24, 48 
and 72h, the media was collected. Half the total volume was lyophilised and 
assayed for plasminogen activator activity, as described by Zhang et al., (1996; 
Section 2.3.1). 
4.2.6 RNA Preparation 
Total cellular RNA was extracted from pooled cells at each time point using the 
acid guanidinium thiocynante (GTC)/phenol-chloroform method of Chomczynski 
and Sacchi (1987; Section 2.5.1). 
4.2.7 RNase Protection Assay (RPA) 
RPAs were performed as described in Section 2.10. Antisense [a32P] labelled RNA 
probes for the IGF-I multiple mRNAs (Section 2.8.1), mature IGF-I (Section 2.8.2), 
IGF-II (Section 2.8.5), IGF-IR (Section 2.8.6), 18S rRNA (Section 2.8.13) and an 
unlabelled sense RNA probe for IGF-I multiple mRNAs, were synthesised by in 
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vitro transcription using T3 or T7 RNA polymerases, according to Section 2.9.2.1. 
Total cellular RNA (lOOpg - 30f.Lg) was hybridised with 1.0 x 105 cpm of RNA 
probe at 42°C for 20h. Samples were treated with 6f.Lg/ml RNase A and 120U of 
RNase Tl at 37°C for 1h. Resulting RNA:RNA hybrids were subjected to 
electrophoresis on a 5% polyacrylamide gel containing 8M urea. Size markers were 
prepared by end-labelling the type IGF-IR construct as described in Section 2.9.3. 
Gels were dried, exposed to phosphoimager screens for 48h, followed by X -OMAT 
autoradiography. Representative autoradiographs were scanned using Deskscan 
software and imported into Corel Draw 7 graphical software. 
4.2.8 Quantification of mRNA 
The amount of mRNA detected/f.Lg of total cellular RNA from the RPA analyses, 
was determined as per Section 3.4 from triplicate RPA experiments. 
4.2.9 Reverse Transcription PCR (RT-PCR) 
The generation of first strand eDNA by RT from SK-N-MC and SK-N-SH RNA 
harvested from cells grown in either serum-containing or serum-free conditions for 
48h, was performed as described in Section 2.6. PCR was used to amplify the four 
major IGF-I mRNAs using 100f.LM each of a 5' and 3' primer from the sets of 
primers described in Table 4.1. Conditions for PCR reactions for each set of 
primers were 1 X [94°C, 5min]; 35 X [94°C, 1min; 56°C, 2min; 72°C, 2min]; 1 X 
[72°C, 7min] 3. The PCR reactions were run on a 1% agarose gel as described in 
Section 2. 7 .4.1. The representative gels were photographed under UV using a 
photometries cooled CCD video camera (Fuji), scanned using Deskscan software 
and imported into Corel Draw 7 graphical software. 
4.2. 10 Statistical Analysis 
The Student's t-test was used for analysing differences between means of two 
variables. Results were considered to be statistically significant when p < 0.05. 
3 The annealing temperature for the class 1 Eb and class 2 Eb sets of primers was 54°C. 
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4.3 Results 
4.3.1 IGF-1 mRNA Expression During Cellular Growth 
For a sensitive and quantitative comparison of the multiple IGF-I mRNAs within 
and between samples, an RNA probe was designed that hybridises to the major 
mRNAs, distinguished by an RPA (Section 2.8.1; Fig. 4.1a). The multiple mRNA 
probe, was used to analyse the expression of the IGF-I mRNAs in SK-N-MC cells 
grown over a 7 day time course in medium containing 10% FBS. Although not 
clear in the representative autoradiograph the four major IGF-I mRNAs were 
expressed at each time point in SK-N-MC cells (n=3; Fig. 4.1b), while in contrast, 
IGF-I expression was either below the limits of detection, or not expressed by SK-
N-SH cells at any stage during the cell growth analysis (n=3; Fig. 4.1 b). These 
results were verified by RT-PCR using exon specific primers for IGF-I described in 
Table 4.1 (n=3; Fig. 4.2). In addition to the four major IGF-I mRNAs detected in 
the SK-N-MC cells, bands of approximately 540, 480, 380 and 320 bp were also 
detected over the 7 days of growth. The expression of these bands was absent in the 
RNase control, CHO-pro- IGF-I Ea, CHO-pro-IGF-I Eb and the SK-N-SH samples 
(Fig. 4.1b). The 380 bp fragment corresponds to the class 2 exon 4-5-6 mRNA, 
however the 540, 480 and 320 bp bands do not correspond to any known mRNA for 
IGF-I (Fig. 4.1a). Whether the additional fragments protected by the IGF-I multiple 
mRNA probe are IGF-I messages, or degradative products, remains to be 
established. 
Class 1 Ea GATAGAGCCTGCGCAATGGA AGTGAAGAGTGACATGCCACCGC 
Exonl Exon 6 
Class 1 Eb GATAGAGCCTGCGCAATGGA GAACACGAAGTCTCAGAGAAGG 
Exonl Exon5 
Class 2 Ea CACATCGGCCTCATAATACC TGAGGAGTGAAGAGTGACATGC 
Exon 2 Exon 6 
Class 2 Eb CACATCGGCCTCATAATACC GAACACGAAGTCTCAGAGAAGG 
Exon 2 Exon 5 
Table 4.1 - Primer sets used for the PCR detection of the different JGF-1 mRNAs. Primers are 
written in a 5' to 3' direction according to the coding strand, with exon locations indicated. 
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Figure 4.1 -A. Human 1GF-I multiple mRNA probe design. Prepro-peptide domains are 
boxed (B, C, D, Eb, Ea; Pre= signal peptide) with corresponding exons in italics. Symbols *and 
+ represent EcoR1 and Pstl restriction enzyme sites respectively, delineating the fragment used 
for sub-cloning. Arrows indicate IGF-1 mRNAs with narrow lines indicating splicing 
opportunities. Expected protected fragments for the major 1GF-I mRNAs and the minor hepatic 
specific exon 4-5-6 mRNA are illustrated. B. Representative autoradiographs of IGF-I multiple 
mRNA expression during growth of the human neuroblastoma cell lines, SK-N-MC and SK-N-SH. 
(M): MW marker; (P): IGF-I multiple mRNA probe; (R): RNase digestion of the IGF-I multiple 
mRNA probe; (1): 10J1g of CHO-pro-IGF-1 Ea RNA hybridised with the IGF-I multiple mRNA 
probe; (2): 10J1g of CHO-pro-IGF-1 Eb RNA hybridised with the IGF-I multiple mRNA probe; 
(3): 30J1g of SK-N-SH Day 4 RNA, hybridised with the IGF-1 multiple mRNA probe; (4 to 8): 
30J1g of SK-N-MC Day 3 to 7 RNA, hybridised with the IGF-1 multiple mRNA probe. Identified 
protected fragments are described in bold with the full length probe in normal text. * marks the 
unidentified protected fragments or degradative products. The CHO-IGF-1 Ea and CHO-IGF-1 
Eb samples (Lanes 1 and 2) were exposed for 7 days, the SK-N-SH sample (Lane 3)for 28 days 
and the SK-N-MC samples (Lanes 4 to 8) were exposed for 21 days. 
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A. 
Class 2 
IGF-1 PROBE (Exon 1, 3, 4, 5) 
Class 1, Eb 
Class 1, Ea 
Class 1, Exon 4-5-6 
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Class 2, Ea 
Class 2, Exon 4-5-6 
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The major IGF-I mRNAs were quantified at each time point in the SK-N-MC cell 
growth experiments (n=3). The overall pattern of expression in each experiment 
was largely the same with the expression of the four major IGF-I mRNAs increasing 
with an increase in the cell confluency (Fig. 4.3). Class 2 synthesis was slightly 
higher than class 1 at each time point and Ea synthesis predominated over Eb. At 
day 5 where the culture media was changed, there was a notable increase in the 
synthesis of the four major IGF-I mRNAs (Fig. 4.3). To see if there were any 
changes between the expression of the 5' variant and between the 3' variant IGF-I 
mRNAs during the growth of SK-N-MC cells, the ratio of class 1 to class 2 and the 
ratio of Ea to Eb were compared over the 7 day time course experiments. There was 
no significant change in the pattern of class 1 relative to class 2 or Ea relative to Eb 
with increasing cell confluency. Interestingly over the entire growth profile, the 
ratio of class 1 to class 2 was approximately 1:1 (n=7; 0.89 ± 0.049) while there was 
a 2-fold higher expression of Ea relative to Eb (n=7; 2.14 ± 0.080\ 
1353 
603 
310 
M 1 2 3 4 5 
08 Class 1 Ea 
7 Class 1 Eb 
Class 2 Ea 
Class 2 Eb 
Figure 4.2- RT-PCR analysis examining the expression of the four major IGF-1 mRNAs in SK-N-
MC cells grown for 48h in culture medium containing 10% FBS. (M): MW marker ¢X 174 Haelll; 
( 1-4): RT-PCR analysis of Day 4 SK-N-MC cells amplified with Class I Eb, Class 1 Ea, Class 2 Eb 
and Class 2 Ea primer sets respectively; (5): Representative water control. 
4 The ratio data is from the representative cell growth study of SK-N-MC cells shown in Figure 4.3. 
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In one SK-N-MC cell growth profile, the effect of over-confluency was tested on 
the expression of the IGF axis. The pattern of IGF-I expression in the over-
confluent experiment, was similar to that seen in the experiments where the cells 
were plated at a lower cell density. The most significant difference was that in the 
over-confluent experiment, the expression of each of the individual IGF-I mRNAs 
could not be detected at day 5, where the number of viable cells had significantly 
declined (Fig. 4.6b). 
No alteration in the relative pattern of expression of the four major mRNAs was 
observed throughout the growth profiles, including at high cell confluency or with 
the addition of fresh culture medium. Overall, an examination of IGF-I expression 
during SK-N-MC cell growth suggests that each of the major IGF-I mRNAs have a 
consistent and coordinated role during cellular proliferation. 
0.08 
~ 0.07 
~ 0.06 
C'C 
~ 0.05 
g> 0.04 
-~ 0.03 
0: E 0.02 
~O.Q1 
0+---t-"-l.d...{-J_-Y __ 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
M 
lime (Days) 
8 
7 
< 
6 Di' 
0' 
5ro () 
4~ 
:tl: 
3>< 
..... 
20 
m 
""" 
0 
-Ciass1 Ea 
c:::::J Class 1 Eb 
-Ciass2Ea 
,_.,Class 2 Eb 
-+-Cell# x 10E7 
Figure 4.3- Representative experiment of the expression levels of the major IGF-I mRNAs at 24h 
time points (Bars) relative to the viable cell number (Line, SE) in SK-N-MC neuroblastoma cells 
grown in serum-containing medium. (M) shows the time point at which the medium was changed to 
fresh culture medium. 
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4.3.2 /GF-11 mRNA Expression During Cellular Growth 
In parallel studies, mRNAs coding for IGF-II (565 bp) and the Ser-29 variant form 
of IGF-II (421+159 bp) were examined in SK-N-MC and SK-N-SH cell growth 
experiments for 7 days by RPA (n=3). Messenger RNAs for IGF-II and the Ser-29 
variant were expressed in SK-N-SH cells throughout each growth profile, but were 
not detected at any stage in the SK-N-MC cells (Fig. 4.4). 
The mRNAs for IGF-II and the Ser-29 variant of IGF-II were quantified in each SK-
N-SH growth experiment (n=3). No overall pattern of expression could be detected 
between each SK-N-SH growth profile, except at high cell confluency where the 
M P R 1 2 3 4 5 6 7 8 9 10 
1 898 IGF-11 Probe 
565 IGF-11 
421 Ser-29 
* 
159 Ser-29 
Figure 4.4- Representative autoradiograph of an RPA depicting the expression of IGF-11 and the 
Ser-29 variant of IGF-1I in SK-N-SH and SK-N-MC neuroblastoma cell lines during a 7 day growth 
profile in serum-containing medium. (M): MW marker; (P): IGF-11 RNA probe; (R): RNase 
digestion of the 1GF-11 RNA probe; (I to 7): I5fJ,g of total cellular RNA from day I to 7 of SK-N-SH 
cells grown in serum, hybridised with the 1GF-I1 RNA probe; (8 to I 0): I5!Jg of total cellular RNA 
from day 4 to 6 of SK-N-MC cells grown in serum, hybridised with the IGF-11 RNA probe. Protected 
fragments are indicated in bold, the full length probe in normal text. * indicate an unidentified 
protected mRNA. The SK-N-SH experiments were exposed for I4 days, while the SK-N-MC 
experiments were exposed for 2I days. 
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expression levels of both IGF-II and Ser-29 decreased (Fig. 4.5a, b, c). To see if 
there was any variation of IGF -II mRNAs relative to the Ser-29 variant, the ratio of 
these mRNAs was analysed (Fig. 4.5a, b, c). The IGF-II mRNAs were 1.3 to 2-fold 
higher in expression than the Ser-29 variant. These results suggest that the relative 
expression pattern ofiGF-II and the Ser-29 variant, is consistent throughout the SK-
N-SH growth profile regardless of cell confluency. Therefore, it is possible that 
each IGF-II protein has a coordinate function during cell growth. 
4.3.3 IGF-IR mRNA Expression with Cell Growth 
IGF-IR mRNA expression was analysed in both SK-N-MC and SK-N-SH growth 
experiments in culture medium containing 10% PBS (n=3). The expected 520 bp 
fragment specific for the IGF-IR was detected in both cell lines as shown by 
representative autoradiographs in Figure 4.6a. The 520 bp IGF-IR mRNA was 
quantified in each of the SK-N-MC (n=3) and SK-N-SH growth experiments (n=3), 
where it was found in each cell line to increase with cell confluency, as represented 
in Figure 4.6b. In this representative SK-N-MC cell growth experiment (Fig. 4.6b), 
the aim was to test the effect of over-confluency on the expression of the IGF axis. 
In this experiment, IGF-IR expression increased parallel with total IGF-I expression 
as cell confluency increased. At day 5 where the cells were over-confluent, IGF-I 
expression could not be detected while the IGF-IR expression reached its highest 
levels (Fig. 4.6b). The increase in IGF-IR expression levels by both cell lines 
suggests that they are sensitive to the autocrine production of IGFs. Where the SK-
N-MC cells are over-confluent and IGF-I synthesis ceases, the IGF-IR may act as a 
survival response, increasing dramatically to capture any available IGFs. With the 
change to fresh culture medium at day 5 in the SK-N-MC cells, the large quantities 
of the IGF-IR may no longer be required due to fresh exogenous IGFs, hence the 
cells appear to shut down their synthesis of the IGF-IR. 
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Figure 4.5 - Expression of IGF-II and the Ser-29 variant of IGF-II during the cell growth of 
SK-N-SH neuroblastoma cells in serum-containing medium. A, B, and C represent three 
individual SK-N-SH growth profiles (Lines, SE) and the expression of IGF-II and Ser-29 variant 
(Bars), over the 7 day time course. Below each graph is a table depicting the ratio of IGF-II to 
the Ser-29 variant at each time point for each profile, with the mean ratio highlighted at the end 
of each table. 
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Figure 4.6 - A. Representative autoradiographs of RPAs depicting the expression of IGF-IR 
mRNAs in both SK-N-MC and SK-N-SH neuroblastoma cells during a 7 day growth profile 
experiment in serum-containing medium. (M): MW marker; (P): IGF-IR RNA probe; (R): RNase 
digestion of the !GF-IR RNA probe; (1-7): 25p.g of total RNA isolated at each 24h time point from 
SK-N-MC cells hybridised with the IGF-IR RNA probe; (8-14): 25p.g of total RNA isolated at each 
24h time point from SK-N-SH cells hybridised with the IGF-IR RNA probe. The protected fragment 
size is depicted in bold, the full length probe in normal text. Both the SK-N-MC and SK-N-SH 
experiments were exposed for 7 days. B. Expression levels of IGF-IR mRNA compared to total IGF-1 
expression (Bars) in a representative SK-N-MC growth profile depicting over-confluency (Line, SE). 
(M) depicts the time point at which the medium was changed to fresh culture medium. 
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4.3.4 IGF-1 mRNA Expression with Cellular Differentiation 
Differentiation of SK-N-MC cells was achieved by the withdrawal of 10% FBS, 
following 48h of plating in 10% FBS. Differentiation was marked by a change in 
the neuroblastoma phenotype, where SK-N-MC cells developed distinct neuronal 
processes and exhibited an independent pattern of growth compared with the cells 
grown in parallel with 10% FBS (Fig. 4.7a, b). Differentiation was further marked 
by a decrease of plasminogen activator activity in SK-N-MC cells grown in serum-
free media. Plasminogens are used as markers for cell invasion in a number of cell 
systems, including SK-N-SH cells (Tiberio et al., 1997). A decrease of 
plasminogen activator activity in serum-free conditions (n=4; p < 0.05; Fig. 4.8) 
while the cells maintained a positive growth profile (n=3; refer Fig. 4.10a), was 
regarded as a departure from cell invasion and was therefore considered a marker 
for differentiation. In contrast, the SK-N-SH cells grown in the absence of 10% 
FBS were stationary in growth (n=3; Fig. 4.10a) and exhibited a starved 
morphology (Fig. 4.7c, d). Plasminogen activator activity decreased in cells grown 
without 10% FBS (n=4; p < 0.05; Fig. 4.8) compared with SK-N-SH cells grown in 
10% FBS. The poor growth profile and lack of plasminogen activator activity in the 
SK-N-SH cells grown in serum-free conditions, is suggestive of a departure from 
cell invasion in these cells. 
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Figure 4.8 - Plasminogen activator activity in SK-N-MC and SK-N-SH cells grown for 72h in 
serum-containing (+FBS) and serum-free (-FBS) medium. Bars, SE. *, p < 0.05 where cells grown 
+FBS were compared to cells grown -FBS by Student's t-test. 
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Figure 4.7 - Morphological comparison of SK-N-MC and SK-N-SH neuroblastoma cells 
grown for 72h in serum-containing or serum-free medium. A. Brightfield photomicrograph of 
SK-N-MC cells grown in serum-containing medium for 72h at X200. B. Brightfield 
photomicrograph of SK-N-MC cells grown in serum-free medium for 72h at X200. Arrows show 
neuronal processes. C. Brightfield photomicrograph of SK-N-SH cells grown in serum-
containing medium for 72h at XJOO. D. Brightfield photomicrograph of SK-N-SH cells grown in 
serum-free medium for 72h at XJOO. Arrows show highly refractive cells which indicate a 
starved morphology. 
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In a large number of cell lines, the withdrawal of FBS from the culture medium, 
stimulates apoptotic cell death. A morphological evaluation of each cell line at 24, 
48 and 72h following the removal of 10% FBS, compared to those cells grown in 
medium containing 10% FBS, showed that apoptosis was not significantly induced 
in either cell line with the withdrawal of 10% FBS (n=3; data not shown). 
IGF-I mRNA expression was analysed after 24, 48 and 72h of serum withdrawal in 
SK-N-MC and the SK-N-SH cells via RPA. In the SK-N-MC cells class 1 Eb was 
the only IGF-I mRNA detected, with the other major IGF-I mRNAs either not 
expressed or below the limits of detection for this assay (n=3; Fig. 4.9a). 
Surprisingly, in contrast to SK-N-SH cells grown in medium containing 10% FBS, 
class 1 Eb mRNAs were detected in cells grown in serum- free medium (n=3). This 
expression although difficult to see in the representative figure, was verified by RT-
PCR analysis with IGF-I exon specific primers (n=3; Fig. 4.9b). 
The class 1 Eb mRNAs were quantified for each time point in both SK-N-MC (n=3) 
and SK-N-SH (n=3) serum-free experiments. Results were pooled and the growth 
curves and the levels of mRNA expression were compared between experiments. 
Although not clear from the representative autoradiograph (Fig. 4.9a), in SK-N-MC 
cells grown under serum-free conditions, class 1Eb mRNA levels increased with 
increasing cell confluency, so that class 1 Eb expression levels at 72h were 1.9-fold 
higher than at 24h (n=3; *, p < 0.05; Fig. 4.10a). In comparison to SK-N-MC cells, 
SK-N-SH cells grown under the same conditions expressed significantly lower 
levels of class 1 Eb mRNAs, being 6.4-fold lower than the levels expressed by SK-
N-MC cells at 24h (n=3; ++, p < 0.01; Fig 4.10a). Unlike the SK-N-MC cells, the 
SK-N-SH cells did not exhibit a significant increase in growth in serum-free 
conditions, reflected by the stationary levels of class 1 Eb mRNA expression (Fig. 
4.1 Oa). These results show that IGF-I mRNAs are differentially expressed between 
cell growth and cell differentiation, induced by the removal of exogenous growth 
factors. 
In an extension to this study, a comparison was made between class 1 Eb expression 
levels at equivalent cell densities in SK-N-MC cells that were grown with or 
without serum (Fig.4.10b). While class 1 Eb mRNAs were expressed in SK-N-MC 
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Figure 4.9 - A. Representative autoradiograph of an RPA depicting the expression of the 
variable mRNAs in SK-N-MC and SK-N-SH neuroblastoma cells grown for 72h in serum-free 
medium. (M): MW marker; (P): IGF-1 multiple mRNA probe; (R): RNase digestion of the IGF-1 
multiple mRNA probe; ( 1 ): 7 day exposure of 24h time point of SK-N-MC experiment A 
hybridised to the 1GF-1 multiple mRNA probe; (2): 10tJg ofCHO pro-IGF-1 Eb RNA hybridised 
with the IGF-1 multiple mRNA probe; (3): 30!Jg of RNA from Day 4 SK-N-MC cells grown in 
serum, hybridised with the IGF-1 multiple mRNA probe; (24, 48, 72): RNA samples from SK-N-
MC or SK-N-SH cells grown for 24, 48 or 72h in serum-free conditions hybridised with the IGF-1 
multiple mRNA probe; (A, B, C): Represent the three individual SK-N-MC cell experiments 
grown in serum-free conditions. Protected fragments are shown in bold, the full-length probe in 
normal text. The CHO-IGF-1 Eb sample (Lane 1) was exposedfor 7 days, while the remaining 
samples were exposed for 21 days. B. RT-PCR analysis of the variant IGF-1 mRNAs in SK-N-MC 
and SK-N-SH cells grown for 48h in serum-containing and serum-free medium. Each IGF-1 
mRNA being analysed is indicated. (M): MW marker rpX 174 Haelll; ( 1): SK-N-MC cells grown 
in 10% FBS for 48h; (2): SK-N-MC cells grown in serum-free conditions for 48h; (3): SK-N-SH 
cells grown in 10% FBS for 48h; (4): SK-N-SH cells grown in serum-free conditions for 48h (for 
class 1 Eb expression 3 PCR reactions were pooled and concentrated); (5): Water control. An 
arrow with the expected size in bp identifies the predicted fragments. 
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cells grown in serum (n=3), the levels were found to be 11.7- (48h) to 21.5-fold 
(72h) lower (n=3; *, p < 0.05), than in the SK-N-MC cells grown in serum-free 
medium. These results provide further evidence that class 1 Eb may have a role in 
determining both the mitogenic and differentiation functions of IGF-I. In SK-N-
MC cells this appears to be regulated by the withdrawal of serum. 
4.3.5 /GF-11 mRNA Expression with Cellular Differentiation 
Where there was sufficient material, no expression of IGF-II mRNA could be 
detected in SK-N-MC cells grown in either serum-containing or serum-free 
environments, whereas both IGF-II and its Ser-29 variant were synthesised by the 
SK-N-SH cells in serum-free conditions (Fig. 4.11a). 
The relative expression levels of IGF-II and its Ser-29 variant were quantified in the 
SK-N-SH cells maintained in serum-free conditions, to look for alterations in their 
pattern of expression from 24-72h (n=2; Fig. 4.11b). No significant difference in 
the pattern of expression was observed. These results however, are not conclusive, 
since there was only sufficient material to perform two experiments and each of 
these had markedly different growth profiles. Interestingly, when the ratio of IGF-II 
to Ser-29 was plotted, the levels of IGF-II mRNA increased relative to the Ser-29 
variant under serum-free conditions (Fig 4.11c). Further experimentation is 
required to confirm this trend and significance. 
4.3.6 IGF-IR mRNA Expression with Cellular Differentiation 
IGF-IR mRNA expression was analysed in both SK-N-MC (n=2) and SK-N-SH 
(n=3) cells grown in serum-free medium to see if there was a change in the pattern 
of expression of the IGF-IR. In both SK-N-MC and SK-N-SH cells, the expected 
520 bp fragment specific for the IGF-IR was detected (Fig. 4.12). However, in 
addition to the expression of the expected IGF-IR mRNA, another protected 
fragment determined to be approximately 500 bp by logarithmic analysis, was also 
detected in both cell lines grown in serum-free conditions. The expression of this 
500 bp fragment, was not detected in either SK-N-MC or SK-N-SH cells grown in 
media containing 10% FBS (Fig. 4.12). 
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Figure 4.10- A. Expression levels of class I Eb mRNAs synthesised by SK-N-MC and SK-N-SH 
neuroblastoma cells grown in serum-free medium (Bars, SE) relative to the viable cell number 
(Lines, SE). n=3; *, p < 0.05 for SK-N-MC 24h compared to 72h by Student's t-test; ++, p < O.OI 
for SK-N-MC at 24h compared to SK-N-SH at 24h and so forth by Student's t-test. B. Comparison 
of class I Eb expression in SK-N-MC cells grown in the presence (+FBS) and absence (-FBS) of 
IO% FBS (Bars, SE) relative to the viable cell numbers (Lines, SE). n=3; *, p < 0.05 for SK-N-MC 
+FBS compared to SK-N-MC -FBS at each 24h time point by Student's t-test. 
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Figure 4.11 -A. Representative phosphoimages of an RPA depicting the mRNA expression of 
JGF-11 and its Ser-29 variant in SK-N-SH and SK-N-MC neuroblastoma cell lines grown for 72h 
in serum-free conditions. (M): MW marker; (P): JGF-11 RNA probe; (R): RNase digestion of the 
IGF-11 RNA probe; (24, 48, 72): RNA samples from either SK-N-MC or SK-N-SH cells grown for 
24, 48 or 72h in serum-free conditions. Protected fragment sizes are indicated in bold, the full 
length probe in normal text. * indicates an unidentified protected mRNA or potential degradative 
product. The SK-N-SH and SK-N-MC serum-free experiments were exposed for 2 days. B. The 
expression levels of IGF-11 and the Ser-29 variant of IGF-II (Bars) in SK-N-SH cells grown in 
serum-free conditions, in relation to the cell growth profiles (Lines, SE). C. The ratio of IGF-11 
to Ser-29 variant expression in SK-N-SH cells over 72h in serum-free medium. 
Page 116 
Walker, 1998 
A. 
B. 
0.9 
<( 0.8 
z 0.7 0:: 
Iii 0.6 0 
1- 0.5 Cl 
::;, 
<( 0.4 
z 0.3 0:: 
E 
Cl 0.2 
c. 
0.1 
0 
c. 
3.5 
3 
m 2.5 ~ 
"' en 2 .. 
il: 
!2 1.5 
0 
:;:; 
.. 
0:: 
0.5 
0 
SK-N..SH SK-N-MC 
P M R 24 48 72 24 48 72 
~ 
24h 48h 72h 24h 48h 72h 
Expt. 1 Expt. 2 
Hours {h) Serum-Free Medium 
24h 48h 72h 24h 48h 72h 
Expt. 1 Expt. 2 
Hours {h) Serum-Free Medium 
Page 117 
898 IGF-11 Probe 
565 IGF-11 
421 Ser-29 
* 
159 Ser-29 
0.9 
0.8 < 
0.7 ;;:;· tT 
0.6 
a; c::::J IG F-11 () 
0.5 ~ -IG F-11 Ser-29 
'It 
_._Cell# x 1 OE7 0.4 >< 
...... 
0.3 0 m 
0.2 .... 
0.1 
0 
ll\lRatio IGF-11: Ser-29 
Walker, 1998 
As described in Section 2.8.6, the IGF-IR RNA probe will hybridise to mRNAs in 
an RP A which contain the very 3' region of ex on 2 through to the very 5' region of 
exon 3 encoding a portion of the a-subunit of the IGF-IR. To determine the identity 
of the unknown 500 bp fragment, the nucleotide sequence protected by the IGF-IR 
RNA probe was compared to the available gDNA sequence information from the 
human insulin receptor (IR), and to the exon/intron donor and acceptor sites for the 
human IGF-IR (Abbott et al., 1992; Fig. 4.13 5). The IGF-IR RNA probe used in the 
representative RP A in Figure 4.12, covers from the Pvuii restriction enzyme site 
through to position 7 42 shown in Figure 4.13. From this comparison it appears that 
1000 
734 
430 
SK-N-SH -FBS SK-N-MC ·FBS +FBS 
A B c A B 
M P R 48 72 24 48 72 24 48 72 24 48 72 2448 MC SH 
586 IGF-IR Probe 
Figure 4.12 - Representative phospho image combined with an autoradiograph of an RP A 
depicting the expression of JGF-IR mRNAs in SK-N-SH and SK-N-MC neuroblastoma cells grown in 
serum-free medium, compared to growth in serum-containing medium. (M): MW marker; (P): JGF-
IR RNA probe; (R): RNase digestion of the JGF-IR RNA probe; (A, B, C): Individual cell 
experiments for either the SK-N-SH or SK-N-MC cell line grown in the absence of serum (-FBS); 
(24, 48, 72): Time spent in serum-free medium; (MC): SK-N-MC cells grown in serum (+FBS) 
harvested at Day 5; (SH): SK-N-SH cells grown in serum (+FBS) harvested at Day 4. The 
phosphoimage for both the SK-N-SH and SK-N-MC serum-free experiments were exposed for 2 
days, while the autoradiograph of the cells grown in serum, were exposed for 7 days. 
5The gDNA sequence for the human IGF-IR is not available on genebank databases, hence the 
gDNA sequence of the human IR was utilised for Fig. 4.13, due to its reasonable homology to the 
IGF-IR. The exon/intron donor and acceptor sites for the human IGF-IR reported by Abbott et al., 
(1992) were also used for comparison. 
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the novel 500 bp protected fragment may be a variant IGF-IR mRNA, which lacks 
the expression the 5' portion of exon 3 or potentially the entire exon 3 itself through 
mechanisms such as alternative splicing (Fig. 4.13). If this is so, it represents an 
important finding because exon 3 codes for the cysteine clusters responsible for 
ligand binding to the IGF-IR and ultimately the initiation of the biological response. 
Using the phosophoimager index, the ratio ofiGF-IR (520 bp) to the 500 bp 
128 CCGCGCTCTCGCTCTGGCCGACGAGT .. GGAGAAATCTGCGGGCCAGGCA 175 
201 GCTACTGGGCGCCGCQGGCCACCTGTACCCCGGAGAGGT~~ 250 
176 TCGACATCCGCAACGACTATCA~GCCTGGAGAACTGCACG 225 
251 TGGATATCCGGAACAACCTCACTAGGTTGCATGAGC~JLTTGCTCT 300 
226 GTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAA ...... GGCCGA 269 
301 GTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGA 350 
270 GGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACT 319 
351 AGATTTCCGAGACCTCAGTTTCCCCAAACTCATCAT~CACTGATTACT 400 
320 '.l'GCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTCCCC 369 
401 TGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAGGACCTGTTCCCC 450 
370 AACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCC'l'GGT 419 
370 AACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTGGT 500 
420 CATCTTCQAQATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGA 469 
501 CATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGA 550 
469 ~TACTCGGGGGGCCATCAGGATTGAGAAAAATGCTGACCTCTGTTAC 519 
469 ACATCACCCGGGGTTCTGTCCG~C~AATGAGCTCTGTTAC 519 
520 CTCTCCACTGTGGACTGGTCCCT~CTGGATGCGGTGTCCAATAACTA 569 
601 TTGGCCACTATCGACTGGTCCCGTATCCTGGATTCCGTGGAGGATAATCA 650 
570 ~TGTGGGGAATA ... AGCCCCCAAAGGAATG'l'GGGGACCTGTGTCCAG 616 
651 CATCGTGTTGAACAAAGATGACAACGAGGAGTGTGGAGACATCTGTCCGG 700 
617 GGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG 666 
701 GTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTCATCAACGGGCAG 750 
TACAACTACCGCTGCTGGACCACAAACCGCTGC~:~1r~GI 667 716 
751 TTTGTCGAACGATGTTGGACTCATAGTCACTGC ~ ~~CGAC 800 
717 ~gtcgacgagctcgagaattc 742 
801 CATCT 805 
Figure 4.13 - Comparison of the IGF-IR nucleotide sequence encoded by the IGF-IR RNA 
probe (upper), to the eDNA sequence of the human IR (lower). Homologous nucleotides are in 
bold. IR exon junctions are labelled and correspond to the exon junctions in the human IGF-IR. 
The Pvull restriction enzyme site is highlighted in blue. The shaded region in yellow represents 
the possible sequence that is absent in the 500 bp IGF-IR protected fragment. 
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protected fragment at each time point in both cell lines, was determined. This 
analysis revealed that the expression levels were similar for both of the IGF-IR 
protected fragments (n=9; 1.18 ± 0.087). This does not take into consideration the 
radiolabelled uracil incorporation of the ~20 bp variation. IGF-IR expression in both 
the SK-N-MC and SK-N-SH cells was quantified. In this preliminary investigation 
of SK-N-MC cells, the IGF-IR (520 bp) expression levels appear to increase over 
the 72h in serum-free conditions, reflecting the increase in class 1 Eb expression 
and the increase in cell confluency (Fig. 4.14). As mentioned previously, the 
variant IGF-IR mRNA (500 bp) is expressed in a 1:1 ratio with the IGF-IR, and its 
levels of mRNA also appear to increase with cell confluency. Very little 
information on the pattern of expression of the 520 bp IGF-IR can be established 
from SK-N-SH cells maintained in a serum-free environment due to the high 
variation in IGF-IR expression levels at each time point between the three 
experiments (Fig. 4.15). However, the levels of IGF-IR expression are lower than 
in SK-N-MC cells grown in the equivalent environment (Fig 4.14). A more detailed 
evaluation may show that IGF-IR expression by the SK-N-SH cells decreases with 
time in serum-free conditions. 
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Figure 4.14 - Expression levels of the 520 bp IGF-IR mRNA in SK-N-MC cells grown in serum-
free conditions for 72h (n=2; Bars) compared to the growth profiles (Lines). 
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Overall, this data suggests that both cell lines are sensitive to the autocrine 
production of IGFs in serum-free conditions. Principally in SK-N-MC cells, this 
sensitivity is to the autocrine production of pro-IGF-I Eb or its proteolytically 
cleaved products, IGF-I and the Eb peptide. The actions of the IGF-I post-
translation products in SK-N-MC cells grown in serum-free conditions may induce 
their biological response through the IGF-IR or its potential variant form. 
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Figure 4.15- Expression levels of the 520 bp JGF-IR mRNA in SK-N-SH cells over 72h in serum-
free culture medium (n=3; Bars, SE), compared to the growth profile (n=3; Line, SE). 
4.4 Discussion 
IGF-I and -II have been shown to play integral roles during growth and 
differentiation (Pahlman et al., 1991; Cohick and Clemmons, 1993; Li et al., 1997), 
they act as survival factors by preventing apoptosis (Barres et al., 1992; Babajko 
and Binoux, 1996; Matthews and Feldman, 1996), and behave as mitogens in 
tumourigenesis (Quinn et al., 1996; Silberstein et al., 1997). These properties 
suggest that the IGF family has a pivotal role in determining cellular fate. The 
functional diversity of IGF-I and -II is achieved by both extracellular and 
intracellular regulation under many physiological and pathological conditions 
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(reviewed LeRoith et al., 1995; Stewart and Rotwein, 1996b). In this study, I have 
investigated a potential mechanism that may contribute to the diverse biological 
effects of the IGFs. This mechanism occurs at the level of transcription, where the 
genes for IGF-I and -II transcribe multiple mRNAs by alternate promoter usage, 
alternative splicing, multiple transcription start sites and multiple poly-adenylation 
signals (Jansen et al., 1983; 1985; Rotwein, 1986; De Pagter-Holthuizen et al., 
1988; Tobin et al., 1990). The major aim of this chapter was to establish whether 
the variant IGF-I mRNAs, and to a lesser degree IGF-II mRNAs, are differentially 
expressed between cells induced to either grow or differentiate. To do this I used 
the SK-N-MC and SK-N-SH neuroblastoma cell models, which express IGF-I and 
IGF-II respectively (Yee et al., 1990). These cells were allowed to grow in the 
presence of 10% FBS and differentiated using serum-free medium. Leftover 
samples from these experiments were used to analyse the levels of IGF-II and its 
Ser-29 variant as well as the IGF-IR. 
The human neuroblastoma cell lines SK-N-MC and SK-N-SH are established cell 
culture lines isolated from metastatic neuroblastoma tissues and have been shown to 
maintain most of their original in vivo characteristics in culture conditions (Biedler 
et al., 1973). These cell lines have been used extensively in the study of 
neuroendocrine regulation of growth and development, and in particular the 
function of the IGF family (Babajko and Binoux, 1996; Kiess et al., 1997). Both 
SK-N-MC and SK-N-SH cells actively grew in the presence of 10% FBS. SK-N-
MC cells expressed mRNAs for IGF-I but not IGF-II (Yee et al., 1990; Kiess et al., 
1997), whereas SK-N-SH cells expressed IGF-II and the Ser-29 variant, but not 
IGF-I mRNAs, with both cell lines expressing the IGF-IR. This pattern of 
expression is consistent with PNET cell lines like SK-N-MC, which possess a 
t(11;22) translocation and express IGF-I but not IGF-II (Yee et al., 1990), while 
those cell lines lacking the translocation such as the SK-N-SH cells, express IGF-II 
but not IGF-I (Yee et al., 1990). Of the IGF-I mRNAs expressed by SK-N-MC 
cells in the presence of 10% FBS, class 1 Eb, class 1 Ea, class 2 Eb and class 2 Ea 
were detected, along with additional protected fragments. It remains to be 
determined whether these additional protected fragments, particularly the fragment 
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that corresponds to the class 2 exon 4-5-6 mRNA, are authentic IGF-I mRNAs or 
degradation products. 
To see if IGF-I mRNAs were differentially expressed during growth in serum-
containing medium, the four major IGF-I mRNAs were quantified and compared 
during growth of these cells over a 7 day time course. Under these conditions, the 
SK-N-MC cells synthesised each of the four major IGF-I mRNAs, which increased 
with an increase in cell number, while their synthesis coordinately decreased when 
cell viability declined. There was no change in the relative expression of class 1 
IGF-I mRNAs relative to class 2, or Ea relative to Eb over the 7 day growth profile. 
Class 2 expression was slightly higher than class 1, as previously identified in rat 
neuronal and glial cells (Adamo et al., 1988), while the expression of Ea was 
greater than Eb, as is seen in most normal human tissues including liver and breast 
tissue (Lowe et al., 1988; Walker et al., 1998). There appeared to be no change in 
the pattern of expression of IGF-II or the Ser-29 variant in the SK-N-SH growth 
profile. Interestingly, at a high cell density, both mRNAs appear to decline in their 
abundance, however a more detailed investigation is required to determine the 
significance of this observation. 
The increase in IGF synthesis by both SK-N-MC and SK-N-SH cells, was paralleled 
with a concomitant increase in IGF-IR expression, suggesting that these cells are 
responsive to autocrine stimulation by IGFs. The autocrine stimulation of 
neuroectodermal tumours by the synthesis of endogenous IGFs, has previously been 
shown by blocking IGF-IR/ligand interactions and reversing this effect with excess 
ligand (ElBadry et al., 1989; Yee et al., 1990; Martin and Feldman, 1993). Both 
SK-N-MC and SK-N-SH cells have functional IGF-IRs which are 
autophosphorylated by ligand binding (Ota et al., 1988; Kiess et al., 1997). It may 
be likely that as the exogenous IGFs are utilised by these cells during growth in 
serum-containing medium, the synthesis of endogenously produced IGF-IRs is 
increased to maintain cell growth and survival. Where cell confluency is maximal 
and the culture medium is depleted of hormones and nutrients, IGF-I synthesis 
declines. This decline in IGF production appears to be compensated by increasing 
the levels of the IGF-IR. In vivo fasting has been shown to result in a 2-fold 
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increase in IGF-IR mRNA and an increase in IGF-I binding (Lowe et al., 1989). 
Thus the up-regulation of IGF-IR expression in the present investigation, is possibly 
regulated by the decrease in IGF levels in the neuroblastoma cell environment, as 
previously proposed in other experimental systems (Thissen et al., 1994). 
To see if the expression of IGF mRNAs could be changed by introducing a different 
cell environment, the four major IGF-I mRNAs, IGF-II and the Ser-29 variant as 
well as the IGF-IR, were quantified and compared in SK-N-MC and SK-N-SH cells 
grown in serum-free conditions. SK-N-MC cells exhibited a change in growth 
pattern and became differentiated in serum-free conditions. The differentiation of 
the SK-N-MC cells, was marked by the development of neuronal processes and a 
decrease in the activity of plasminogen activators (tissue type plasminogen activator 
[tPA] and urokinase plasminogen activator [uPA]), when compared with their 
serum containing counterpart. While these cells were differentiated, they also 
maintained a positive growth profile comparative to those cells grown in serum. 
Thus the decrease in plasminogen activator activity was regarded as a marker for 
differentiation (Tiberio et al., 1997). In contrast to SK-N-MC cells, SK-N-SH cells 
in serum-free conditions were stationary in growth yet also exhibited a lower 
plasminogen activator activity when compared to cells grown in serum. The poor 
growth response and the lack of a differentiated phenotype by the SK-N-SH cells in 
a serum-free environment, could be due to the fact that they are density dependent. 
Of the four major IGF-I mRNAs synthesised by SK-N-MC cells in the presence of 
exogenous growth factors, only the class 1 Eb mRNAs could be detected in SK-N-
MC cells which proliferated and differentiated in serum-free conditions. Over 72h, 
class 1 Eb mRNAs increased with an increase in cell number while in a parallel 
study, no IGF-II or Ser-29 mRNAs were detected, making their role as agents for 
differentiation and growth in these cells unlikely. Surprisingly, SK-N-SH cells 
which had previously synthesised IGF-II mRNAs exclusively in serum-containing 
medium, expressed class 1 Eb mRNAs in serum-free conditions, while continuing 
to express the mRNAs for IGF-II and the Ser-29 variant. Over time, the levels of 
class 1 Eb mRNAs were unchanged reflecting the stationary growth profile of these 
cells. The physiological trigger for the transcriptional selection of class 1 over class 
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2 mRNAs in a serum-free environment for both cell lines, can only be speculated. 
Exon 1 and 2 are driven by separate promoters and code for the first 21 aa of the 
signal peptide for class 1, or the first 5 aa for class 2 (Jansen et al., 1983; Rotwein, 
1986; Tobin et al., 1990). The signal peptide is hypothesised to function as a co-
translationally cleaved peptide, directing nascent peptides to the secretory pathway 
(Sussenbach et al., 1992; Rotwein et al., 1993). Studies in rat model systems have 
shown that class 1 and 2 mRNAs are differentially regulated, specifically in the 
liver during development, fasting and diabetes (Adamo et al., 1989; 1991 b). Class 
1 mRNAs are generally the predominant mRNAs with class 2 mRNAs being more 
growth hormone sensitive and highly tissue specific (Lowe et al., 1987; Roberts et 
al., 1987; Adamo et al., 1989). The presence of class 2 mRNAs in SK-N-MC cells 
grown in serum but not in cells grown without serum, suggests that the absence of 
exogenous peptides such as growth hormone in serum-free media, is responsible for 
the predominant use of class 1 mRNAs, over class 2. It may be that the use of the 
Pl promoter is a more efficient means of generating the 3' Eb mRNA, whereas the 
choice of Ea or Eb mRNAs may be the key to determining the biological actions of 
IGF-I. 
The physiological trigger for transcribing exon 5 and splicing exon 6 is unknown. 
Both the Ea and Eb propeptide mRNAs code largely for the same peptide, but they 
vary in the size and sequence of their terminal E domains and 3' UTR sequences 
(Jansen et al., 1983; Rotwein, 1986). It is known that both propeptides are cleaved 
during post-translational modification to produce the same mature IGF-I protein, as 
this protein is found in serum (Rinderknecht and Humbel, 1978a). It is therefore 
possible that the pro-hormones or the proteolytically released Ea and Eb domains 
have independent biological functions. For example, IGF-IB-(103-124)E1 amide 
(IBE1), a portion of the Eb propeptide, has been reported to have growth promoting 
activities in normal and malignant human bronchial cells, mediated by its own 
receptor (Siegfried et al., 1992), while Ea peptides have been detected in the serum 
of patients with renal failure (Powell et al., 1987). In the present study, the 
preferential selection of Eb mRNAs over Ea by both SK-N-MC and SK-N-SH cells 
in serum-free conditions, suggests that the splicing factors which process the IGF-I 
pre-mRNAs are regulated by growth factors and/or other proteins present in serum. 
Page 125 
Walker, 1998 
Splicing factors include the SR proteins, which are a large family of nuclear 
phosphoproteins. Some of these nuclear phosphoproteins have recently been shown 
to shuttle between the nucleus and cytoplasm (Caceres et al., 1998) and regulate 
alternative splice site selections in a concentration-dependent fashion (Jumaa and 
Nielsen, 1997; Caceres et al., 1997). Splicing factors are regulated by serum 
withdrawal. For example, SRp20 the smallest member of the SR protein family, 
has been shown to be differentially regulated when cells are grown in serum-free 
conditions as opposed to serum-containing conditions (Jumaa and Nielsen, 1997). 
It is feasible that the removal of insulin, glucocorticoids, glucose or even IGFs or 
their binding proteins as well as other hormones and factors provided by serum, 
may trigger the use of alternative splicing factors or alter their concentrations or 
even modify their peptide structure, thereby altering their function. 
Both SK-N-MC and SK-N-SH cells synthesised the expected IGF-IR mRNA in 
serum-free conditions. However, a novel feature for both of these cell lines was the 
synthesis of a potential variant mRNA which may code for an IGF-IR lacking the 
very 5' region of exon 3 or exon 3 itself. An IGF-IR lacking exon 3, does not 
contain the extracellular cysteine rich region, a region specific for IGF-I ligand 
binding. The cysteine rich region was shown to be important for ligand binding 
through experiments that blocked IGF-I binding to the IGF-IR. This was done by 
using an aiR3 antibody, whose epitopes are directed against amino acid 223-274 
and 184-283 which reside within the cysteine rich domain of the IGF-IR (Soos et 
al., 1992). Splice variants of the human IGF-IR are not unusual. Another splice 
variant has previously been reported, where an arginine or a threonine and glycine 
are present or absent in exon 14 of the ~-subunit (Yee et al., 1989b; Abbott et al., 
1992). The splice variant described in the present study has not previously been 
reported for the human IGF-IR and it remains to be authenticated. However 
assuming that the variant lacks exon 3, following translation both neuroblastoma 
cell lines have the potential to generate three possible receptors; (1) a functional 
heterotetrameric IGF-IR with the cysteine rich region in both a-subunits; (2) a 
chimeric receptor possessing a truncated a-subunit lacking the cysteine rich domain 
and a functional a-subunit; (3) a heterotetrameric receptor with two truncated a-
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subunits. Hybrid receptors consisting of a-~-hemireceptor of IGF-I and a-~­
hemireceptor of the insulin receptor have been identified in placental membranes 
and cell lines (Moxham et al., 1989; Soos et al., 1990) and they have been shown to 
favour insulin binding rather than IGF-I binding (Soos et al., 1993). Of the three 
IGF-IR species described, the intact IGF-IR will bind IGF-I and -II inducing the 
expected cellular responses, while the hybrid and truncated receptors may bind IGFs 
or novel ligands producing altered conformational changes to the receptor, which 
may result in novel signal transducing capabilities. 
The differential expression of IGF-I may be a mechanism involved in determining 
the biological actions of IGF-1. In SK-N-MC and SK-N-SH cells grown in serum-
free conditions, the lack of exogenous hormones upregulates or initiates the 
synthesis of class I Eb mRNAs and initiates the synthesis of a potential variant IGF-
IR mRNA while continuing to express functional IGF-IRs. The functional 
significance of class I Eb expression and the synthesis of an alternate IGF-IR may 
only be hypothesised at this stage. I propose that IGF-I Ea and IGF-I Eb serve 
distinct functions in cell growth, differentiation and tumourigenesis which is 
determined by the regulation of their expression. This is proposed to occur via two 
possible mechanisms. Firstly, I hypothesise that serum-free conditions stimulate the 
synthesis of pro-IGF-I Eb, which is cleaved within the cell to produce IGF-I and Eb 
peptides. IGF-I is then secreted from the cell where it acts on the IGF-IR 
stimulating growth in the SK-N-MC cells and cell maintenance in the SK-N-SH 
cells (Fig. 4.16a). Assuming the cleaved Eb or pro-IGF-I Eb remains intracellular, 
they can act on the nucleus where they can regulate transcription and pre-mRNA 
processing of genes such as the potential truncated IGF-IR (Fig. 4.16a). The Eb 
peptide is a similar size to IGF-I and contains several highly basic regions, which 
may be important for cell surface and nuclear binding, indicating a probable role for 
the Eb peptide distinct from IGF-1. It is likely that pro-IGF-I Eb is cleaved 
intracellularly since the processing enzymes which are proposed to contribute to the 
cleavage of this peptide (including the family of subtilisin-related proprotein 
converting (SPC) enzymes) process a broad range of prohormones and are widely 
distributed (Duguay et al., 1995). 
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A. Intracellular Mechanisms 
B. Extracellular Mechanisms 
Hybrid IGF-1 
Receptor 
· -----
IGF-1 
Receptor 
/ 
-
•• Truncated IGF-1 
•• Receptor 
Figure 4.16 - A, B Two hypothesised mechanisms of IGF-1, pro-IGF-1 Eb and Eb action 
induced by a sentm-free environment in both neuroblastoma eel/lines. 
Page 128 
Walker, 1998 
My second hypothesis is that pro-IGF-I Eb is cleaved either intracellularly or 
extracellularly to produce IGF-I and Eb which are secreted into the extracellular 
environment (Fig. 4.16b ). Secreted IGF-I would bind and elicit its biological 
effects, as previously described. Secreted Eb or intact pro-IGF-I Eb may also bind 
their own receptor, possibly the truncated IGF-IR or hybrid-IGF-IR to elicit their 
own biological effects (Fig. 4.16b ). Overall it is tempting to hypothesise that the 
biological response to IGF-I Eb is both growth and differentiation via the regulation 
and/or use of the IGF-IR and its variant form. Future investigations focusing on 
varying levels of expression of pro-IGF-I Eb and the verification of the potential 
variant IGF-IR mRNA are required to clearly define their role in cellular fate. 
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Chapter 5 
HUMAN INSULIN-LIKE GROWTH FACTOR-
BINDING PROTEIN (IGFBPs) EXPRESSION 
DURING CELL GROWTH AND 
DIFFERENTIATION OF THE HUMAN 
NEUROBLASTOMA CELL LINE SK-N-MC: A 
PRELIMINARY INVESTIGATION 
5.1 Introduction 
As described in prior chapters, both insulin-like growth factor-! (IGF-1) and -II have 
been identified as playing essential roles in normal cellular growth and development 
(Liu et al., 1993; Baker et al., 1993; Powell-Braxton et al., 1993). As for other 
peptide hormones, the biological actions of IGFs are regulated by their interactions 
with transmembrane receptors (Section 1.4.4). The availability of the IGFs for 
receptor binding is regulated by their association with high and low affinity binding 
proteins, the insulin-like growth factor-binding proteins (IGFBPs) and the IGFBP-
like binding proteins (Section 1.4.6). 
The IGFBPs are a highly homologous family of proteins, which regulate IGF actions 
in both a functional and tissue specific fashion (Table 1.1 ). Currently six high 
affinity IGFBPs (IGFBP-1 to -6), have been identified in the circulation or within 
extracellular compartments (Table 1.1; Baxter and Martin, 1989; Clemmons, 1992; 
Rechler, 1993). The diversity of IGFBP regulation is enhanced by the fact that 
certain members of the IGFBP family can be post-translationally modified and thus 
are capable of yielding phosphorylated, glycosylated or proteolytically cleaved forms 
(Jones et al., 1991; Drop et al., 1992; Rechler, 1993). According to the type and 
form, IGFBPs can serve to prolong the IGF half-lives and behave as carrier 
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molecules. Once in the vicinity of the target cell they can regulate the ability of IGFs 
to interact with transmembrane receptors, and depending on the type and form either 
potentiate or inhibit the biological actions of IGFs (DeMellow and Baxter, 1988; 
Blum et al., 1989; Liu et al., 1991). As well as their IGF regulatory role, it has been 
reported more recently that IGFBP-3 and -5 have biological effects independent of 
IGFs (Jones et al., 1993; Oh et al., 1993a), mediated by cell surface receptors (Oh et 
al., 1993b; Andress, 1995). Leal et al., (1997) have identified the type V 
transforming growth factor~ receptor as the putative IGFBP-3 receptor. Overall the 
presence and the function of IGFBPs and IGFBP-like binding proteins, increases the 
diversity of IGF actions. 
An alteration in IGFBP expression as well as secretion has been observed during the 
proliferation, differentiation and mineralisation of primary cultures of rat osteoblasts 
(Birnbaum and Wiren, 1994). In addition, des (1-3) IGF-I, which has a reduced 
affinity for IGFBPs, was shown to have more dramatic effects on cell growth and 
differentiation of the human neuroblastoma cell line SH-SY5Y, than intact IGF-I 
(Cianfarani et al., 1996). The intention of this preliminary study was to investigate 
IGFBP expression patterns in growing and differentiating SK-N-MC cells, to 
establish a basis for a more in depth investigation. In the previous chapter (Chapter 
4), the human neuroblastoma cell line SK-N-MC, was shown to differentially express 
the major IGF-I mRNAs as well as an altered IGF-IR expression pattern when the 
cells were induced to either grow or differentiate by the presence or absence of 10% 
FBS. The aim of the present study was to investigate whether the altered expression 
observed previously for IGF-I and the IGF-IR in these cells, could be observed 
throughout the rest of the IGF axis, as has been observed in other cell systems. 
5.2 Material and Methods 
5.2.1 Cell Culture 
The human neuroblastoma cell line SK-N-MC (P42) was grown in MEM 
supplemented with 10% heat inactivated FBS and glutamine in the presence of 
50U/ml penicillin G and 50!-Lg/ml of streptomycin sulphate, 1mM sodium pyruvate 
and 2.2g/L sodium bicarbonate. Cells were grown in a humidified incubator at 37°C 
with 5% C02 
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5.2.2 Cell Growth 
The SK-N-MC cell growth experiments were performed as described in Section 2.2. 
Every 24h, 1 plate of cells was harvested for a viable cell count with another 4 plates 
harvested for total cellular RNA extractions (Section 2.5.1). RNA was used for the 
analysis of IGFBP expression from two of the cell growth profiles for the SK-N-MC 
cells, described in Chapter 4. A lack of total cellular RNA prevented a more detailed 
analysis. It is important to note that one of these growth profiles was purposely 
plated at a higher cell density. This was done in order to examine the effect of over-
confluency on IGF expression (Chapter 4). 
5.2.3 Differentiation 
Differentiation of the SK-N-MC cells was performed as described in Section 2.3. At 
the 24h, 48 and 72h time points, 1 plate of cells grown in serum-free medium and 1 
plate of cells grown in culture medium, were photographed and harvested for cell 
counts (Section 2.2.1 ), with another 6 plates harvested for total cellular RNA 
extraction (Section 2.5.1). Culture medium from a 48h time point was collected and 
assayed for plasminogen activator activity (Section 2.3.1), a biochemical marker used 
to select for differentiation in SK-N-MC cells. In independent serum-containing and 
serum-free experiments, SK-N-MC cells were harvested at 24, 48 and 72h, fixed and 
embedded in paraffin (Section 2.3.2). The blocks were cut in 5!-Lm sections and 
stained with H&E as described in Section 2.4.1, to evaluate whether serum 
withdrawal induced programmed cell death (apoptosis; n=3). RNA from one of the 
differentiation profiles for the SK-N-MC cells performed in Chapter 4, was used to 
analyse the expression of IGFBPs. 
5.2.4 RNase Protection Assay (RPA) 
RP As for IGFBP-1 to -6 as well as triplicate experiments for the 18S rRN A internal 
standard, were performed for each time point in the cell growth and differentiation 
profiles for SK-N-MC cells, where sufficient total cellular RNA was available. 
Antisense [a32P]-labelled RNA probes for IGF-I (Section 2.8.1), IGFBP-1 to -6 
(Section 2.8.7 to Section 2.8.12), 18S rRNA (Section 2.8.13) and an unlabelled sense 
IGF-I RNA probe, were synthesised from eDNA constructs as described in Section 
2.9.2.1. Total cellular RNA (lOOpg- lO~g) was hybridised with 1.0 x 105 cpm of 
RNA probe at 42°C for 20h (Section 2.1 0). Resulting RNA: RNA hybrids were 
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electrophoresed with MW markers (Section 2.7.4) on a 5% polyacrylamide gel 
containing 8M urea (Section 2.8.1 ). Gels were dried and exposed for 48h to 
phosphoimager screens (BAS-IIIS) for quantification, followed by X-OMAT or 
CURIX RP 1 autoradiography. Identified protected fragments were quantified as 
described in Section 2.8.2 with mRNA expression defined as pg mRNAI)lg total 
RNA. Representative autoradiographs were scanned using Deskscan software and 
imported into Corel Draw 7 graphical software. 
5.2.5 RT-PCR 
To confirm the RPA experiments, RNA extracted from Day 4 of SK-N-MC cell 
growth profiles (n=2) and the 48h time point of SK-N-MC serum-withdrawal 
experiments (n=2), were analysed for IGFBP expression by RT-PCR. Breast tumour 
tissue is known to express IGFBP-2 to -6 but not IGFBP-1, therefore total cellular 
RNA isolated from breast tumour was used as a control. Reverse transcription was 
performed as described in Section 2.6. PCR was performed to amplify the specific 
IGFBP mRNAs using 1 OO)lM of a forward and reverse primer from the sets of 
primers described in Table 5.1. Conditions for the PCR reactions were 1 X [94°C, 
5min]; 30 X [94°C, lmin; +, 2min; 72°C, 2min]; 1 X [72°C, 7min] 5. 
5.2.6 Statistical Analysis 
The Student's t test was used for analysing differences between means of two 
variables. Results were considered to be statistically significant when p < 0.05. 
5.3 Results 
5.3.1 IGFBP Expression During Cellular Growth 
The mRNAs for the six IGFBPs were analysed by RPA in SK-N-MC cells grown in 
culture medium with 10% FBS over a 7 day time course (n=2). Messenger RNAs for 
IGFBP-1, -3 and -5 could not be detected at any at any time point in the experiments 
(n=2; Fig. 5.la, c, e). These results were verified for IGFBP-1 and -3 using RT-PCR 
with specific IGFBP primers described in Table 5.1. A PCR product corresponding 
5 + indicates the variable annealing temperatures between the sets of primers given in Table 5.1. 
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IGFBP-1 5' AACCTCTGCACGCCCTCACC 68 
3' CCTCTTCCCATTCCAAGGGTAGAC 
IGFBP-2 5' ACTGTGACAAGCATGGCCTGT 63 
3' CCTCCTGCTGCTCATTGTAGA 
IGFBP-3 5' GGAAATGCTAGTGAGTCGGAGG 60 
3' GCTCTGCATGCTGTAGCAGTGC 
IGFBP-4 5' CTGTGCCCCAGGGCTCCTGC 70 
3' TCACCCCGTCTTCCGGTCCA 
IGFBP-5 5' GCTCAAAGCCAGCCCACGCAT 68 
3' GTCGAAGGTGTGGCACTGAA 
IGFBP-6 5' AAGCTGAGGGCTGTCTCAGG 63 
3' AGCTTCCATTGCCATCTGGAG 
Table 5.1 ·Primer sets used for the PCR detection of the IGFBPs in SK-N-MC cells during growth 
and differentiation, written in a 5' to 3' direction from the coding strand. Primer sets for /GFBP-1, -
2, -4, -5 and -6 were obtained from David Frazer, CMB, Queensland University of Technology, QLD, 
Australia (Frazer et al., 1997). 
to the expected size was detected for IGFBP-5 (n=2; Fig. 5.2). The detection of 
IGFBP-5 by RT-PCR but not by RPA, suggests that the level ofiGFBP-5 expression 
was below the limits of detection for the RPA technique. It was anticipated that the 
IGFBP-2 RNA probe would protect three fragments in an RPA, a 446 bp fragment 
and 323/123 bp fragments. The anticipated fragments for IGFBP-2 and the expected 
505 bp fragment for IGFBP-4, were detected in growing SK-N-MC cells throughout 
the 7 day time course experiments (n=2; Fig. 5.1). Although not clear in figure 5.1f, 
an RP A analysis of IGFBP-6 revealed a very weak expression of the expected 264 bp 
fragment in the SK-N-MC cells. The RPA results for IGFBP-2, -4 and -6 in SK-N-
MC cells grown in culture medium containing 10% FBS were all verified by RT-
PCR (n=2; Fig. 5.2). Therefore in this preliminary study, it appears that IGFBP-1 
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Figure 5.1 - Representative autoradiographs of RNase protection assays depicting the expression 
of 1GFBP-1 to -6 in SK-N-MC cells grown in 10% FBS over a 7 day time course. The respective 
antisense RNA probes were hybridised with 1 Oj.lg of total RNA isolated from each 24h time point. 
Protected fragment sizes are indicated in bold, full-length probes in normal text. (M): MW marker; 
(P): full-length RNA probe; (R): RNase treatment of P; (T): Breast tumour RNA hybridised with the 
binding protein RNA probe; ( 1 to 7): RNA from each 24h time point hybridised with an antisense 
RNA probe. A. Expression of IGFBP-1. The representative autoradiographfor 1GFBP-1 in SK-N-
MC cells was exposed for 18 days, and 8 days for the breast tumour sample (T). B. Expression of 
1GFBP-2. The 323 bp fragment is the result of PCR error as described in Section 3.3.10. The 
representative auto radiograph for SK-N-MC cells was exposed for 14 days and 5 days for the breast 
tumour sample (T). C. Expression of IGFBP-3. The representative autoradiographfor 1GFBP-3 was 
exposed for 5 days. D. Expression of IGFBP-4. The representative auto radiograph for IGFBP-4 
expression in SK-N-MC cells and a breast tumour sample (T) was exposed for 17 days and 2 days 
respectively. E. Expression for IGFBP-5. Representative auto radiographs for IGFBP-5 expression 
in SK-N-MC cells and a breast tumour sample (T) were exposed for 8 and 5 days respectively. F. 
Expression of IGFBP-6. A representative autoradiograph of IGFBP-6 expression in SK-N-MC cells 
and a breast tumour sample (T) were both exposed for 10 days. 
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and -3 are not expressed in growing SK-N-MC cells while IGFBP-2, -4, -5 and -6 are 
expressed by SK-N-MC cells grown in culture medium containing 10% FBS. The 
expression of IGFBP-5 and -6 identified by RT -PCR, could have been verified by 
increasing the concentration of RNA in the RP A experiment, however at this point 
no more RNA sample was available. 
The IGFBP-2 and -4 fragments were quantified and compared to total IGF-I 
expression in the two cell growth profiles, with the 446 and 323 bp fragments of 
IGFBP-2 pooled to give IGFBP-2 expression levels (Fig. 5.3a, b) 7 8. The levels of 
IGFBP-6 expression were below the range of detection for the phosphoimager and 
hence were not quantified. Results for each of the SK-N-MC growth experiments 
(n=2) were treated individually due to the variability in the growth profiles and the 
IGFBP-1 IGFBP-2 IGFBP-3 
1353 
439 603 1 310 281/271 
194 
2 168 
3 467 IGFBP-4 IGFBP-5 IGFBP-6 
4 204 M G D T c G D T c G D T c 
1353 
5 196 603 
310 
281/271 
6 518 194 
Figure 5.2 - RT-PCR analysis of 1GFBP-1 to -6 mRNA expression profiled in SK-N-MC cells 
during cell growth and differentiation. (M): MW marker </JX 174 Haelll; (G): Day 4 SK-N-MC 
neuroblastoma cells grown in 10% FBS; (D): SK-N-MC cells grown in serum-free medium for 48h; 
(T): Breast tumour; (C); Water control. The IGFBP analysed is indicated with the expected PCR 
products marked with a white arrow head and their sizes shown in the corresponding table. 
7 IGF-I expression levels were derived from results in Chapter 4. 
8 IGF-II and the IGF-II Ser-29 variant were not expressed by SK-N-MC cells at any stage of the 
growth profiles (Section 4.3.2), hence total IGF expression constitutes the expression of IGF-I. 
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Figure 5.3 - A, B. Analysis of IGFBP and 1GF-1 mRNA expression in SK-N-MC cells during two 
separate 7 day time course cell growth experiments. 1GF-1 expression levels were derived from a 
previous set of experiments peiformed in Chapter 4. (*) indicates where expression levels were not 
peiformedfor 1GFBP-2 and -4 due to insufficient total cellular RNA. (M) indicates where cells were 
given fresh culture medium. Bars, SE. C, D. The ratio of 1GF-1 to 1GFBP-2 and 1GF-1 to 1GFBP-4 
over a 7 day time course SK-N-MC cell growth experiment. Bars, SE. Note that the scales for graphs 
A and B as well as C and D respectively, are significantly different. Graphs B and D represent an 
experiment where the cells were seeded at a higher cell density to observe the effect of over-
conjluency. 
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variability in the levels of mRNA expression due to the low levels being measured. 
As described in Chapter 4, the growth experiment shown in Figure 5.3b was plated at 
a higher cell density in order to test the effect of over-confluency on IGF expression. 
Very few similarities were observed between IGF expression in each experiment. In 
the over-confluent experiment (Fig. 5.3b, d), it was apparent that both IGFBP-2 and-
4 expression levels were substantially greater when compared to IGF-I expression 
levels. However, with increasing confluency, the increase in IGF-I expression was 
more dramatic relative to both IGFBPs (Fig. 5c, d). Interestingly, in Figure 5.3d at 
day 4 where the cells were over-confluent with declining health, IGFBP-4's 
expression levels increased more dramatically than IGF-I while IGFBP-2's levels 
behaved in the converse fashion. The significance of the IGFBP synthetic rate 
relative to IGF-I requires further investigation. However, overall these results 
suggest that IGFBP-2 and -4 are potentially major regulators of IGF-I action for SK-
N-MC cells during cell growth, with IGFBP-5 and -6 presenting additional levels of 
regulation during growth that can't be ignored. 
5.3.2 IGFBP Expression with Cellular Differentiation 
Differentiation of the human neuroblastoma cell line SK-N-MC, was achieved by the 
withdrawal of 10% FBS, as described in Section 2.3. Differentiation was marked by 
a change in the neuroblastoma phenotype, where the cells developed neuronal 
processes and exhibited an independent pattern of growth (Fig. 4.7). Differentiation 
was also marked by a decrease in the level of plasminogen activator activity (Fig. 
4.8). Growth factor withdrawal has been shown to induce apoptosis in a number of 
cell lines, therefore the SK-N-MC cells were analysed at 24h, 48 and 72h serum 
withdrawal by morphological analysis for cells undergoing apoptosis (Section 2.3.2). 
No change in the number of apoptotic cells was observed over the 72h of serum 
withdrawal in the SK-N-MC cells compared with cells grown in culture medium 
containing 10% FBS. This is unusual and may be due to the absence of the negative 
regulation of IGFBP-3, allowing the autocrine production of IGF-I to induce its 
survival response by binding to the IGF-IR, also synthesised by these cells (Chapter 
4). 
In this preliminary study, the mRNAs for the six IGFBPs were analysed by RPA in 
SK-N-MC cells grown in serum-free culture medium over a 72h period (n=l), as for 
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the cell growth experiment (Section 5.3.1). Messenger RNAs for IGFBP-1, -3, -5 
and -6 could not be detected at any stage of the 72h time course (data not shown). 
The anticipated 446 and 3231123 bp fragments for IGFBP-2 and the predicted 505 bp 
fragment for IGFBP-4, were detected in the differentiated SK-N-MC cells throughout 
the 72h of serum-withdrawal (n=1; Fig 5.4a, b). These results were verified by RT-
PCR analysis for IGFBP-1, -2, -3, -4 and -6, however a very weak IGFBP-5 product 
was also amplified by RT-PCR (n=2; Fig. 5.2). An increase in the concentration of 
RNA in the RPA analysis may allow the detection of IGFBP-5 by RPA and thus 
requires further analysis. Overall, these results suggest that IGFBP-1, 3 and -6 do not 
appear to have a role in SK-N-MC cells that have been induced to differentiate by 
serum-withdrawal, whereas IGFBP-2, -4 and -5 are expressed and potentially have a 
biological function. Interestingly, when IGFBP-6 expression was compared between 
SK-N-MC cells grown in medium containing 10% FBS and cells grown in the 
absence of serum, IGFBP-6 mRNA expression was turned off. Whether this 
differential expression pattern for IGFBP-6 is due to the withdrawal of growth 
A. B. 
MCSS MCSS 
M p R 24 48 72 72 48 24 R p M 
734 
509 
446 561 430 505 
341 430 
315 323 
341 
Figure 5.4 - Representative autoradiographs of RNase protection assays depicting the expression 
of IGFBP-2 and IGFBP-4 in SK-N-MC cells grown in serum-free medium for 24, 48 and 72h. The 
respective antisense RNA probes were hybridised with l0j1g total RNA. Protected fragment sizes are 
indicated in bold, full length probes in normal text. (M): MW marker; (P): full length RNA probe; 
(R): RNase treatment of P; (24, 48, 72): Time points of SK-N-MC cells grown in serum-starved [ss] 
conditions. A. Expression of IGFBP-2. B. Expression of IGFBP-4. Representative autoradiographs 
were exposed for 14 days. 
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factors within the serum or the actual differentiation of the SK-N-MC cells, remains 
to be elucidated. 
The IGFBP-2 and -4 expression was quantified and compared between the SK-N-
MC cells cultured in serum-free conditions 9. Overall, the expression of IGFBP-2 
was higher than the expression of IGFBP-4 throughout the 72h of serum-withdrawal 
(Fig. 5.5a, b). When compared to the cells grown in 10% FBS, the dominance of 
IGFBP-2 over IGFBP-4 was in contrast to the observations made in the cell growth 
experiments where IGFBP-2 and -4 expression largely paralleled each other. 
Maximal IGFBP-2 and -4 levels were seen at 72h serum-withdrawal where the SK-
N-MC cells are mostly differentiated. From these preliminary investigations, IGFBP-
2 and -4 and possibly IGFBP-5, potentially have a differential pattern of expression 
when SK-N-MC are induced to differentiate as a result of serum-withdrawal, 
compared to cells grown in serum-containing medium. 
5.4 Discussion 
The IGFBPs are an important family of peptides, contributing to the biological 
diversity of IGFs. They achieve this by controlling receptor/ligand interactions (De 
Mellow and Baxter, 1988; Blum et al., 1989; Liu et al., 1991) as well as in some 
cases, possessing intrinsic biological activities independent of IGFs (Jones et al., 
1993; Oh et al., 1993a). In the previous chapter (Chapter 4), the human 
neuroblastoma cell line, SK-N-MC was shown to differentially express the major 
IGF-I mRNAs as well as an altered IGF-IR expression pattern when the cells were 
induced to either grow or differentiate through the presence or absence of 10% FBS. 
A differential pattern of expression has previously been observed for IGFBPs in 
neuroblastoma and other cell culture systems (Birnbaum and Wiren, 1994; Cianfarani 
et al., 1996). The aim of this preliminary study, was to investigate IGFBP expression 
patterns during the induction of cell growth or differentiation in SK-N-MC cells and 
whether the altered expression pattern observed for IGF-I and the IGF-IR in these 
9 IGF-1 mRNA analysis was not performed in this particular serum-withdrawal experiment, therefore 
as a preliminary investigation IGFBP expression patterns were compared to the SK-N-MC profile 
when grown in serum-free conditions. 
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Figure 5.5.- The expression levels of 1GFBP-2 and -4 in SK-N-MC cells induced to differentiate by 
the withdrawal of 10% FBS. Bars, SE. A. IGFBP-2 expression. B. IGFBP-4 expression. Note that the 
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cells, could be observed throughout the IGF axis. These preliminary results suggest 
that there is a differential pattern of IGFBP expression between each of these fates, 
which warrants a more detailed investigation. 
During the growth of SK-N-MC cells in serum-containing medium, mRNAs for 
IGFBP-2, -4, -5 and -6 were detected, whereas IGFBP-1 and -3 were not detected, by 
either RPA or RT-PCR analysis. The observed IGFBP expression pattern, is 
comparable to results obtained by Kiess et al., (1997), who examined the expression 
of IGFBPs in SK-N-MC cells under growth conditions (10% FBS). Using RPA 
analysis, they identified mRNAs for IGFBP-2, -4, -5 and -6. In addition, my findings 
show that SK-N-MC cells induced to differentiate by the withdrawal of FBS, also 
express IGFBP-2 and -4 with weak expression of IGFBP-5, whereas IGFBP-6 could 
no longer be detected. 
The differential expression of IGFBP-6 between the two states under examination, is 
fascinating. While IGFBP-6 binds IGF-I, it binds IGF-II preferentially with a 10-fold 
higher affinity (Kiefer et al., 1992). Studies have shown that IGFBP-6 functions as a 
negative regulator of IGF-II induced growth and differentiation in a range of cell 
lines; it does this by preventing IGF-II interactions with the IGF-IR (Bach et al., 
1994; Manni et al., 1994; Babajko et al., 1997). In osteoblast cultures, the addition 
of purified IGFBP-6 had largely no effect on IGF-I actions, however it inhibited IGF-
II-induced DNA synthesis (Schmid et al., 1995). SK-N-MC cells synthesise the 
major IGF-I mRNAs but fail to synthesise IGF-II or its Ser-29 variant (Chapter 4). It 
has been shown in SK-N-MC cells, that the autocrine production of IGF-I acts via the 
IGF-IR to stimulate cellular proliferation. An a-IR3 antibody directed against the 
IGF-IR of SK-N-MC cells in serum-free conditions resulted in an inhibition of 
mitogenic activity (Kiess et al., 1997). Hence in SK-N-MC cells growing in the 
presence of FBS, IGFBP-6 may regulate serum IGF-II or other peptides including 
IGF-I, or it may have independent actions. In the absence of serum, IGFBP-6 
synthesis is turned off. Therefore it appears that the switch in IGFBP-6 synthesis is 
the result of serum-withdrawal, perhaps even the absence of IGF-II. Such a question 
may be answered by examining the synthesis of IGFBP-6 following the 
administration of IGF-II. IGFBP-6 has been shown to be hormonally sensitive. 
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Ovariectomy in an N-nitrosomethyl-urea (NMU)-induced rat mammary tumour 
model increased the production of IGFBP-6, while hormone replacement normalised 
the levels (Babajko et al., 1997). Other factors have been shown to regulate the 
expression of IGFBP-6, including retinoic acid (RA) which increased IGFBP-6 
expression in an estrogen receptor negative (ER-) human breast cancer cell line 
(Sheikh et al., 1993). While transforming growth factor-~ (TGF-~) has been shown 
to decrease the expression of IGFBP-6 in human fibroblasts and bone cells (Martin et 
al., 1994; Gabbitas and Canalis, 1997). RA is a natural morphogen and a key 
regulator of cellular growth and differentiation, while TGF-~ is regarded as an 
inhibitor of cellular growth. In serum-free conditions, the removal of RA or the 
stimulation in production of TGF-~ may well be the catalyst that prevents the 
synthesis of IGFBP-6. The levels of IGFBP-6 mRNA appear to be altered 
significantly depending on the tissue type, whether it is an in vitro or in vivo study 
and the components being administered or removed. Specifically what component or 
components of serum are responsible for the regulation of IGFBP-6 warrants further 
investigation. 
While the presence of IGFBP-4 and -5 can be justified by the presence of IGF-I, it is 
difficult to contemplate a role of IGFBP-2 in SK-N-MC cells during both cell growth 
and differentiation. IGFBP-2, like IGFBP-6, binds IGF-II with a 10-fold higher 
affinity than IGF-I (Roghani et al., 1991) and as already described, SK-N-MC cells 
do not express IGF-II or its Ser-29 variant. IGFBP-2 has been shown to have both 
negative and positive growth modulatory roles (Delhanty and Han, 1993; Manni et 
al., 1994; Jaques et al., 1994). Thus, IGFBP-2 may have a role in regulating the 
expression of IGFBP-6 in the SK-N-MC cell model system. IGFBP-4 has been 
shown in numerous in vitro studies to be a negative regulator of IGF action (LaTour 
et al., 1990; Schiltz et al., 1993). IGFBP-5 however, has been hypothesised to fix 
both IGF-I and -II to the ECM potentiating ligand/receptor interactions. Both 
IGFBP-4 and -5 may function as negative/or positive modulators of IGF-I during the 
growth and differentiation of SK-N-MC cells. 
This study suggests that both IGFBP-2 and -4 are differentially expressed between 
cell growth and the differentiation of SK-N-MC cells. Like IGFBP-6, IGFBP-2 has 
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been shown to be hormonally sensitive in the NMU-induced rat mammary tumour 
model (Manni et al., 1994). Therefore, IGFBP-2 has the potential to be regulated by 
the presence or absence of FBS in the SK-N-MC studies. This can also be said of 
IGFBP-4. In bone cells, IGFBP-4 has been shown to be physiologically regulated by 
growth hormone (Schmid et al., 1989), parathyroid hormone (Tarring et al., 1991) 
and gluccocorticoids (Okasaki et al., 1994). IGFBP-2 possesses an arginine-glycine-
aspartic acid (RGD) amino acid sequence, which enables it to cell associate (Bourner 
et al., 1992). This cell association is thought to facilitate the presentation of IGF-II to 
its cognate receptor (Delhanty and Han, 1993). Whether IGFBP-2 facilitates the 
presentation of IGF-I is unknown, however the SK-N-MC cells provide a good model 
system to investigate this question. The mechanism by which IGFBP-4 inhibits IGF 
actions involves the sequestering of IGFs, therefore preventing receptor/ligand 
interactions (Cheung et al., 1991; Kiefer et al., 1992). The release of this inhibition 
is determined by the presence of an IGFBP-4-specific protease, which in turn is 
activated by IGF-I or -II. A variety of cell types, including neuroblastoma cells 
(Cheung et al., 1994), secrete the IGFBP-4-specific protease. In the over-confluent 
SK-N-MC growth profile, IGFBP-4 undergoes a dramatic increase in expression at 
Day 4, relative to IGF-I expression. This coincides with the drop in IGF-I 
expression, suggesting that IGFBP-4 synthetic pathway may well be regulated by 
feedback mechanisms between the IGFBP-4- specific protease and IGF-I. 
The neuroblastoma cell line, SK-N-MC differentially expresses the major IGF-I 
mRNAs as well as an altered IGF-IR expression pattern when the cells were induced 
to either grow or differentiate by the presence or absence of 10% FBS. The purpose 
of this preliminary investigation was to test the possibility that IGFBPs are also 
differentially regulated between growth and differentiation states of SK-N-MC cells. 
The present findings suggest that this is the case, however it remains to be 
determined what serum factors are responsible for regulating IGFBP expression, in 
particular the dramatic variation in IGFBP-6 expression between the two states. In 
addition, since most of the IGFBPs expressed by these cells primarily regulate the 
actions of IGF-II, this study also raises some questions regarding other possible 
functions of these IGFBPs. The SK-N-MC model system provides a good tool to 
investigate the role of IGFBP regulation of IGF-I. 
Page 146 
Walker, 1998 
Chapter 6 
MESSENGER RIBONUCLEIC ACIDS (mRNAs) 
CODING FOR HUMAN INSULIN-LIKE 
GROWTH FACTOR-I AND -II ARE 
DIFFERENTIALLY EXPRESSED IN BREAST 
TUMOURS 
6.1 Introduction 
Insulin-like growth factors (IGFs) are essential for normal cellular growth and 
development (Baker et al., 1993; Liu et al., 1993). In vitro and in vivo studies have 
demonstrated that IGFs are synthesised and secreted by breast tumour cells and 
adjacent stromal fibroblasts, stimulating tumour cell proliferation in a paracrine 
manner (Yee et al., 1988; 1989a; Cullen et al., 1990; Paik, 1992). Within the IGF 
family, both IGF-I and IGF-II are highly mitogenic in breast cancer, with IGF-I 
synthesis reported to be exclusively stromal in origin (Yee et al., 1989a) while IGF-
II is synthesised by both the stromal and tumour epithelial cells (Cullen et al., 1991; 
Paik, 1992). The mitogenic functions of IGF-I and -II in breast cancer are mediated 
by their interaction with the transmembrane type I IGF receptor (IGF-IR; Osborne et 
al., 1989; Cullen et al., 1990) which has been shown to be synthesised by tumour 
epithelial cells of breast tumours (Cullen et al., 1990). 
Transcriptional regulation is a common mechanism of gene regulation, with altered 
gene expression shown to contribute to human diseases (Quinn et al., 1996; 
Silberstein et al., 1997). The human IGF-I gene generates four major mRNAs by 
alternate promoter usage and alternative splicing of its 5' and 3' exons, referred to 
as class 1, 2 and Ea, Eb respectively (Jansen et al., 1983; Rotwein, 1986). Rat 
model systems have shown these mRNAs to be tissue specific as well as 
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the presense or absense of tumour cells in adjacent lymph nodes). Approval for the 
use of these samples was obtained from the Ethics Committees of the Queensland 
University of Technology (QUT 1033H) and the Wesley Medical Centre (96/14). 
6.2.2 RNA Preparation 
Total cellular RNA was extracted from frozen tissue specimens using the method 
described in Section 2.5.1. The RNA concentration and integrity were established 
by spectrophotometry at 260nm and denaturing gel electrophoresis. 
6.2.3 RNase Protection Assay (RPA) 
RP As were carried out on 4 normal breast tissue samples and 23 breast tumour 
samples as described in Section 2.1 0. Antisense [ a 32P]-labelled RNA probes for 
IGF-I multiple mRNAs (Section 2.8.1), IGF-II (Section 2.8.5), IGF-IR (Section 
2.8.6) and 18SrRNA (Section 2.8.13) were synthesised by means of in vitro 
transcription as described in Section 2.9.2.1. Total cellular RNA (100pg - 30)lg), 
was hybridised with 1.0 x 105 cpm of RNA probe at 42°C for 20h (Section 2.1 0). 
Samples were processed with resulting RNA:RNA hybrids subjected to denaturing 
electrophoresis on a 5% polyacrylamide gel containing 8M urea (Section 2.1 0.1 ). 
Gels were dried, exposed to phosphoimager screens (BAS-IllS) for 48h, followed 
by X-OMAT autoradiography. Protected fragments were quantified as described in 
Section 2.8.2 with mRNA expression defined as pg mRNAI)lg total RNA. 
Representative autoradiographs were scanned using Deskscan software and 
imported into Corel Draw 7 graphical software. 
6.2.4 RT-PCR 
The generation of first strand eDNA from representative samples of normal breast 
and breast tumour RNA by RT, was performed as described in Section 2.6. PCR 
was used to amplifY the four major IGF-I mRNAs using lOO)lM of a forward and 
reverse primer from the sets of primers described in Table 6.1. Conditions for PCR 
reactions for each set of primers were 1 X [94°C, 5min]; 35 X [94°C, I min; 56°C, 
2min; 72°C, 2min]; 1 X [72°C, 7min] 10. The PCR reactions were run on a 1% 
10 The annealing temperature for the class 1 Eb and class 2 Eb sets of primers was 54°C. 
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Class 1 Ea GATAGAGCCTGCGCAATGGA AGTGAAGAGTGACATGCCACCGC 
Exonl Exon 6 
Class 1 Eb GATAGAGCCTGCGCAATGGA GAACACGAAGTCTCAGAGAAGG 
Exonl Exon6 
Class 2 Ea CACATCGGCCTCATAATACC TGAGGAGTGAAGAGTGACATGC 
Exon 2 Exon 5 
Class 2 Eb CACATCGGCCTCATAATACC GAACACGAAGTCTCAGAGAAGG 
Exon 2 Exon5 
Table 6.1 ·Primer sets used for the PCR detection of the four major IGF-1 mRNAs in normal and 
breast tumour tissue. Primers are written in a 5' to 3' direction according to the coding strand, 
with exon locations indicated. 
agarose gel as described in Section 2.7 .4.1. The representative gel was scanned 
using Deskscan software and imported into Corel Draw 7 graphical software. 
6.2.5 In Situ Hybridisation Histochemistry 
High grade (n=5) and low grade (n=7) ductal carcinomas and normal breast tissue 
samples (n=3), were analysed by in situ hybridisation histochemistry as described in 
Section 2.11, with modifications required for each set of antisense and sense RNA 
probes. For pre-hybridisation, sections were de-waxed and digested with 
proteinase-K at 50 11g/ml at 37°C for 10min for the mature IGF-I, Ea specific, Eb 
specific and 18S rRNA probes. A proteinase-K digestion at 100 11g/ml at 37°C for 
lOmin was performed for the IGF-ll and IGF-IR probes. Post-fixing in 4% 
paraformaldehyde, acetylation and dehydration followed the digestion. Sections 
were immersed for 18h at 60°C in hybridisation cocktail containing 1.0 x 105 cpm 
of antisense or sense RNA probe, with the sense RNA probe serving as a negative 
control. Slides were processed as described in Section 2.11 and exposed to 
Hyperfilm-~max film for 48h. Slides were coated with LM-1 emulsion, exposed 
for 10 days, developed, fixed and counterstained in Mayer's haematoxylin. 
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Representative photomicrographs were prepared using llford P ANF 50 black and 
white film. 
6.2.6 Statistical Analysis 
Student's t test, ANOVA and Duncan's multiple range test were used to determine 
the significance. Results were considered to be statistically significant when p < 
0.05. 
6.3 Results 
6.3.1 IGF-1 mRNA expression in Breast Tumours 
Although not clear in the representative autoradiograph, the four major IGF-I 
mRNAs were detected in both normal and breast tumour tissues via RP A using the 
multiple IGF-I mRNA probe (Fig. 6.1b). In addition, bands of approximately 540 
and 395 bp were also detected at significant levels in all tissues. The 540 bp band 
does not correspond to any known mRNA for IGF-I and will require further 
analysis. The 395 bp band corresponds to the expected size of the class 2 exon 4-5-
6 (Fig. 6.1a), an IGF-I mRNA which includes a 49 bp cassette of exon 5 and exon 
6, which had previously been reported to be liver specific. 
To verify the presense of the variable IGF-I mRNAs detected in the RPA analyses 
on normal and breast tumour tissue samples, RT -PCR was performed using specific 
sets of primers for each of the major IGF-I mRNAs (Table 6.1). All four mRNAs 
were detected in both the normal and breast tumour sample analysed (n=3; Fig. 
6.1c). 
Alternative IGF-I exon usage in normal and breast tumour samples was analysed by 
quantifying the expression levels of the major IGF-I mRNAs using RPAs. In 
normal breast tissues it was established that expression of Ea > class 1 ""' class 2 > 
Eb, whereas in breast tumours, the expression of class 2 ""' Ea > Eb ""' class 1 
indicating a change in exon usage in malignant breast tissue (Fig. 6.2). To establish 
if the change in exon switching is occurring in early or later stage breast cancer, the 
levels of IGF-I mRNA were compared in normal breast tissue, low grade and high 
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Figure 6.1 - A. Human lGF-1 multiple mRNA probe design. Prepro-domains are boxed, Pre = 
signal peptide with associated exons in italics. Symbols * and # represent the EcoRl and Pstl 
restriction enzyme sites respectively. Arrows indicate the lGF-l mRNAs with the narrow lines 
indicating splicing opportunities. The expected protected fragments for the major lGF-l mRNAs and 
the minor hepatic specific exon 4-5-6 mRNA are illustrated. B. Expression of IGF-l alternatively 
spliced mRNAs in normal and malignant breast tissue. The multiple mRNA probe was hybridised with 
30J.1g of total RNA from normal and breast tumour tissue in an RPA, as described in Section 6.2.3. 
Class lEa protected fragment is 591 bp, classlEb is 698 bp, class 2Ea is 346 bp and class 2Eb is 453 
bp. * indicate the additional protected fragments, the approximate 395 bp fragment is potentially the 
class 2 exon 4-5-6 mRNA. (M): MW marker; (P): full length IGF-l multiple mRNA probe; (R): RNase 
treated probe; (Nl and N2): Normal breast tissue RNA hybridised with IGF-l multiple mRNA probe 
exposed for 7 days; (Tl to T5): Breast tumour tissue RNA hybridised with lGF-l multiple mRNA probe 
exposed for 7 days; (Nl* and N2*): 28 day exposure of Nl and N2. C. RT-PCR analysis of the 
different lGF-l mRNAs in normal breast and tumour tissue samples. (M): MW marker ¢X 174 Haelll; 
(N): Normal breast; (T): Tumour tissue; (C): Water controlO Primer sets are indicated. Class lEa 
fragment, 641 bp; Class 1 Eb fragment, 587 bp; Class 2Ea fragment, 506 bp; Class 2 Eb fragment, 458 
bp. 
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grade invasive ductal carcinomas (Table 6.2). An increase in the expression levels 
of the four major mRNAs was apparent in both low and high grade ductal 
carcinomas. Class 2 and Eb mRNAs exhibited the greatest increase relative to the 
expression in normal breast tissue, being 12.9-fold and 21-fold respectively. To 
further analyse the differential induction of alternative exon expression, the ratios of 
class 1 : class 2 and Ea : Eb were determined (Figs. 6.3a, b). These results show a 
change in transcriptional activity with an altered abundance of the alternatively 
spliced mRNAs between normal and malignant breast tissue. The ratio of class 1 : 
class 2 was significantly lower in both low and high grade ductal carcinomas 
compared to normal breast tissue (p < 0.001) as was the Ea to Eb ratio (p < 0.001). 
Interestingly the ratio of Ea : Eb was also significantly reduced in low grade ductal 
carcinomas relative to high grade carcinomas (p < 0.01). 
The expression levels for each of the maJor IGF-I mRNAs were compared 
statistically to the ER status and the nodal infiltration for each breast cancer patient. 
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Figure 6.2 · The relative expression of the variable IGF-l mRNAs in normal breast tissues (N; 
n=4) and breast tumour tissues (BC; n=19). Bars, SE. ***, p < 0.001 by Student's t-test. 
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Table 6.2- Quantification of IGF-I exon usage in normal breast tissue, low and high grade ductal carcinomas1 
Breast Tissue Type 
NORMAL 
(n = 4) 
LOW GRADE 
(n= 6) 
HIGH GRADE 
(n = 13) 
IGF-ImRNAs 
Class 1 
Class 2 
Ea 
Eb 
Class 1 
Class 2 
Ea 
Eb 
Class 1 
Class 2 
Ea 
Eb 
mRNA Expression (Mean) 
(pg mRNA I 1-lg RNA) 
0.08 ± 0.02 
0.09 ± 0.02 
0.14 ± 0.03 
0.03 ± 0.01 
0.56 ± 0.18 
1.16 ± 0.3 
1.09 ± 0.29 
0.63 ± 0.18 
0.31± 0.11 
0.77 ± 0.23 
0.72 ± 0.22 
0.36 ± 0.12 
Fold Induction (X) 
(cf Normal Levels) 
1 
1 
1 
1 
72 
12.93 
7.83 
213 
3.93 
8.63 
5.13 
123 
1 The levels ofiGF-I mRNA were analysed by RPA and calculated as described in Section 3.4, with results grouped according to exon usage. Each value represents mean±SE 
of the number of (n) samples. 2 p < 0.05, 3 p < 0.01 compared with normal breast tissue by Student's t test. 
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Figure 6.3 -A. Mean ratio of class 1 to class 2 IGF-l mRNAs in normal (N), low (LGD) and high 
grade ductal carcinomas (HGD). Bars, SE. ***, p < 0.001 comparing N with LGD and HGD by 
Student's t-test B. Mean ratio of Ea to Eb in normal (N), low (LGD) and high grade ductal 
carcinomas (HGD). Bars, SE. II, p < 0.01 comparing N to LGD and HGD by Student's t-test; 
***, p < 0.001 comparing LGD to HGD by Student's t-test .. 
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There was no significant correlation to the ER status or nodal infiltration of the 
patients (p > 0.05). 
6.3.2 Examination of /GF-11 mRNAs in Breast Tumours 
The expression levels of IGF-II mRNAs were determined in normal and breast 
tumour samples, again using RP A. All samples analysed expressed mRNAs coding 
for IGF-II (565 bp) and the Ser-29 variant form of IGF-II (421+159 bp; Figs.6.4a, 
b). Additional protected fragments of approximately 340 and 240 bp were 
observed. The 340 bp fragment was present in all of the samples, both normal and 
malignant and in an identical ratio to IGF-II mRNAs. The 240 bp fragment was not 
detected in the normal breast tissues analysed but was detected in only 8 of the 23 
breast tumour samples. It was the predominant protected fragment for patients T5 
and T7 in Figure 6.4b. An examination of the patients that expressed the 240 bp 
fragment, revealed that an equal population were node positive or negative and of 
mixed histological classifications, however 7 of 8 patients were ER+. 
An increase in expression of IGF-II and Ser-29 IGF-II mRNA was apparent in both 
low and high grade ductal carcinomas (Table 6.3). The relative proportions of IGF-
II and the Ser-29 variant expression were analysed to determine if IGF-II, like IGF-
I, undergoes any transcriptional changes from normal to malignant breast tissue. 
The ratio of IGF-II : Ser-29 variant was found to be significantly lower in breast 
tumours than in normal breast tissue (p < 0.001), suggesting a change in the 
transcription of IGF-II (Fig. 6.5). A more detailed examination of these ratios in 
breast tumours, showed that high grade invasive ductal carcinomas had significantly 
lower ratios (p < 0.05) than low grade specimens. 
The levels of IGF-II and the Ser-29 variant mRNAs, were compared statistically to 
the prognostic indicators examined in this study. No correlation was identified with 
nodal infiltration. However when compared to the ER status, IGF-II and the Ser-29 
variant mRNAs were found to be significantly higher in ER+ samples rather than 
ER- samples (p < 0.05; Table 6.4). 
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Figure 6.4 · A. Human IGF-ll probe design. Domains of the prepro-peptides are boxed with 
associated exons in italics. Locations of the IGF-ll Ser-29 and Ser-33 variants are illustrated. The 
symbol * represents the Pstl restriction enzyme sites. The region encoded by the probe is shown with 
the expected protected fragments for the major IGF-II mRNA and IGF-ll Ser-29 variant illustrated. B. 
IGF-II and IGF-II Ser-29 variant mRNA expression in normal and breast tumour tissue. The IGF-II 
antisense RNA probe was hybridised to 1 Ojlg of total RNA isolated from normal and breast tumour 
tissue samples in an RPA, described in Section 6.2.3. The IGF-ll protected fragment is 565 bp with 
the Ser-29 variant protected fragments being 421 I 159 bp; * indicate additional protected fragments. 
(M); MW marker; (P): Full length IGF-II RNA probe; (R): RNase treated probe; (Nl and N2): Normal 
breast tissue RNA hybridised with IGF-II RNA probe exposed for 7 days; (T1 to T9): Patient breast 
tumour RNA hybridised with IGF-ll RNA probe exposed for 7 days. 
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Table 6.3- Quantification of IGF-II and the IGF-IR in normal breast tissue, low and high grade ductal carcinomas 1 
Breast Tissue Type 
NORMAL 
(n=4) 
(n =4) 
LOW GRADE 
(n=7) 
(n= 8) 
HIGH GRADE 
(n = 13) 
(n = 13) 
IGF-11 mRNAs 
IGF-II 
IGF-II Ser-29 
IGF-IR 
IGF-II 
IGF-II Ser-29 
IGF-IR 
IGF-II 
IGF-II Ser-29 
IGF-IR 
mRNA Expression (Mean) 
(pg mRNA I )lg RNA) 
0.6 ± 0.19 
0.26 ± 0.09 
0.83 ± 0.17 
2.28 ± 0.65 
1.55 ± 0.46 
9.14± 1.87 
1.70 ± 0.56 
1.15 ± 0.36 
5.53 ± 2.33 
Fold Induction (X) 
(cf Normal Levels) 
1 
1 
1 
3.82 
62 
113 
2.82 
4.42 
6.72 
1 The levels of IGF-II and IGF-IR mRNA analysed by RPA, were calculated as described in Section 3.4 with results grouped according to exon usage. Each value represents 
mean±SE of n samples. 2 p < 0.05, 3 p < 0.01 compared with normal breast tissue by Student's t test. 
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Figure 6.5 ·Mean ratio of 1CF-Il to the Ser-29 variant of ICF-11 in normal (N), low grade (LCD) 
and high grade (HCD) ductal carcinomas. Bars, SE. + < 0.05 comparing LCD to HCD by 
Student's t-test, ***, p < 0.001 comparing N to LCD and HCD by Student's t-test. 
6.3.3 Examination of /GF-IR mRNAs in Breast Tumours 
IGF-IR mRNA expression was analysed in normal and breast tumour samples via 
RP A, with all samples protecting the expected 520 bp fragment specific for the 
IGF-IR (Fig. 6.6). The IGF-IR mRNA levels were significantly higher in both low 
(11-fold) and high (6.7-fold) grade ductal carcinomas, compared with levels in 
normal breast tissue samples (Table 6.3). An examination of the ratio of IGF-IR : 
total IGF-II expression revealed a significantly higher value for both low (5.1-fold, 
p < 0.05) and high grade (3-fold, p < 0.01) ductal carcinomas than for normal breast 
tissue. In contrast, the ratio of the IGF-IR to total IGF-I showed no significant 
difference between normal and malignant breast tissue. The expression levels for 
the IGF-IR were also compared statistically to the prognostic indicators examined in 
this study (Table 6.4). IGF-IR mRNA expression was found to be significantly 
higher in ER+ patients (p < 0.05), with no correlation to nodal infiltration. 
6.3.4 Cellular Localisation of /GF-1 mRNA in Breast 
Tumours 
To establish the cell types synthesising the IGF mRNAs detected by RP A, in situ 
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Table 6.4- The correlation of IGF-II, Ser-29 IGF-II and the IGF-IR to major prognostic indicators of breast cancer1 
IGFmRNA ER Status 
+ (n=13) - (n=9) 
Nodal Infiltration Status 
+ (n=8) - (n=13) 
IGF-II 2.56 ± 0.53 
IGF-II Variants 1.73 ± 0.36 
IGF-IR 9.08 ± 2 
1.03 ± 0.414 
0.69 ± 0.254 
3.38 ± 1.052'4 
4.89 ± 3.05 
1.20 ± 0.32 
6.92 ± 1.343 
1Values represent prospective IGF mRNAs given as mean (pg mRNA I 11g RNA) ±SE of n samples, calculated as described in Section 3.4. 2n = 10. 3 n = 9. 
4 p < 0.05. 
1.87 ±0.57 
1.24 ± 0.37 
5.99 ± 2.32 
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Figure 6.6 - JGF-IR expression in normal breast and breast tumour tissue. The JGF-IR antisense 
RNA probe was hybridised to 20j1g of total RNA isolated from normal and breast tumour tissue, in 
an RPA, as described in Section 6.2.3. The JGF-IR protected fragment is 520 bp, as indicated in 
bold. (M): MW marker; (P): full-length IGF-IR antisense RNA probe (586 bp); (R): RNase treated 
probe; (Nl and N2): Normal breast tissue RNA hybridised with IGF-IR antisense RNA probe 
exposed for 5 days; (Tl to T7): Breast tumour RNA hybridised with IGF-JR RNA probe exposed for 
2 days. 
hybridisation histochemistry was performed. IGF-I mRNA in normal breast tissue 
localised to the stromal component (data not shown). Similarly, in low grade ductal 
carcinomas of both DCIS (ductal carcinoma-in-situ) and invasive forms, IGF-I 
mRNA localised exclusively to portions of the stroma, while being absent from the 
tumour epithelium (Figs. 6.7a, b, c). In contrast, high grade invasive ductal 
carcinomas localised IGF-I mRNA expression to the tumour epithelial cells as well 
as adjacent stroma (Figs.6.7d, e, f). 
6.3.5 Cellular Localisation of Ea and Eb specific mRNA in 
Breast Tumours 
In order to investigate whether the differential Ea/Eb expression between normal 
and breast tumour tissue is related to differential sites of synthesis within each 
tissue, in situ hybridisation histochemistry was performed using Ea and Eb specific 
RNA probes. In a preliminary study, Ea synthesis was found to be comparable to 
IGF-I expression in normal breast tissue (n=l), being synthesised by the supportive 
stromal fibroblasts (Fig 6.8a, b, c). Similarly in low grade ductal carcinomas (n=2) 
of both DCIS and invasive forms and high grade ductal carcinomas (n=2), IGF-I 
mRNA localised strongly to the stroma, with weak or no expression in the tumour 
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epithelium (Figs. 6.8d, e, f). In contrast, Eb synthesis was identified in distinct 
populations of stromal fibroblast cells in normal breast tissue (n=1; data not shown 
due to high background). This pattern of synthesis was also apparent in low grade 
ductal carcinomas (n=2; data not shown due to high background) of both DCIS and 
invasive forms. In high grade ductal carcinomas (n=2), Eb mRNA could not be 
distinguished from control slides and will require further investigation with the 
more sensitive technique of in situ PCR. 
6.3.6 Cellular Localisation of IGF-11 mRNA in Breast 
Tumours 
In normal breast tissue IGF-II expression was localised in the stroma (Figs. 6.9a, b, 
c) with weaker expression in the epithelial or myoepithelial cell layers of the ductal 
structures. DCIS tumour epithelial cells were weakly positive for IGF-II, however 
the surrounding stromal tissue was strongly positive for IGF-II expression (Figs. 
6.9d, e, f). Both low and high grade invasive ductal carcinomas were positive for 
IGF-II mRNA in the stroma and to a lesser extent in the invasive tumour epithelial 
cells. Interestingly, intense expression was observed in distinct populations of 
tumour epithelial cells of high grade carcinomas (Figs. 6.9g, h, i). 
6.3.7 Cellular Localisation of IGF-IR mRNA in Breast 
Tumours 
A 700 bp antisense RNA probe covering the a-subunit of the IGF-IR, was used to 
localise its expression in normal and breast tumour specimens. IGF-IR mRNA 
expression could not be detected in normal breast tissue (data not shown), while 
both low and high grade invasive ductal carcinomas expressed IGF-IR mRNAs in 
the tumour epithelial cells (Figs. 6.1 Oa, b, c) with weak expression in DCIS (data 
not shown). The lack of expression of IGF-IR mRNA in normal breast tissue, 
despite clear expression using the RP A technique, may be due to the sensitivity of 
in situ hybridisation histochemistry in this case where a section of normal breast 
tissue is but a small representation of the amounts used in an RP A. 
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Figure 6. 7 - The cellular localisation of total IGF-I mRNA synthesis in low grade ductal and high 
grade ductal breast tumours. 1GF-I antisense and sense RNA probes were hybridised to fixed tissue 
sections via in situ hybridisation histochemistry, as described in Section 2.11. A. Darkfield 
photomicrograph of antisense IGF-I in a representative low grade invasive ductal carcinoma. (S) 
Stroma; (T) Tumour epithelial cells. B. Brightfield photomicrograph of Fig. 6. 7 a. C. Darkfield 
photomicrograph of sense IGF-I in a representative serial section of a low grade invasive ductal 
carcinoma. D. Darkfield photomicrograph of antisense 1GF-1 in a representative high grade invasive 
ductal carcinoma. E. Brightfield photomicrograph of Fig. 6.7d. F. Darkfield photomicrograph of 
sense IGF-I in a representative serial section of a high grade invasive ductal carcinoma. 
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Figure 6.8 - The cellular localisation of total Ea mRNA synthesis in normal breast and breast 
tumour samples. Ea antisense and sense RNA probes were hybridised to fixed tissue sections via in 
situ hybridisation histochemistry, as described in Section 2.11. (S) Stroma; (DCIS) Ductal cell in 
situ; (BM) Basement membrane; (T) Tumour epithelial. A. Darkfield photomicrograph of antisense 
IGF-l in a normal breast tissue sample. B. Brightfield photomicrograph of Fig. 6.8a. C. Darkfield 
photomicrograph of sense 1GF-l in a representative serial section of a normal breast tissue sample. D. 
Darkfield photomicrograph of antisense 1GF-l in a representative low grade invasive ductal 
carcinoma. E. Brightfield photomicrograph of Fig. 6.8d. F. Darkfield photomicrograph of sense IGF-
l in a representative serial section of a low grade invasive ductal carcinoma. 
Page 167 
Walker, 1998 
Page 168 
Walker, 1998 
Figure 6.9 - The cellular localisation of total1GF-11 mRNA synthesis in normal breast tissue, low 
grade ductal and high grade ductal breast tumours. IGF-II antisense and sense RNA probes were 
hybridised to fixed tissue sections via in situ hybridisation histochemistry, as described in Section 2.11. 
(S) Stroma; (T) Tumour epithelial cells; A. Darkfield photomicrograph of antisense IGF-II in normal 
breast tissue. B. Brightfield photomicrograph of Fig. 6.9a. C. Darkfield photomicrograph of sense 
IGF-11 in a serial section of a normal breast tissue. D. Darkfield photomicrograph of antisense IGF-II 
in a representative low grade invasive ductal carcinoma. E. Brightfield photomicrograph of Fig.6.9d. 
F. Darkfield photomicrograph of sense IGF-II in a representative serial section of a low grade 
invasive ductal carcinoma. G. Darkfield photomicrograph of antisense IGF-II in a representative high 
grade invasive ductal carcinoma. Arrow head indicates a population of cells with more intense IGF-II 
expression. H. Brightfield photomicrograph of Fig. 6.9g. I. Darkfield photomicrograph of sense IGF-
II in a representative serial section of a high grade invasive ductal carcinoma. 
Page 169 
Walker. 1998 
Page 170 
Walker, 1998 
Figure 6.10 - The cellular localisation of total1GF-1R mRNA synthesis in high grade ductal breast 
tumours. 1GF-IR antisense and sense RNA probes were hybridised to fixed tissue sections via in situ 
hybridisation histochemistry, as described in Section 2.11. (S) Stroma; (T) Tumour epithelial cells. 
A. Darkfield photomicrograph of antisense 1GF-1R in a representative high grade invasive ductal 
carcinoma. B. Brightfield photomicrograph of Fig. 6.10a. C. Darkfield photomicrograph of sense 
1GF-1 in a representative serial section of a high grade invasive ductal carcinoma. 
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6.4 Discussion 
IGFs are synthesised by normal breast tissue and breast tumours and are potent 
mitogens for breast cancer cell lines (Yee et al., 1988; Osborne et al., 1989; Cullen 
et al., 1990), suggesting that the IGF family of peptides plays a pivotal role in breast 
cancer development. In this study, the expression of the variable mRNAs of IGF-I 
and, to a lesser degree, IGF-ll and the IGF-IR, has been compared during the 
development and progression of breast cancer to establish if alternative exon usage 
is a mechanism associated with IGFs involvement in tumour development. 
Consistent with other studies utilising breast tumours (Yee et al., 1989a; Paik, 
1992), we have shown that all breast tumour samples examined expressed IGF-I 
mRNA, with total expression levels 7 .1-fold higher than in normal breast tissue. In 
normal breast and breast tumour samples, the four major mRNAs generated by 
alternate promoter and alternative splicing were present, along with two additional 
fragments. Of these, the 395 bp fragment corresponded to the expected size of the 
recently identified class 2 exon 4-5-6 mRNA (Chew et al., 1995). Exon 4-5-6 
splicing is similar to the splicing arrangement for rat IGF-I Eb, which is expressed 
in a range of normal rat tissues (Roberts et al., 1987). However, in normal human 
tissues exon 4-5-6 mRNA is the result of a rare splicing event and until now has 
only been found in liver tissue at equivalent levels to Eb mRNAs. The function of 
exon 4-5-6 mRNA is unknown, however this preliminary data suggests that exon 4-
5-6 mRNAs can no longer be considered as liver specific. 
IGF-I exon usage in human tissues has not been extensively studied and a specific 
function for the variant mRNAs has yet to be defined. The examination of exon 
usage during the development and progression of breast cancer indicates a change 
in exon usage during cellular transformation, with an increase of class 2 relative to 
class 1 mRNAs in tumours, and Eb relative to Ea during the progression of the 
disease. The increase of class 2 mRNAs in breast tumour samples is in accordance 
with observations made in T61, a human breast xenograft, and an ovarian 
carcinoma cell line, NIH OVCAR3 (Tobin et al., 1990). However, the 
physiological significance of alternative exon usage at the 5' end of the IGF-I gene 
remains unknown. Studies in rat model systems have shown that class 1 and 2 
mRNAs are differentially regulated in the liver, in particular during development, 
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fasting and diabetes (Adamo et al., 1989; 1991a), with class 2 mRNAs being more 
growth hormone sensitive (Lowe et al., 1987; Adamo et al., 1989). Exon 1 and 2 
are driven by separate promoters and code largely for different 5' UTRs, along with 
the first 21 aa of the signal peptide for class 1 or the first 5 aa for class 2. The 
hypothesised function of the signal peptide is that it functions as a co-translationally 
cleaved peptide, directing nascent peptides to the secretory pathway (Sussenbach et 
al., 1992; Rotwein et al., 1993). As a consequence, the up-regulation of class 2 
mRNAs in breast tumours suggests that the promoter and/or the very 5' region of 
the signal peptide may differentially target IGF-I action in the development and 
progression of tumours. 
This study shows for the first time that an Ea!Eb ex on change of the IGF-I gene 
occurs as breast tissue progresses from normal through to high grade invasive ductal 
carcinoma. While differences in alternative splicing of the 3' exons of various 
genes, such as parathyroid related protein (PTHrP; Campos et al., 1994), have been 
identified between tumours and normal tissue, no specific patterns of exon usage 
emerged. Although both the Ea and Eb mRNA code for the same mature IGF-I 
peptide, they vary in the size and sequence of their prospective E-domains and 3' 
UTR sequences (Jansen et al., 1983; Rotwein, 1986). BothE peptides are cleaved 
during post-translational modification to produce the same mature IGF-I protein, 
leading to the possibility that the proteolytically released Ea and Eb domains may 
have independent biological functions. No such function has been ascribed as yet to 
the Ea peptide. However, IGF-IB-(103-124)E1 amide (IBE1), a portion of the Eb 
propeptide, has been reported in human lung cells to have growth promoting 
activities mediated by its own receptor (Siegfried et al., 1992). Overall, these 
results suggest that the alternatively spliced mRNAs of IGF-I play a differential role 
in normal and tumour growth. 
Due to the heterogeneous nature of normal and malignant breast tissue, I identified 
that IGF-I mRNA expression is differentially expressed between cell types. In 
accord with previous studies (Yee et al., 1988; Cullen et al., 1991), the expression 
of IGF-I was localised to the stromal cells of normal breast tissue and low grade 
ductal carcinomas. However, we also identified that high grade invasive ductal 
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carcinomas expressed IGF-I mRNAs not only in the stroma, but also in the invasive 
tumour epithelium. These observations would suggest that in lower grade tumours, 
IGF-I acts in a paracrine fashion on the tumour epithelial cells. As the tumours 
progress to the more invasive high grade state, IGF-I synthesis is also switched on 
in the tumour epithelium, suggesting both autocrine and paracrine modes of action 
for IGF-I. 
Whether the change in cellular synthesis of IGF-I throughout tumour development 
is associated to the differential synthesis of the variable IGF-I mRNAs, was 
investigated with in situ hybridisation histochemistry. The preliminary study 
revealed that Ea mRNAs are clearly synthesised by stromal tissues at all stages, 
from normal through to high grade ductal carcinomas, whereas Eb was identified in 
specific foci of stromal fibroblast cells in a normal breast tissue sample and a low 
grade ductal carcinoma. These results suggest that due to its broad synthetic 
pattern, Ea production may provide a general function, such as the maintenance of 
cell proliferation. In contrast, Eb expression may have a more specialised role, such 
as cellular differentiation, as suggested by its distinct pattern of localisation. These 
preliminary results need further analysis with the more sensitive technique of in situ 
RT-PCR. 
Reports of the site of synthesis of IGF-I mRNAs by breast tumour epithelial cells 
are somewhat conflicting. In early studies, IGF-I was reported to be expressed by 
the breast tumour epithelial cells (Huff et al., 1988) but later studies showed IGF-I 
was synthesised exclusively by stromal cells in breast tumours and fibroblast cell 
lines (Yee et al., 1989a; Paik, 1992; Cullen et al., 1991). Recently, Guerra et al., 
(1996) demonstrated in vitro IGF-I mRNA expression in a malignant murine 
epithelial mammary cell line. There are several possible reasons for the variability 
of results. One is that much of this data has been obtained from transformed cell 
lines that lose properties possessed by tumour epithelial cells in vivo (Rudland, 
1987). The most metastatic breast tumour epithelial cells have been described as 
slow growing, loosely adherent cells (Lasfargues et al., 1978) which generally die 
following transfer to in vitro conditions, although some adapt to their new growth 
environments (Owens et al., 1976). It is also possible that in the IGF-I localisation 
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studies (Yee et al., 1989a), only lower grade breast tumours were examined. In the 
present study, we have found that IGF-I expression is largely confined to stromal 
tissue except in the population of high grade invasive ductal carcinomas examined, 
where the epithelial cells also synthesise IGF-I. 
Over-expression of IGF-II in several systems results in ligand-dependent 
transformation and/or tumourigenesis, with antisense IGF-II inhibiting tumour 
formation in vivo (Christofori et al., 1994). Our results show that IGF-II and IGF-
IR mRNA are present in normal tissue samples and are up-regulated in breast 
tumour samples, consistent with previous data from breast cancer cell lines (Yee et 
al., 1988; Osborne et al., 1989; Cullen et al., 1990) and breast tumours (Yee et al., 
1988; Cullen et al., 1990; Papa et al., 1993). We also identified for the first time, in 
both normal and malignant breast samples, the alternatively spliced mRNA coding 
for the Ser-29 variant of IGF-II along with a significant as yet uncharacterised 
fragment expressed in only 35% of tumour samples at varying levels of abundance. 
Whether this fragment proves to be an IGF-II breast tumour specific mRNA, 
remains to be elucidated. 
This study has indicated that an increase in the variant IGF-II prohormone Ser-29 
relative to IGF-II itself is associated with breast carcinogenesis and its progression, 
providing further evidence that transcriptional changes are a potential mechanism 
by which IGF-II is associated with cellular transformation. Specialised roles for the 
IGF-II variant prohormones have not been identified. The Ser-29 variant protein 
isolated from human plasma is active, as it binds to IGF receptors, but is 3-fold less 
potent in stimulating growth of MCF-7 cells, compared with IGF-II (Hampton et 
al., 1989). Interestingly, the affinity of Ser-29 for the type II IGF receptor (IGF-
II/M-6-PR) has been shown to be 110% that of IGF-II and its affinity for IGFBP-3 
171% that of IGF-II (Luthi et al., 1992). One hypothesised role for IGF-II/M-6-PR 
is that it acts as a tumour suppressor by binding, internalising and degrading IGF-II, 
thus reducing its availability for the IGF-IR (Ellis et al., 1996). I hypothesise that 
an up-regulation of the Ser-29 variant of IGF-II may compete with IGF-II for both 
the IGF-II/M-6-PR and IGFBP-3 and hence, reduce the IGF-II inhibitory control 
mechanisms. Such a scenario would increase the availability of IGF-II for the IGF-
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IR which itself exhibits a concomitant 9.3-fold increase in expression from normal 
to malignant breast tissue. 
Total IGF-II and IGF-IR expression was significantly higher in ER+ tumours. This 
agrees with observations that estrogen increases the expression of IGF-II and IGF-
IR mRNA and protein in breast cancer cell lines (Yee et al., 1988; Osborne et al., 
1989; Lee eta!., 1994) and breast cancer cells grown in vivo (Manni eta!., 1994). 
The positive correlation of Ser-29 IGF-II mRNA expression to ER status, suggests 
that the tetrapeptide sequence variation does not influence estrogen regulation of 
IGF-II mRNA expression. Overall, these correlation's provide evidence to support 
the model that estrogen may act directly to modulate the transcription of genes such 
as IGF-II and the IGF-IR which, in turn, influence cellular proliferation (Yee et al., 
1988; Osborne eta!., 1989; Lee et al., 1994; Manni eta!., 1994). 
Studies performed by Paik, (1992) and Singer eta!., (1995) found IGF-II expression 
localised to the tumour epithelial cells, but more significantly to the stromal 
fibroblasts in breast tumours. The present findings show that in normal breast 
tissue, IGF-II occurs primarily in the stroma. In contrast, low grade ductal 
carcinomas and DCIS components express IGF-II weakly in the tumour epithelial 
cells, with significant localisation in distinct populations of epithelial cells in the 
high grade carcinomas. These results suggest that, similarly to IGF-I, there is a 
switch in the mode of action of IGF-II during the growth and progression of ductal 
breast carcinomas. In normal breast tissue, IGF-II action is likely to be via 
paracrine mechanisms, which change to autocrine/paracrine actions as breast 
tumour development progresses. 
IGF-IR expression, while not localised to any specific cell type in normal breast 
tissue, was clearly expressed in the tumour epithelial cells of low and high grade 
ductal tumours, supporting earlier in vitro studies (Cullen et a!., 1990; Papa et al., 
1993). These results show that with the development and progression of ductal 
breast cancer there is not only a cellular shift in the site of IGF production, but there 
is also an increase in the sensitivity of the tumour epithelial cells to these growth 
factors, reflected by the induction of IGF-IR synthesis by the tumour epithelial cells. 
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This supports the paracrine to autocrine/paracrine switch in the mechanism of 
action of IGF-I and IGF-ll in developing ductal breast cancers. 
In this study, we have quantified the different mRNAs of IGF-I along with IGF-ll 
and its Ser-29 variant and the IGF-IR and established their cellular sites of synthesis 
during the development and progression of breast cancer. The present findings 
have shown that in comparison to normal breast tissue, breast tumours express 
higher levels and a different pattern of IGF-I mRNA, providing evidence of exon 
changes during the development and progression of breast cancer. This is also 
apparent for IGF-ll expression, where an up-regulation of the IGF-ll Ser-29 variant 
relative to IGF-ll during the progression of the disease was observed. With the 
concomitant increase in IGF-IR and the localisation of synthesis of the IGF family, 
these findings indicate a specific role for the different mRNAs of IGF-I and -IT 
during breast tumourigenesis. Establishing the specific function of the peptides 
encoded by these mRNAs may provide an important therapeutic strategy for this 
disease. 
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Chapter 7 
HUMAN INSULIN-LIKE GROWTH FACTOR-
BINDING PROTEINS (IGFBPs) EXHIBIT A 
DISTINCT PATTERN OF EXPRESSION DURING 
THE DEVELOPMENT AND PROGRESSION OF 
BREAST CANCER 
7.1 Introduction 
Insulin-like growth factors (IGFs) have essential roles in normal cellular growth and 
development (Liu et al., 1993; Baker et al., 1993). Studies have shown that an 
inappropriate activation and over-expression of the IGFs can contribute to the 
deregulated cellular proliferation observed in breast cancer and other types of cancer 
(Quinn et al., 1996; Silberstein et al., 1997). The IGF family consists of two 
structurally related ligands, insulin-like growth factor-! (IGF-I) and -IT both of which 
have been shown to be highly mitogenic in a range of in vitro experimental models 
(Yee et al., 1988; 1989a; Cullen et al., 1991). They are also synthesised and secreted 
by breast tumour cells and adjacent stromal fibroblasts in solid tumours (Yee et al., 
1988; 1989a; Paik, 1992; Walker et al., 1998), stimulating the cellular proliferation 
of tumour epithelial cells by either a paracrine and/or autocrine mode of action. The 
mitogenic actions of the IGFs are mediated by their interaction with the 
transmembrane type I IGF receptor (IGF-IR; Osborne et al., 1989; Cullen et al., 
1990). 
In contrast to other peptide hormones in particular insulin, the availability of IGFs 
for receptor/ligand interactions is regulated by their association with high affinity 
binding proteins, the insulin-like growth factor-binding proteins (IGFBPs). 
Currently six classical IGFBPs, IGFBP-1 to -6, have been identified in the 
circulation or within extracellular compartments (Baxter and Martin, 1989; 
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Clemmons, 1992; Rechler, 1993). These IGFBPs have been isolated and structurally 
characterised (Shimasaki and Ling, 1991). More recently, additional IGFBP-like 
secreted proteins which have a lower affinity for IGFs (IGFBP-rPs), have been 
isolated and characterised, including IGFBP-rP1 (IGFBP-7/mac 25) and IGFBP-rP2 
(IGFBP-8/CTGF; Murphy et al., 1993; Swisshelm et al., 1995; Oh et al., 1996; Kim 
et al., 1997). Certain members of the IGFBP family, are post-translationally 
modified, yielding phosphorylated, glycosylated or proteolytically cleaved forms 
(Jones et al., 1991; Drop et al., 1992; Rechler, 1993). According to the type and 
form, IGFBPs can serve to prolong the half-life of IGFs, as well as alter their ability 
to interact with transmembrane receptors, thereby serving to either potentiate or 
inhibit the biological actions of IGFs (DeMellow and Baxter, 1988; Blum et al., 
1989; Liu et al., 1991). It has also been reported more recently, that some the 
IGFBPs, specifically IGFBP-3 and -5, have ligand (IGF) independent effects (Jones 
et al., 1993; Oh et al., 1993a). 
IGFBPs are synthesised and secreted in a variety of breast cancer cell lines and 
breast tumours (DeLeon et al., 1989; Yee et al., 1991a; Manni et al., 1992; Sheikh et 
al., 1992, Pekonen et al., 1992). The synthesis of IGFBPs by tumours is important, 
as they can regulate the mitogenic actions of IGFs on tumour epithelial cells. In vivo 
studies have shown that IGF-mediated proliferation of cancer cells can be either 
inhibited or enhanced by the administration of the different IGFBPs (Hsu and 
Olefsky, 1992). Most of the data relating to IGFBP function in breast cancer has 
largely been collected from ER characterised breast cancer cell lines. It has been 
concluded from these studies that the production of IGFBPs is heterogeneous and 
their regulation complex (DeLeon et al., 1989; Clemmons et al., 1990b; Yee et al., 
1991a; Sheikh et al., 1992). Studies of the collective IGFBP family in breast 
tumours are less prevalent, but have shown that production of specific IGFBPs is 
more significant in tumour epithelial cells than adjacent normal breast tissue, 
suggesting that a high binding protein content is associated with malignant 
transformation (Pekonen et al., 1992). 
The aim of the present study was to investigate whether there are distinct patterns of 
expression for the six classic IGFBPs and their correlation to total IGF expression 
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during the development and progression of this disease, in order to provide insight 
into IGFBP function in breast tumourigenesis. The cell types comprising breast 
tumours are heterogeneous, therefore the sites of IGFBP synthesis were also 
analysed. This study shows that there are distinct patterns of IGFBP mRNA 
expression during the development of this disease. This observation may be useful 
for the development of potential new therapeutic strategies. 
7.2 Material and Methods 
7.2.1 Patients 
Breast tumours and normal breast tissue samples were obtained post-surgery, frozen 
in liquid nitrogen and stored at -70°C until required. Formaldehyde fixed and 
paraffin embedded tissue blocks were provided following histopathological 
examination. Breast tumours were histologically classified as low grade ductal 
carcinomas (histopathological grades 1 and 2), and high grade ductal carcinomas 
(histopathological grade 3). Approval for the use of these samples was obtained 
from the Ethics Committees of the Queensland University of Technology (QUT 
1033H) and the Wesley Medical Centre (96114). 
7.2.2 RNA Preparation 
Total cellular RNA was extracted from the frozen tissue specimens using the acid 
guanidinium thiocynante (GTC)/phenol-chloroform method as described by 
Chomczynski and Sacchi, (1987; Section 2.5.1). The RNA concentration and 
integrity were established by spectrophotometry and denaturing gel electrophoresis. 
7.2.3 RNase Protection Assay (RPA) 
RP As were performed on 4 normal breast tissue samples and 23 breast tumour 
samples as described in Section 2.8. Antisense [a32P]-labelled RNA probes for IGF-
I (Section 2.8.1), IGFBP-1 to -6 (refer to Section 2.8.7 to 2.8.12), 18S rRNA 
(Section 2.8.13) and an unlabelled sense IGF-I RNA probe, were synthesised from 
the eDNA constructs as described. Total cellular RNA (1 OOpg - 1 O)lg) was 
hybridised with 1.0 x 105 cpm of RNA probe at 42°C for 20h (Section 2.1 0). 
Resulting RNA:RNA hybrids were electrophoresed with MW markers (Section 
2.9.3) on a 5% polyacrylamide gel containing 8M urea (Section 2.10.1). Gels were 
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dried and exposed for 48h to phosphoimager screens (BAS-IllS) for quantification, 
followed by X-OMAT or CURIX RPl autoradiography. Identified protected 
fragments were quantified as described in Section 3.4 with mRNA expression 
defined as pg mRNNJ.lg total RNA. Representative autoradiographs were scanned 
using Deskscan software and imported into Corel Draw 7 graphical software. 
7.2.4 RT-PCR for /GFBP-rP1 (/GFBP-7/mac-25) 
First strand eDNA from representative samples of normal breast tissue and breast 
tumour RNA, was prepared by RT as described in Section 2.6. PCR was used to 
amplify IGFBP-rP1 using 100J.lM of 5' primer TGCGAGCAAGGTCCTT CCAT 
and 100J.1M 3' primer GACAGAACTCCTGCCTGGTG read in a 5' to 3' direction 
off the coding strand derived from the eDNA sequence determined by Murphy et al., 
(1993). Conditions for the PCR reaction for this set of primers were 1 X [94°C, 
5min]; 35 X [94°C, 1min; 56°C, 2min; 72°C, 2min]; 1 X [72°C, 7min]. The PCR 
reactions were run on a 1% agarose gel as described in Section 2.7.4.1. The 
representative gel was scanned using Deskscan software and imported into Corel 
Draw 7 graphical software. 
7.2.5 In Situ Hybridisation Histochemistry 
High grade ductal carcinomas (n=5), low grade ductal carcinomas (n=7) and normal 
breast tissue samples (n=3), were analysed by in situ hybridisation histochemistry as 
described in Section 2.11 with modifications required depending on the set of 
antisense and sense probes used. For pre-hybridisation, sections were dewaxed 
followed by digestion with proteinase-K (50 J.lg/ml) at a temperature of 37°C for 
1 Omin, postfixed in 4% paraformaldehyde, acetylated and dehydrated. Sections were 
immersed in a hybridisation cocktail of 1.0 x 105 cpm of antisense RNA probe for 
18h at 60°C, with the sense RNA probe serving as the negative control. Slides were 
processed as described in Section 2.11 and exposed to Hyperfilm-Bmax for 48h. 
Slides were coated with LM-1 emulsion and exposed for 10 days, developed in D-
19, fixed in Hypam Rapid Fixer and counterstained in Mayer's haematoxylin. 
Representative photomicrographs were taken using llford PANF 50 black and white 
film. 
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7.2.6 Statistical Analysis 
Student's t test was used for analysing differences between means of two variables. 
Results were considered to be statistically significant when p<0.05. 
7.3 Results 
7.3.1 Expression of IGFBP-1 to -6 in Breast Tumours 
The mRNA levels for the six IGFBPs were analysed by RPA in normal breast tissue, 
low grade and high grade ductal carcinomas. IGFBP-1 could not be detected in 
either normal (n=4) or tumour tissue samples (n=13) using a specific antisense RNA 
probe for IGFBP-1 in an RP A (Fig. 7.1 a). This result suggests that either IGFBP-1 
is not expressed in breast tumours or its levels are below the limits of detection for 
this assay. 
Due to the PCR error in the IGFBP-2 construct described in the Section 2.8.8, it was 
anticipated that the IGFBP-2 RNA probe would protect three fragments, a 446 bp 
fragment, and 323/123 bp fragments. The anticipated fragments for IGFBP-2 were 
detected in normal breast tissue (n=4) and breast tumour samples analysed (n=18; 
Fig. 7.1b). The 446 and 323 bp fragments were quantified and the results were 
pooled to give IGFBP-2 mRNA expression levels (Table 7.1). The levels of IGFBP-
2 were found to significantly increase during the development and progression of 
breast tumourigenesis, with levels 24-fold higher in low grade carcinomas (n=3; p < 
0.05) and 14.2-fold higher (n=12; p < 0.01) in high grade ductal carcinomas 
compared to normal breast tissue (Table 7.1). All normal breast tissue samples and 
breast tumours examined also expressed the predicted protected fragments for 
IGFBP-3, -4, -5 and IGFBP-6 by RPA analysis (Fig. 7.1c, d, e, f), while IGFBP-rP1 
was detected in normal and malignant tissues by RT-PCR (Fig. 7.2). As for IGFBP-
2, the expression levels of IGFBP-3, -4 and -5 increased significantly in both low 
grade and high grade ductal carcinomas relative to normal breast tissue (Table 7.1 ). 
The most significant increase in expression was observed for IGFBP-4 which 
exhibited 100-fold higher levels in low grade ductal carcinomas (n=5; p < 0.05) and 
50-fold in high grade ductal carcinomas (n=12; p < 0.01) relative to normal breast 
tissue (n=4; Table 7.1). In contrast to the increase in expression for IGFBP-2 to -5, 
IGFBP-6 levels progressively decreased in expression being 3.7-fold lower in high 
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Figure 7.1 - Representative auto radiographs of RNase protection assays depicting the expression of 
1GFBP-1 to -6 in normal and malignant breast tissue. The respective antisense RNA probes were 
hybridised with 5Jig of total RNA isolated from normal breast tissue and 1 Ojlg breast tumour tissue RNA 
(except for 1GFBP-4 where 15jlg of breast tumour RNA was used). Protected fragment sizes are 
indicated in bold, full length probes in normal text. (M): MW marker; (P): Full-length RNA probe; (R): 
RNase treatment of P; (N1 to N2): Normal breast tissue RNA hybridised with antisense RNA probe; (T1 
to T5): Breast tumour RNA hybridised with antisense RNA probe. A. Expression of IGFBP-1. 
Representative autoradiographfor IGFBP-1 was exposed for 8 days. B. Expression of IGFBP-2. The 
323 bp fragment is the result of PCR error as described in Section 2.8.8. Representative 
autoradiographs were exposed for 5 days. C. Expression of IGFBP-3. Representative autoradiographs 
for 1GFBP-3 were exposed for 5 days. D. Expression of IGFBP-4. Representative auto radiographs for 
1GFBP-4 expression were exposed for 2 days. E. Expression for IGFBP-5. Representative 
autoradiographs for IGFBP-5 expression were exposed for 5 days. F. Expression of IGFBP-6. 
Representative autoradiogrpahsfor IGFBP-6 were exposed for 10 days. 
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Table 7.1- Quantification of IGFBP-2 to -6 mRNA expression in normal breast tissue, low and high grade ductal carcinomas. 1 
Breast Tissue Type IGFBP 
NORMAL (n=4) IGFBP-2 
IGFBP-3 
IGFBP-4 
IGFBP-5 
IGFBP-6 
LOW GRADE (n=3) IGFBP-2 
(n=3) IGFBP-3 
(n=5) IGFBP-4 
(n=4) IGFBP-5 
(n=3) IGFBP-6 
HIGH GRADE (n=12) IGFBP-2 
(n=lO) IGFBP-3 
(n=12) IGFBP-4 
(n=7) IGFBP-5 
(n=7) IGFBP-6 
mRNA Expression (Mean) 
(pg mRNA I fig RNA) 
0.32 ± 0.01 
0.38 ± 0.1 
0.32 ± 0.1 
1.47 ± 0.3 
7.22 ± 2.3 
7.7 ± 1.9 
5.27 ± 2.0 
32.37 ± 5.5 
8.64 ± 4.4 
2.74 ± 1.1 
4.54 ± 1.08 
3.53 ± 0.9 
15.98 ± 4.4 
13.19 ± 5.7 
1.93 ± 0.3 
Fold Induction (X) 
(cf Normal Levels) 
1 
1 
1 
1 
1 
242 
13.9 
1012 
5.9 
0.37 
14.23 
9.33 
503 
92 
0.262 
1 The levels of IGFBP mRNA analysed by RPA were calculated as described in Section 3.4. Each value represents mean±:SE ofn samples. 2 p < 0.05, 3 p < 0.01 compared 
with normal breast tissue by the Student's t test. 
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Figure 7.2 · RT-PCR examination of IGFBP-rPl in normal and malignant breast tissue. IGFBP-
rP 1 PCR product is 169 bp. (M): MW marker ¢>X 174 Haelll; (Nl to N2): Normal breast tissue; (Tl 
to 12): Breast tumour tissue; (C): Water control. 
grade ductal carcinomas (n=7; p < 0.05) relative to normal breast tissue (n=4). 
An important function of IGFBPs is to regulate the bioavailabilty of the IGFs for 
receptor binding. To establish if a distinct pattern of IGFBP expression was 
apparent as breast tissues progressed from a normal state through to poorly 
differentiated high grade ductal carcinomas, a comparison was made between IGFBP 
expression levels and total IGF expression levels (total IGF levels were determined 
in Chapter 6). From this comparison distinct patterns were evident during the 
development and progression of breast carcinogenesis (Fig. 7.3). In normal breast 
tissue (n=4), IGFBP-2, -3 and -4 were all approximately 3-fold lower in expression 
than total IGF expression levels (p < 0.05), while IGFBP-5 was equivalent and 
IGFBP-6 was 6.3-fold higher (p < 0.05). With the development of breast 
carcinogenesis (represented by low grade ductal carcinomas), total IGF levels 
increase 4.8-fold (n=6; p < 0.001) relative to normal breast tissue (n=4), with 
IGFBP-2, -3 and -5 increasing to be equivalent to total IGF levels. Interestingly, 
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Figure 7.3 ·A comparison between normal breast tissue (N) and low grade ductal (LGD) or high 
grade ductal (HGD) carcinomas for 1GFBP and total IGF mRNA expression. Total IGF mRNA 
expression data was derived from the previous set of experiments performed in Chapter 6. Bars, SE. 
*, p < 0,05; **, p < 0.01 where comparisons were made between Nand either LGD or HGD for 
1GF-1 and 1GFBP-2 to -6 by Student's t-test. 
IGFBP-4 dramatically overcompensates for the increase in total IGF levels being 6-
fold higher (n=3; p < 0.001) than total IGF expression in low grade ductal 
carcinomas, while IGFBP-6 decreases to be equivalent to total IGF levels. With 
disease progression (represented by high grade ductal carcinomas), IGFBP-2 and -3 
maintain their 1: 1 expression with total IGF expression while IGFBP-4 levels drop 
back to be 4.1-fold greater (n=12; p < 0.05) than total IGF expression. The most 
interesting change in expression between low and high grade ductal carcinomas, is 
the trend for IGFBP-5 to continue to increase and IGFBP-6 to continue to decrease 
(Fig. 7.3). Overall, the levels of mRNA synthesis suggest complex interactions 
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within the IGF axis with a set pattern during the development and progression of 
breast carcinogenesis. IGFBP-4 and -6 may have significant roles in the earlier 
stages of the disease, while IGFBP-5 may be involved in the more advanced stages. 
These conclusions need to be verified with an examination of protein production. 
7.3.2 Cellular Localisation of IGFBP mRNAs in Breast 
Tumours 
To determine the cell types synthesising the mRNAs for IGFBP-2 to -6 detected in 
the RP A analysis, in situ hybridisation histochemistry was performed on 
formaldehyde fixed tissues. In normal breast tissue (n=3), IGFBP-2 and -3 localised 
significantly to the supportive stromal fibroblasts of the breast as shown by the 
example ofiGFBP-3 expression in Figure 7.4a, b, c. In low grade ductal carcinomas 
of both DCIS (ductal carcinoma-in-situ), the precursor to tumour invasion, and 
invasive forms, both IGFBP-2 (n=7) and -3 (n=3) continued to be expressed by the 
stromal fibroblasts as shown by the representative micrographs of IGFBP-3 
localisation (Fig. 7.4d, e, f). However, expression of IGFBP-2 was also observed in 
the invasive margins or advancing front of the more advanced low grade and in high 
grade ductal carcinomas (n=4; Fig. 7.5a, b, c). IGFBP-3 synthesis in low grade 
ductal carcinomas also exhibited localisation to neoplastic cell types, which was 
further evident in high grade ductal carcinomas, but expression was absent from the 
poorly differentiated tumour epithelial cells (n=5; Fig. 7.4g, h, i). 
No significant expression could be detected in normal breast tissue for IGFBP-4 
(n=3; data not shown) suggesting its expression is below the limits of detection for 
this assay. In contrast, both low grade (n=4) and high grade (n=3) invasive ductal 
carcinomas localised IGFBP-4 expression exclusively to the tumour epithelial cells, 
with no detectable expression in the stromal components (Fig. 7.5d, e, f). Generally, 
components of DCIS did not express mRNA for this binding protein, although a few 
populations of DCIS tumour epithelial cells in one patient, expressed significant 
levels of IGFBP-4 mRNA (data not shown). 
An examination of IGFBP-5 expression in breast tumours showed in some cases a 
similar pattern of expression to IGFBP-3. While weak expression was observed in 
the cells comprising ductal structures of the breast, largely IGFBP-5 was not detected 
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Figure 7.4 - The cellular localisation of JGFBP-3 mRNA synthesis in normal breast tissue, low grade 
ductal and high grade ductal tumours. JGFBP antisense and sense RNA probes were hybridised to fixed 
tissue sections via in situ hybridisation histochemistry. (8) Stroma; (E/M) Epithelial and myoepithelial 
cells of the ducts; (T) Tumour epithelial cells; (N) Neoplastic cells. A. Darkfield photomicrograph of 
antisense JGFBP-3 in a representative normal breast tissue. B. Brightfield photomicrograph of Fig. 
7.4a. C. Darkfield photomicrograph of a serial section hybridised with the sense JGFBP-3 control probe 
. D. Darkfield photomicrograph of antisense JGFBP-3 in a representative low grade ductal carcinoma. 
E. Brightfield photomicrograph of Fig. 7.4d. F. Darkfield photomicrograph of a serial section 
hybridised with the sense JGFBP-3 control. G. Darkfield photomicrograph of antisense JGFBP-3 in a 
representative high grade ductal carcinoma. H. Brightfield photomicrograph of Fig. 7.4g. I. Darkfield 
photomicrograph of a serial section hybridised with the sense JGFBP-3 control probe. 
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Figure 7.5 - The cellular localisation of JGFBP-2, -4, -5 mRNA synthesis in low and high grade ductal 
tumours. JGFBP antisense and sense RNA probes were hybridised to fixed tissue sections via in situ 
hybridisation histochemistry. (S) Stroma; (T) Tumour epithelial cells; (AT) Advanced tumour epithelial 
cells. A. Darkfield photomicrograph of antisense JGFBP-2 in a representative high grade ductal 
carcinoma. B. Brightfield photomicrograph of Fig. 7.5a. C. Darkfield photomicrograph of a serial 
section hybridised with the sense JGFBP-2 control probe. D. Darkfield photomicrograph of antisense 
IGFBP-4 in a representative low grade ductal carcinoma. E. Brightfield photomicrograph of Fig. 7.5d. 
F. Darkfield photomicrograph of sense JGFBP-4 control. G. Darkfield photomicrograph of antisense 
IGFBP-5 in a representative high grade ductal carcinoma. H. Brightfield photomicrograph of Fig. 7.5g. 
I. Darkfield photomicrograph of a serial section hybridised with the sense IGFBP-5 control probe. 
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in normal breast tissue (data not shown) probably due to the limits of detection for 
this assay. However, the more advanced poorly differentiated tumour epithelial cells 
present in both low grade (n=6) and high grade (n=4) invasive ductal carcinomas, 
exhibited strong IGFBP-5 expression (Fig. 7.5g, h, i). In contrast, IGFBP-5 
expression in DCIS tumour epithelial cells as well as the less aggressive cell types of 
invasive ductal carcinomas was not significant( data not shown). 
Confirming IGFBP-6 expression via RPA, IGFBP-6 expression significantly 
localised to the stromal fibroblasts of normal breast tissue (n=3; data not shown). 
However, no significant expression could be detected in either low grade or high 
grade ductal carcinomas examined, possibly due to the sensitivity of this assay (data 
not shown). 
7.4 Discussion 
A body of evidence has shown that IGFBPs regulate the availability of IGFs for 
receptor/ligand interactions (De Mellow and Baxter, 1988; Blum et al., 1989; Liu et 
al., 1991 ), as well in some cases, possessing intrinsic biological activities that are 
independent of IGFs (Jones et al., 1993; Oh et al., 1993a). As IGFs are synthesised 
by both normal breast tissue and breast tumours (Yee et al., 1988; 1989a; Paik, 
1992), and are potent mitogens of breast cancer cell lines (Yee et al., 1988; Osborne 
et al., 1989; Cullen et al., 1990), it seems inevitable that IGFBPs should play a 
pivotal role in the development and maintenance of breast cancer. In vitro studies of 
cancer cell lines have confirmed that !OF-mediated cell proliferation can be 
enhanced or inhibited by the administration of IGFBPs (Hsu and Olefsky, 1992). 
The aim of the present study was to establish whether there are distinct patterns of 
IGFBP synthesis during the development and the progression of breast cancer, thus 
enabling speculation of IGFBP function in breast carcinogenesis. 
In normal breast and breast tumour tissue, all samples analysed using RPA, RT-PCR 
and in situ hybridisation histochemistry, expressed mRNA for IGFBP-2 to -6 and 
IGFBP-rPl, consistent with collective data from human biopsies (Pekonen et al., 
1992) and the N-nitrosomethyl-urea (NMU)-induced rat mammary tumour model 
(Manni et al., 1992; 1994). As with the RT-PCR evaluation of IGFBP-1 to -5 by 
Pekonen et al., (1992), it was observed that the levels of IGFBP-2 to -5 were 
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significantly elevated in all breast tumour samples when compared to the normal 
breast tissue controls. In contrast it was observed for the first time that IGFBP-6 
expression levels were significantly lower in breast tumour samples in comparison to 
normal breast tissue. Analysis of the cellular synthesis of IGFBP-6 by in situ 
hybridisation histochemistry summarised in Figure 7.6, although not quantitative in 
this study, showed a strong stromal localisation in normal breast tissue, while for 
both low and high grade ductal carcinomas, expression was significantly lower. 
IGFBP-6 has a 10-fold greater affinity for IGF-II than IGF-I (Kiefer et al., 1992) and 
has been identified as having a negative growth modulatory role in a range of cell 
types (Manni eta!., 1994; Babajko et al., 1997), principally by reducing IGF-IIs 
availability for receptor binding. In addition, IGFBP-6 has been shown to be 
hormonally sensitive in the NMU-induced rat mammary tumour model. In this 
model ovariectomy increases IGFBP-6 production, resulting in decreased IGF-II 
bioavailability, with hormone replacement resulting in the inverse effect (Manni et 
al., 1994). IGFBP-6 synthesis has also been shown to be down-regulated by 
transforming growth factor beta 1 (TGF ~ 1) in human osteoblast cell culture 
(Gabbitas and Canalis, 1997). However as IGFBP-6 is sensitive to other hormones, 
such as the sex hormones (Manni et al., 1994), its de-regulation in breast tumours 
relative to normal breast tissue may be due to any number of control mechanisms, 
such as the introduction of hormone independence with tumour progression or the 
action of a negative regulator such as TGF ~ 1. It is conceivable that the elevation of 
IGF expression observed in breast tumours, in particular IGF-II (Cullen et al., 1990; 
Walker et al., 1998), is the result of a decrease in IGFBP-6 synthesis and the 
subsequent loss of IGFBP-6's negative regulation of IGF action. This appears to 
occur early in tumour development, as a decrease in IGFBP-6 mRNA is seen in low 
grade ductal carcinomas, and drops further in high grade samples. These 
mechanisms require further investigation, as it is possible that by restoring IGFBP-6 
synthesis, control of IGF-IT bioavailability may be regained. Further research in this 
area may also prove useful for the early detection of breast cancer and possibly other 
forms of cancer. 
In normal breast tissue, IGFBP-2 expression levels, like IGFBP-3, -4 and -5, were 
approximately 3-fold less than total IGF expression, while IGFBP-6 was 6.3-fold 
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Figure 7.6 - Summary of IGFBP expression during the development and progression of breast 
cancer. A. IGFBP expression in normal breast tissue. B. IGFBP expression in low grade and high 
grade ductal carcinomas. 
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higher. As for IGFBP-3, -4 and -6, IGFBP-2 expression was localised to the stromal 
fibroblasts, suggesting autocrine/paracrine mechanisms of action on the adjacent 
epithelial cells of normal breast tissue. With cellular transformation and the 
appearance of the tumourigenic phenotype (low grade ductal carcinomas), total IGF 
and IGFBP-2 expression levels exhibited a concomitant increase, effectively to be in 
a 1:1 ratio. As summarised in Figure 7.6 IGFBP-2 exhibited a stromal expression 
pattern as for normal breast tissue, however it was also detected in the tumour 
epithelial cells positioned in the advancing margins of some low grade ductal 
tumours. This suggests that the elevation of IGFBP-2 synthesis observed with RP A 
analysis in the tumour samples, may come from these tumour epithelial cells. With 
disease progression (high grade ductal carcinomas), total IGF and IGFBP-2 mRNA 
levels remained constant (1: 1 ratio), with IGFBP-2 maintaining the same pattern of 
cellular synthesis. These results indicate a possible role for IGFBP-2 in the early 
stages of tumour epithelial formation, which appear to be maintained in the more 
advanced tumours. IGFBP-2, binds IGF-II with a moderately higher affinity than 
IGF-I (Roghani et al., 1991) and has been identified as having both negative and 
positive growth modulatory roles (Delhanty and Han, 1993; Manni et al., 1994; 
Jaques et al., 1994). In the NMU-induced rat mammary tumour model, IGFBP-2 
like IGFBP-6, exhibited a similar yet less potent hormone sensitivity (Manni et al., 
1994). However, unlike IGFBP-6, IGFBP-2 levels were elevated with breast 
carcinogenesis. IGFBP-2 possesses an arginine-glycine-aspartic acid (RGD) amino 
acid sequence which enables binding to integrin receptors on the cell surface. Cell 
association of IGFBP-2 has been observed (Bourner et al., 1992) and shown to 
contribute to the positive modulation of IGF-II (Delhanty and Han, 1993). Since 
there appears to be a stimulation of IGFBP-2 synthesis by the tumour epithelial cells 
at the advancing tumour margin, it could be speculated that IGFBP-2 binds the 
integrin receptors of the same or neighbouring cells. This cell association may 
facilitate the presentation of IGF-II to its cognate receptor, suggesting that the 
function ofiGFBP-2 is associated with cell growth and tumour invasion. 
IGFBP-3 is the major binding protein in human serum where it serves as a carrier for 
IGFs bound in a ternary complex with an acid labile subunit (ALS; Baxter and 
Martin, 1989). RPA and in situ hybridisation analyses show that IGFBP-3 is 
Page 197 
Walker 1998 
synthesised in normal breast tissue by the stromal fibroblasts. With the onset of the 
tumourigenic phenotype, the level of IGFBP-3 synthesis increases parallel to the 
measured levels of total IGF expression (1: 1 ratio) and are maintained with the 
progression to high grade ductal carcinomas. While this synthesis was still apparent 
in the stroma, specific localisation of IGFBP-3 was identified in neoplastic cells 
throughout both low and high grade ductal carcinomas (Fig.7.6). This suggests that 
the increase in the levels of IGFBP-3 mRNA detected in tumour tissue relative to 
normal breast tissue, maybe largely due to synthesis by neoplastic cells. IGFBP-3 
has been shown to act as a growth inhibitor in most (Knauer and Smith, 1980; Cohen 
et al., 1993) but not all experimental systems (DeMellow and Baxter, 1988; Blum et 
al., 1989). Studies have identified that IGFBP-3's inhibitory effect is achieved by 
binding to and reducing the bioavailability ofiGF-I and/or IGF-II for receptor/ligand 
interactions (Knauer and Smith, 1980). More recently IGF independent biological 
functions have been recognised for IGFBP-3. IGFBP-3 has been shown to inhibit 
monolayer ·growth of an ER- breast cancer cell line, Hs578T (Oh et al., 1993a) by 
binding to specific cell surface receptors (Oh et al., 1993b ). IGFBP-3 has also been 
identified as being an agent of apoptosis induced by TGF-P (Rajah et al., 1997). The 
potentiating effects of IGFBP-3 appear to be due to its cellular association and 
proteolysis to forms that have a decreased affinity for IGFs, therefore allowing 
receptor binding (Conover, 1991). The inhibitory functions of IGFBP-3 seem at 
odds with tumour physiology, where ligand levels are higher and known to stimulate 
tumour proliferation (Quinn et al., 1996; Silberstein et al., 1997). If IGFBP-3 
mRNA is translated, it is more likely that in both grades of ductal breast tumours, 
IGFBP-3 may serve to potentiate IGF action by cell association and proteolytic 
processing to produce IGFBP-3 fragments with altered affinity for IGFs, enabling 
receptor binding and mitogenesis (Conover, 1991). A report by Firth et al., (1998) 
has shown that MCF-7 breast cancer cell lines can develop a resistance to the 
inhibitory effects of IGFBP-3. While in the T47D breast cancer cell line, IGFBP-3 
has a growth stimulatory effect (Chen et al., 1994) 
In this study, the most dramatic change in IGFBP synthetic pattern observed during 
the development (low grade ductal carcinomas) and progression (high grade ductal 
carcinomas) of breast cancer, was the significant increase in expression ofiGFBP-4 
in breast tumour tissues relative to the normal breast tissue controls. Expression 
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levels for IGFBP-4 in low grade ductal carcinomas, increased 100-fold compared to 
levels in normal breast tissue, with synthesis exclusive to the invasive tumour 
epithelial cells as summarised in Figure 7 .6. This pattern was maintained in high 
~rade ductal carcinomas, although expression levels declined somewhat to be 50-
fold the normal breast tissue levels. IGFBP-4 has been shown by numerous in vitro 
studies to negatively regulate IGF action (LaTour et al., 1990; Schiltz et al., 1993) 
but with a positive correlation to cellular proliferation (Pratt and Pollak, 1993). The 
mechanism by which IGFBP-4 inhibits IGF actions appears to be like that of IGFBP-
3, whereby it sequesters local IGFs thereby inhibiting receptor/ligand interactions 
(Cheung et al., 1991; Kiefer et al., 1992). Like IGFBP-3, IGFBP-4's inhibitory 
regulation of IGFs coupled with the dramatic levels of IGFBP-4 synthesised by the 
tumour epithelial cells shown in this study, is difficult to reconcile with the notion of 
tumour physiology. If IGFBP-4 mRNA is translated, it remains possible that it may 
have little effect on IGF action, as the IGFBP-4 inhibitory actions are lost following 
IGFBP-4 proteolysis (Fowlkes and Freemark, 1992; Camacho-Hubner et al., 1992). 
The protease responsible is specific to IGFBP-4 and has been shown to be activated 
by the presence of IGFs, more specifically IGF-II (Fowlkes and Freemark, 1992; 
Camacho-Hubner et al., 1992; Conover et al., 1993). Therefore, it is conceivable 
with the development of breast cancer and the increase in IGF synthesis, the increase 
in IGFBP-4 synthesis occurs early in this disease, being synthesised as a survival 
factor to inhibit the mitogenic actions of the IGFs on the nascent tumour epithelial 
cells. However, such an exercise is futile as the higher levels of IGFs induce the 
IGFBP-4 protease which negates the inhibitory actions of IGFBP-4, allowing tumour 
proliferation to continue. Future investigations should focus on the co-localisation 
of IGFBP-4 and its protease in normal breast tissue and breast carcinomas to provide 
further evidence for this hypothesis. Nevertheless, the dramatic increase in IGFBP-4 
expression levels in low grade invasive breast tumours, make it an ideal candidate 
for early detection in this disease. As such, further investigation of IGFBP-4 
regulation is warranted. 
As identified by this and other studies (Pekonen et al., 1992), IGFBP-5 showed high 
expression levels in normal breast tissue. Although no stromal expression was 
apparent, possibly due the detection limits of the assay, IGFBP-5 mRNA was weakly 
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detected in the epithelial and myoepithelial cells that comprise the ductal system of 
the breast (Fig.7.6). With the development of breast carcinogenesis, IGFBP-5 
mRNA levels increased in parallel with total IGF levels and continued to increase 
steadily with tumour progression. Interestingly, IGFBP-5 synthesis localised to 
specific populations of the more advanced, highly nucleated and poorly 
differentiated tumour epithelial cells in both stages of the disease, suggesting that 
IGFBP-5 is more specialised in the later stages where the tumour epithelial cells are 
actively and rapidly dividing. Using a bone matrix, Mohan et al., (1994) proposed 
that IGFBP-5 functions as an agent that fixes both IGF-I and -II to the cellular 
surface and ECM, promoting ligand/receptor interactions. IGFBP-5 peptide levels 
are also controlled by proteolysis, but when bound to IGFs or the ECM, IGFBP-5 is 
protected from cleavage (Conover and Kiefer, 1993; Mohan et al., 1994). Such a 
model for IGFBP-5 function, supports the synthesis and translation of this binding 
protein by the more advanced tumour epithelial cells of ductal breast carcinomas. At 
this stage these cells are largely hormone-independent, therefore it is possible that 
IGFBP-5 synthesis is regulated by endogenously produced growth factors, in 
particular IGFs, with increased levels promoting ligand/receptor interactions 
(Conover and Kiefer, 1993; Mohan et al., 1994). It is also possible that the 
regulatory mechanisms in place to control IGFBP-5 bioavailability, such as protease 
levels, may be lost in the more advanced tumour epithelial cells enabling IGFBP-5 to 
function as a potentiator of IGF action, or to act independently (Jones et al., 1993). 
With a clear role in later stage tumourigenesis, inhibition of IGFBP-5 production 
may provide an important therapeutic tool for patients with a poor prognosis, and is 
worthy of further investigation. 
As previously identified, IGFBP-1 mRNA was not detected in any of the normal 
breast tissue or breast tumour samples analysed (Manni et al., 1992; Figueroa et al., 
1993). IGFBP-1 is proposed to have limited in vivo regulatory functions as its 
synthesis is confined to the liver and decidualised endometrium (Figueroa et al., 
1993). However, it has been shown that IGFBP-1 has largely inhibitory actions in a 
range of cell model systems (Ritvos et al., 1988; Liu et al., 1991). This has also 
been observed in breast cancer where IGFBP-1 blocks the mitogenic action of IGF-I, 
estradiol and other serum growth factors in MCF-7 breast cancer cell line, when 
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administered and endogenously produced (McQuire et al., 1992; Figueroa et al., 
1993; Yee et al., 1994). As a consequence, numerous studies are focusing on this 
binding protein as a candidate for breast cancer therapy. 
IGFBP-rP1 (IGFBP-7/mac-25) was originally isolated from leptomeningial cells and 
human mammary epithelial cells (Murphy et al., 1993; Swisshelm et al., 1995). It 
was suggested that IGFBP-rP1 was another member of the IGFBP family as it was 
shown to have 20-25% identity to IGFBPs, possessed the common IGFBP NH2 
terminus motif GCGCCXXC, contained 11 of the 12 conserved cysteines and bound 
IGF-1 and -11, however with 5-6- and 20-25-fold lower affinity than IGFBP-3 (Oh et 
al., 1996). Previous studies have shown that IGFBP-rP1 mRNA expression was 
down-regulated in mammary carcinoma cell lines in comparison to senescent 
epithelial cells (Murphy et al., 1993; Swisshelm et al., 1995), hence the study was to 
examine the expression of IGFBP-rP1 during the development and progression of 
breast carcinogenesis. IGFBP-rP1 mRNA was detected in both normal breast tissue 
and breast tumour tissue, however the quantitation of its expression was 
discontinued due to new experimental evidence of its function. More recently, 
IGFBP-rP1 has been shown to have a high affinity to insulin, whereby it blocks 
insulin binding to the insulin receptor inhibiting the autophosphorylation of the 
insulin receptor ~ subunit and the phosphorylation of IRS-1 (Yamanaka et al., 1997). 
It is therefore more likely that IGFBP-rP1 is an insulin binding protein that may 
contribute to conditions of insulin resistance, such as type II diabetes mellitus. 
This is the first study to address the pattern of IGFBP synthesis during the 
development and progression of breast carcinogenesis (Fig. 7.6). An examination of 
protein production by a series of breast cancer cell lines that represent the different 
stages of the disease, described IGFBP-2 and -5 as the predominant IGFBPs in early 
stage tumour epithelial cell lines and IGFBP-4 in the more advanced hormone 
independent cell line (Dubois et al., 1995). However, these studies in breast cancer 
cell lines fail to take into consideration the stromal component of the tumour and the 
potential paracrine interactions that have been identified in breast tumourigenesis 
(Manni et al., 1994). Bearing in mind these stromal/epithelial interactions, I 
quantified mRNAs for IGFBP-1 to -6 and established their cellular sites of synthesis 
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in normal breast tissue, low grade and high grade ductal carcinomas. The present 
findings summarised in Figure 7.6 show that there is a definite pattern of IGFBP 
synthesis during the development and progression of breast carcinogenesis, that is 
distinguishable for each stage of the disease, enabling speculation about their 
specific biological functions during malignancy. Support for these hypotheses 
requires an investigation of the distribution and production of the protein counterpart 
and their association with the changes in mRNA synthesis, as well as the distribution 
of the relevant protease's. 
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Chapter 8 
IS HUMAN INSULIN-LIKE GROWTH FACTOR 
BINDING PROTEIN-3 (IGFBP-3) 
ALTERNATIVELY SPLICED? 
8.1 Introduction 
The biological actions of insulin-like growth factors (IGFs) during normal cellular 
growth and development, are mostly achieved through their interactions with the 
type I IGF receptor (IGF-IR; Liu eta!., 1993; Baker eta!., 1993). The availability of 
IGFs for receptor/ligand interactions is primarily regulated by their association with 
high affinity binding proteins, the insulin-like growth factor-binding proteins 
(IGFBPs). IGFBP-3 is one of the six specific, high affinity IGFBPs which regulate 
the biological effects of IGFs. IGFBP-3 is a 40-45 kDa glycoprotein which binds 
with an 85 kDa acid labile subunit (ALS) and either IGF-I or -II to form a ternary 
complex (Baxter and Martin, 1989). Most serum IGFs are found in this complex, 
which increases the half-life of the IGF peptides and regulates their transport to 
target cells (Rosenfeld et al, 1990; Gargosky eta!., 1991; Baxter, 1994). At the 
target cell, soluble IGFBP-3 inhibits IGF actions by binding and sequestering the 
peptide thus preventing receptor interactions. In contrast, IGFBP-3 can also 
facilitate the action of IGFs. This is suggested to occur through the cell association 
of IGFBP-3 and its proteolysis to forms which have a lower IGF affinity (Conover, 
1992). More recently, IGFBP-3 has also been shown to have IGF independent 
effects (Oh et al., 1993a; Cohen et al., 1993; Valentinis et al., 1995) mediated by 
cell surface receptors (Oh et al., 1993b ). In mink lung epithelial cells, the 
independent growth inhibitory effects of IGFBP-3 were shown to be mediated by the 
type V transforming growth factor ~ receptor (Leal eta!., 1997). In all, IGFBP-3 
exhibits a diverse range of functions which adds to the complexity ofiGF regulation. 
In a previous investigation described in detail in Chapter 7, IGFBP-3 expression was 
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analysed along with IGFBP-1 to -6 in a series of normal breast tissue and low and 
high grade ductal carcinomas of the breast. The intention of this study was to 
determine whether there was differential IGFBP expression patterns during the 
development and progression of breast carcinogenesis, which could be further 
investigated for potential therapeutic strategies. It was established that IGFBP-3 
mRNA was expressed at all stages of breast carcinogenesis. However, in addition to 
the mRNA for IGFBP-3, another specific fragment not shown in figure 7.1c 
(approximately 350 bp in length), was protected by the IGFBP-3 RNA probe in both 
normal and malignant breast tissue (not shown in Chapter 7). The aim of the present 
investigation was to determine the identity of the potential IGFBP-3 variant mRNA, 
and whether it exhibits a differential pattern of expression during the development 
and progression of breast carcinogenesis. 
8.2 Material and Methods 
8.2.1 Patients 
Breast tumours and normal breast tissue samples were obtained post-surgery, frozen 
in liquid nitrogen and stored at -70°C until required. Breast tumours were 
histologically classified as "low grade" ductal carcinomas (histopathological grades 
1 and 2), and "high grade" ductal carcinomas (histopathological grade 3). Approval 
for the use of these samples was obtained from the Ethics Committees of the 
Queensland University of Technology (QUT 1033H) and the Wesley Medical Centre 
(96114). 
8.2.2 RNA Preparation 
Total cellular RNA was extracted from the frozen tissue specimens and human cell 
lines using the acid guanidinium thiocynante (GTC)/phenol-chloroform method as 
described by Chomczynski and Sacchi, (1987; Section 2.5.1). 
8.2.3 RNase Protection Assay (RPA) 
RPAs for IGFBP-3 expression were performed on 4 normal breast tissue samples, 4 
low grade and 10 high grade ductal carcinomas of the breast, as well as the SK-N-
MC neuroblastoma cell line over a 7 day time course, as described in Section 2.11. 
Antisense [a32P]-labelled RNA probes for IGFBP-3 (Section 2.8.9) and 18S rRNA 
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(Section 2.8.13), were synthesised from the eDNA constructs as described in Section 
2.9.2.1. Total cellular RNA (lOOpg- 10~g) was hybridised with 1.0 x 105 cpm of 
RNA probe at 42°C for 20h (Section 2.10). Resulting RNA:RNA hybrids were 
electrophoresed along side MW markers (Section 2.9.3) on a 5% polyacrylamide gel 
containing 8M urea (Section 2.1 0.1 ). Gels were dried and exposed for 48h to 
phosphoimager screens (BAS-IllS) for quantification, followed by X-OMAT or 
CURIX RP1 autoradiography. Identified protected fragments were quantified as 
described in Section 3.4 with mRNA expression defined as pg mRNA/~g total RNA. 
Representative autoradiographs were scanned using Deskscan software and imported 
into Corel Draw 7 graphical software. 
8.2.4 Identification of the Variant /GFBP-3 
First strand eDNA synthesis was performed by RT as described in Section 2.6 on 
RNA from normal breast tissue (n=2), breast tumours (n=3) and neuroblastoma cell 
lines SK-N-MC (n=2) and SK-N-SH (n=4) taken from Day 4 of growth in 10% FBS. 
PCR was then performed to amplify IGFBP-3 and its potential variant using 100J..LM 
of a forward and reverse primer from the sets of primers described in Table 8.1. 
PCR conditions for both sets of primers were 1 X [94°C, 5min]; 35 X [94°C, 1min; 
60°C, 2min; 72°C, 2min]; 1 X [72°C, 7min]. Representative gels were scanned 
using Deskscan software and imported into Corel Draw 7 graphical software. PCR 
products were isolated and purified as described in steps c - j of Section 2. 7 .1.1. The 
products were then ligated into a pGEM-T expression vector and transformed into 
E. Coli, as described in Sections 2.7.2 and 2.7.3. 
5'GGAAATGCTAGTGAGTCGGAGG 5'GCTCTGCATGCTGTAGCAGTGC 467 
Exon 2 Exon 4 
5' GGAAATGCT AGTGAGTCGGAGG 5 'CATGAAGTCTGGGTGCTGTGCTC 7 64 ! 641 
Exon2 Exon5 
Table 8.1 - Primer sets used for the amplification of 1GFBP-3 mRNA and the potential variant 
1GFBP-3 mRNA in breast tissue samples and neuroblastoma cells. Primers were designed from the 
eDNA sequence described by Wood et al., ( 1988) and Cubbage et al., ( 1990). 
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Following a positive identification by restriction enzyme digestion, samples from 
miniplasmid extractions were then sequenced to confirm the identity of the insert, as 
described in Section 2.7.5.2. 
8.2.5 Statistical Analysis 
The Student's t test was used for analysing differences between means of two 
variables. Results were considered to be statistically significant when p<0.05. 
8.3 Results 
8.3.1 Expression of IGFBP-3 mRNA 
The expression of IGFBP-3 mRNAs were analysed by RPA in normal breast tissue, 
low grade and high grade ductal carcinomas (Chapter 7) and in the human 
neuroblastoma cell line SK-N-MC grown in 10% FBS over a 7 day time course 
(Chapter 5). All normal breast tissue samples and breast tumour samples examined 
expressed the predicted 475 bp protected fragment specific for IGFBP-3 mRNAs, 
while IGFBP-3 synthesis could not be detected in SK-N-MC neuroblastoma cells at 
any stage of growth (Fig. 8.1a, b). Unexpectedly, an additional protected fragment 
of approximately 350 bp was also protected by the IGFBP-3 RNA probe in normal 
breast and breast tumour samples, but not by the SK-N-MC neuroblastoma cells at 
any stage of the growth profile. This fragment was also absent in the RNase control 
sample, suggesting that a fragment of this size could be a legitimate additional 
IGFBP-3 mRNA. 
8.3.2 Sequence Possibilities for the 350 bp Fragment 
If the RNA probe and mRNA are not entirely homologous they will be cleaved 
during the RNase digestion. Therefore, to begin to identify the 350 bp fragment 
protected by the IGFBP-3 RNA probe, RPA gels were analysed for a fragment 
approximately 125 bp in size to determine whether the 350 bp protection was due to 
base pair variation. A faint yet dispersed band was present roughly around the 
expected location of 125 bp (Fig. 8.2). This suggests that the 350 bp fragment 
protected by the IGFBP-3 RNA probe may be due to a sequence mismatch between 
the probe and the mRNA synthesised by the normal breast tissue and breast tumours. 
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Figure 8.1 - Representative autoradiographs of IGFBP-3 expression in normal breast tissue, low 
and high grade invasive ductal carcinomas of the breast, and SK-N-MC neuroblastoma cells. (M): 
MW marker; (P): IGFBP-3 RNA probe; (R): RNase digestion of IGFBP-3 RNA probe. The full 
length probe is shown in normal text, with the expected 475 bp IGFBP-3 and unidentified 350 bp 
fragment shown in bold. The representative autoradiograph was exposed for 3 days. A. (l-5): 10j1g 
RNA from breast tumour tissue hybridised with the IGFBP-3 RNA probe; (6-9): lOjlg RNA from 
normal breast tissue hybridised with the IGFBP-3 RNA probe. B. (1-7): 10jlg RNA harvested every 
24hfrom SK-N-MC cells grown over a 7 day time course hybridised with the IGFBP-3 RNA probe; 
(NJ, N2): lOjlg RNA from normal breast tissue samples hybridised with the JGFBP-3 RNA probe. 
The representative autoradiograph was exposed for 3 days. 
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Figure 8.2 · Representative phosphoimage of 1GFBP-3 expression in SK-N-MC neuroblastoma 
cells and breast tumour samples depicting a potential band at 125 bp. (MC): 10 Jig RNA from day 7 
of SK-N-MC cells grown in 10% FBS hybridised with the 1GFBP-3 RNA probe; (R): RNase digestion 
of the IGFBP-3 RNA probe; (P): IGFBP-3 RNA probe; (M): MW marker; (1-5): 10 Jig of different 
breast tumour RNA samples hybridised with the 1GFBP-3 RNA probe. The full length probe is shown 
in normal text, with the potential protected fragments shown in bold. The representative image was 
exposed to the phospho imager screen for 48h. 
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To address whether a sequence variation may be caused by the RNA probe, the 
construct used to generate the IGFBP-3 RNA probe was sequenced and analysed for 
possible variations to the reported eDNA sequence which would cause the cleavage 
of RNA:RNA hybrids during the RNase digestion of the RPA. When the IGFBP-3 
RNA probe was compared to the reported human IGFBP-3 sequence, there were no 
sequence variations found in the IGFBP-3 RNA probe within the expected regions 
where cleavage could occur, suggesting that the 350 bp fragment was not the result 
of an error in the IGFBP-3 expression vectoru. It is therefore possible that the 350 
bp protected fragment is due to IGFBP-3 sequence variations in the human tissues 
and human cell lines examined. 
To determine whether the 350 bp protected fragment could be caused by differential 
mRNA synthesis in both normal breast tissue and breast tumour tissue, the IGFBP-3 
RNA probe sequence was compared to the gDNA sequence of human IGFBP-3. 
Such an analysis would determine whether the 350 bp product could be the result of 
transcriptional variations, such as alternative splicing. The IGFBP-3 RNA probe can 
detect IGFBP-3 mRNAs encoding the entire exon 2 sequence through to the end of 
exon 4 in human IGFBP-3. Interestingly, when the RNA probe was aligned with the 
gDNA sequence of IGFBP-3, removal of 125 bp from the 3' end of the IGFBP-3 
RNA probe corresponded exactly to the exon3/4 junction in the IGFBP-3 gene (Fig. 
8.3). This provides another option for the identification of the 350 bp fragment such 
that it may be the product of alternative splicing of the IGFBP-3 pre-mRNAs, where 
exon 4 is removed during post-transcriptional processing generating a mRNA 
containing only exons 1, 2, 3 and 5. 
8.3.3 RT-PCR Analysis of /GFBP-3 mRNAs 
To investigate the possibility that IGFBP-3 is alternatively spliced, RT-PCR was 
performed on RNA from normal breast tissue, breast tumour tissue and the 
neuroblastoma cell lines SK-N-MC and SK-N-SH at Day 4 of growth. This was 
done by using two sets of IGFBP-3 specific primers as shown in Table 8.1 and 
11 The expected regions were between 110 to 140 bp in from both the 5' and 3' ends of the IGFBP-3 
RNA probe, allowing for errors in determining the size of the 350 bp protected fragment in the RP A. 
Page 209 
Walker, 1998 
Human IGFBP-3 
Exon 1 H Exon 2 H Exon 3 H Exon 4 H Exon 5 
Mature Peptide 3'UTR 
/GFBP-3 RNA Probe 475bp 
/GFBP-3 mRNA 475bp 
???? 350bp 
Figure 8.3 - Diagrammatic representation of the human IGFBP-3 gene and protein aligned to 
the IGFBP-3 RNA probe. Boxes shaded in yellow represent the five IGFBP-3 exons. IGFBP-3 
protein is shown with the green box representing the signal peptide and the white the mature 
IGFBP-3 protein. The expected 475 bp mRNA protected by the IGFBP-3 RNA probe is indicated in 
red, with the potential identity of the 350 bp fragment shown. 
Figure 8.4a. The exon 2/4 primer set was designed to amplify eDNA encoding exon 
2 through to 4 of IGFBP-3, while the exon 2/5 primer set was designed to amplify 
the eDNA encoding exon 2 through to 5 (Fig. 8.4a). In all of the normal breast, 
breast tumour and SK-N-SH samples tested, an IGFBP-3 PCR product was detected 
at the expected size (467 bp) using the exon 2/4 primer set, while no product was 
detected in the SK-N-MC cells (Fig. 8.4b). When each sample was tested using the 
exon 2/5 set of primers, three PCR products were amplified in normal breast, breast 
tumour and SK-N-SH cells while no PCR products were amplified in SK-N-MC cells 
(Fig 8.4c). The PCR products which were approximately 764 and 641 bp, 
corresponded to the expected size of IGFBP-3 either containing or not containing 
exon 4 respectively, while the 194 bp PCR product could not be identified. Overall 
the RT-PCR and RPA results, confirmed the existence of an additional IGFBP-3 
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Figure 8.4 - RT-PCR analysis examining the expression of IGFBP-3 and a potential IGFBP-3 
variant mRNA. A. Diagrammatic representation of the human IGFBP-3 gene. Yellow boxes 
represent the exons. IGFBP-3 mRNA (black) and the potential splice variant (red) are shown. B. 
RT-PCR with the exon 214 primers to detect IGFBP-3 mRNA. (M): MW marker eX 174 Hae!II; (1): 
Normal breast; (2): Breast tumour; (3): SK-N-MC Day 4; (4): SK-N-SH Day 4; (5): Water control. 
The predicted 467 bp PCR product is shown by the white arrow. C. RT-PCR using the exon 215 
primers to distinguish the IGFBP-3 mRNA from the potential variant IGFBP-3. (M): MW marker 
eX 174 Haeiii; (1): Normal breast tissue; (2): Breast tumour; (3): SK-N-SH neuroblastoma cells; 
(4): Water control. PCR products are distinguished by the white arrows. 
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mRNA in normal breast tissue, breast tumour tissue and SK-N-SH neuroblastoma 
cells while both were absent in SK-N-MC cells. 
8.3.4 Cloning and Sequencing of IGFBP-3 PCR Products 
To verify the identity of each of the three PCR products amplified using the IGFBP-
3 exon 2/5 primers, each PCR product was to be cloned and sequenced. The 
unidentified 194 bp PCR product was successfully cloned and sequenced and was 
identified as an exon 2/3 IGFBP-3 product caused by the mispriming of the reverse 
primer in exon 3. The 761 and 640 bp products remain to be cloned and sequenced 
as unfortunately time did not permit the completion of this analysis. 
8.3.5 A Comparison of IGFBP-3 and the Variant IGFBP-3 
Expression during the Development and Progression of 
Breast Carcinogenesis 
The following analysis was made with the assumption that both IGFBP-3 and a 
variant IGFBP-3 mRNA lacking exon 4 were expressed by both normal and 
malignant breast tissues. To see if there was differential expression between IGFBP-
3 and the potential variant IGFBP-3 mRNA during the development and progression 
of breast carcinogenesis, the ratio of IGFBP-3 expression levels to the potential 
variant IGFBP-3 expression levels were examined (Fig. 8.5). The potential variant 
IGFBP-3 levels were found to increase significantly relative to the expression of the 
Q. 
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"' 0:::
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Figure 8.5- A comparison in the expression of the 475 bp ICFBP-3 mRNA to the 352 bp potential 
ICFBP-3 variant mRNA in normal breast tissue, low grade (LCD) and high grade ductal (HCD) 
carcinomas of the breast. Bars, SE. *, p < 0.05 comparing LCD and HCD to normal breast tissue 
by Studen 'ts t-test. 
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IGFBP-3 mRNA when both low grade and high grade ductal carcinomas were 
compared to normal breast tissue. These results suggest that if IGFBP-3 is 
alternatively spliced, then the IGFBP-3 mRNAs are differentially expressed between 
normal and malignant breast tissues, potentially contributing to the tumour 
physiology. 
8.4 Discussion 
IGFBP-3 is the major binding protein in human serum where it serves as a carrier for 
IGFs bound in a ternary complex with an ALS (Baxter and Martin, 1989). A body of 
evidence supports IGFBP-3 regulation of IGF/receptor interactions in both a positive 
and negative fashion (Knauer and Smith, 1980; DeMellow and Baxter, 1988; Blum 
et al., 1989; Cohen et al., 1993). Studies have identified that IGFBP-3's inhibitory 
effects are achieved by binding to and reducing the bioavailability of IGF-I and/or -II 
for receptor/ligand interactions (Knauer and Smith, 1980). The potentiating effects 
of IGFBP-3 appear to be due to its cellular association and proteolysis to forms that 
have a decreased affinity for IGFs, therefore allowing receptor binding (Conover, 
1992; Booth et al., 1996). More recently IGF independent biological functions have 
been recognised for IGFBP-3. IGFBP-3 has been shown to inhibit monolayer 
growth of an ER- breast cancer cell line, Hs578T (Oh et al., 1993a) by binding to 
specific cell surface receptors (Oh et al., 1993b) as well as being an agent of 
apoptosis induced by TGF-~ (Rajah et al., 1997). As it stands IGFBP-3 already 
provides a large contribution to the diversity of the IGF axis. 
In the previous chapter (Chapter 7), IGFBP expression patterns were examined 
during the development and progression of breast carcinogenesis. RP A and in situ 
hybridisation analyses show that IGFBP-3 is synthesised in normal breast tissue and 
breast tumour tissues with an increase in expression with malignant transformation. 
However, in addition to the expected 475 bp protected IGFBP-3 mRNA, a 
significant fragment of 350 bp protected by the IGFP-3 RNA probe was also 
observed in both normal and malignant breast tissues. In this chapter, the aim was to 
identify the 350 bp protected fragment and establish whether it is differentially 
expressed during the development and progression of breast carcinogenesis. 
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The unknown 350 bp fragment protected by the IGFBP-3 RNA probe in an RPA, 
was found to be specific, due to its size and intensity as well as its lack of expression 
in RNase controls and in the SK-N-MC neuroblastoma cells, which as previously 
reported fail to synthesise IGFBP-3 (Kiess et al., 1997; Chapter 5). Extended 
exposures of IGFBP-3 RPAs were analysed for an additional product caused by 
cleavage around the 350 bp mark, from both the 5' and the 3' ends of the probe. 
Faint yet dispersed products were observed in the range of 125 bp. The expression 
vector used to generate the IGFBP-3 RNA probe was compared to and matched the 
expected IGFBP-3 eDNA sequence (Wood et al., 1988; Cubbage et al., 1990) and 
thus was ruled out as the cause for the additional 350 bp fragment. It was therefore 
concluded that the 350 bp protected fragment was the result of either sequence 
variations within the IGFBP-3 gene in both normal and malignant breast tissue or 
was the result of differential post-transcriptional processing. 
To investigate the possibility of differential post-transcriptional processing of 
IGFBP-3 pre-mRNAs, the IGFBP-3 RNA probe was aligned to the human gDNA 
sequence. Interestingly the alignment of the 350 bp product coincided with the exon 
3/4 junction of the IGFBP-3 gene. In other words if exon 4 was absent in the 
IGFBP-3 mRNA, the IGFBP-3 RNA probe would generate a 350 bp protected 
fragment. The removal of exon 4 from IGFBP-3 during post-transcriptional 
processing is theoretically feasible. Unlike the other five IGFBPs, the human 
IGFBP-3 gene is comprised of 5 exons instead of 4 (Cubbage et al., 1990). Exon 5 
encodes 3' UTR sequence exclusively and the transcription termination signals 
(Cubbage et al., 1990). Therefore, it is possible that during the post-transcriptional 
processing of IGFBP-3, exon 4 is removed by splicing factors, while exon 5 is 
maintained. It is also possible that both exon 4 and 5 are absent in the 350 bp 
fragment. It has previously been reported that human IGFBP-3 transcribes a single 
mRNA (reviewed by Rechler and Nissley, 1990; Shimasaki and Ling, 1991; 
Krywicki and Yee, 1992; Kelley et al., 1996), therefore to investigate the possibility 
of an additional mRNA lacking exon 4 or both exon 4/5, RT-PCR was performed 
with exon specific primers. Normal breast tissue, breast tumour tissue and the 
neuroblastoma cell line SK-N-SH which are all known to express IGFBP-3, 
expressed a PCR product at the expected size for mRNA which would lack exon 4. 
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Unfortunately, time constraints did not permit the verification of the 764 and 641 bp 
PCR products. 
It is also possible that the 350 bp fragment could be caused by a short sequence 
variation in the IGFBP-3 gene in each cell type. Allelic variation was ruled out as a 
cause, because every normal breast tissue and breast tumour sample expressed the 
350 bp fragment in an RPA. Sequence analysis of the 764 bp PCR product which 
encodes exon 2 to 5 of the IGFBP-3 gene, is required to see if the 350 bp fragment 
could be due to polymorphism(s) that may exist in both normal and malignant breast 
tissue and the SK-N-SH neuroblastoma cells. 
At this stage, the results from the present investigation suggest an IGFBP-3 mRNA 
lacking ex on 4 may account for the 350 bp protected fragment in the RP A. The 
implications of the human IGFBP-3 gene transcribing mRNAs lacking exon 4 are 
significant, if proven to be legitimate. Exon 4 of human IGFBP-3 gene encodes part 
of the conserved C-terminal domain of the IGFBP-3 mature peptide, from amino 
acid 224 to 265 (Wood et al., 1988; Cubbage et al., 1990). Within the C-terminal 
domain is a highly basic region (IGFBP-3 215-232) which overlaps the exon 3/4 
junction and has a strong homology to a previously identified nuclear localisation 
signal (NLS; Radulescu, 1994). Schedlich et al., (1998) and Wraight et al., (1998) 
have shown the nuclear uptake of IGFBP-3 in rapidly dividing T47D breast cancer 
cells and basal keratinocytes, with Schedlich's group establishing that the process is 
not receptor mediated. The nuclear localisation of IGFBP-3 has been proposed to be 
a mechanism by which IGFBP-3 achieves its independent effects (Schedlich et al., 
1998). It is therefore possible that a variant IGFBP-3 lacking exon 4 and a portion of 
the NLS, may not translocate to the nucleus, thereby losing its IGF independent 
effects. 
Within the NLS is a highly basic region composed of five residues, KGRKR 
(IGFBP-3 228-232) which is encoded by exon 4 of the IGFBP-3 gene. Baxter and 
Firth, (1995) mutated these 5 residues to MDGEA, the corresponding residues in 
IGFBP-1 which altered the overall charge conformation of IGFBP-3. In two 
separate studies, they have shown that the mutated IGFBP-3 e28KGRKR -+ 
MDGEA) has a normal affinity for IGF-I, a slightly lower affinity for IGF-ll and a 
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90% reduced affinity for the ALS (Baxter and Firth, 1995; Firth eta!., 1998). They 
also found that the mutant IGFBP-3 had no ability to cell associate, which is a key 
feature of IGFBP-3/IGF regulation (Baxter and Firth, 1995; Firth eta!., 1998). In a 
separate study, Booth eta!., (1996) showed that an 18 residue peptide encompassing 
the KGRKR region bound heparin and stimulated glucose uptake in cultures of 
endothelial cells. Firth et al., (1998) also examined an IGFBP-3 deletion construct 
lacking residues 185 to 264, a construct very similar to an IGFBP-3 mRNA lacking 
exon 4. The IGFBP-3 protein encoded by this deletion construct had a 20-fold lower 
affinity for IGF-I and a 40-fold lower affinity for IGF-II and no affinity for the ALS 
(Firth et al., 1998). They concluded that both theN- and C-terminus were involved 
in ligand binding, while the IGFBP-3 228KGRKR region was important for ALS 
interactions and the cell association. An IGFBP-3 mRNA lacking exon 4, would 
encode an IGFBP-3 peptide which lacks residues 224 to 265. This peptide would 
have a lower affinity for IGF-I and -II, would not interact with the ALS and would 
lack the ability to associate with the cell. The function of this potential variant 
IGFBP-3 is difficult to hypothesise. A decreased affinity for the IGF ligands, no 
ALS binding and cell association would mean theoretically that there would be less 
IGF regulation. Such a theory is in line with an increase in expression of the 350 bp 
fragment relative to IGFBP-3 with the development and progression of breast cancer. 
In summary, the existence of an IGFBP-3 variant mRNA at this stage is speculative. 
However, the implications of such a variant are significant. It is possible that the up-
regulation of a truncated IGFBP-3 peptide lacking its C-terminus by a cellular 
environment, may contribute to a decrease in IGF-regulation and the progression to 
hormone independence observed within a number of malignancies including those of 
the breast. However, the existence of an alternatively spliced IGFBP-3 mRNA as 
well as its ability to translate and produce a stable protein, remains to be confirmed. 
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Chapter 9 
GENERAL DISCUSSION 
The diversity of IGF actions is achieved by numerous means, including the 
regulation of IGF ligand/receptor interactions and intracellular post-receptor 
signalling. The objective of this doctoral thesis has been to investigate another 
potential mechanism by which the biological actions of IGF-I, and to a much lesser 
degree IGF-II, may be regulated. Both the human IGF-I and IGF-II genes transcribe 
multiple mRNAs via multiple promoter usage (DePagter-Holthuizen et al., 1987; 
1988; Holthuizen et al., 1990; Jansen et al., 1991; 1992), multiple transcription start 
sites (Smale and Baltimore, 1989; Jansen et al., 1991), multiple polyadenylation 
signals (Lund et al., 1989) and alternative splicing (Jan sen et al., 1983; Rotwein, 
1986; Chew et al., 1995). The primary aim of this thesis was to investigate the 
expression of the multiple IGF-I mRNAs during cell fate, specifically the expression 
of class 1, class 2, Ea and Eb mRNAs as well as IGF-II and its Ser-29 variant. The 
specific question was: Are the variant IGF-I mRNAs differentially expressed when 
cells are undergoing normal cellular growth compared with differentiation and 
tumourigenesis? If so, what are the implications of a differential pattern of 
expression? 
In vitro cellular growth and different~ation studies were performed using the 
human neuroblastoma cell line SK-N-MC, previously reported to express IGF-I 
mRNAs (Yee et al., 1990; Kiess et al., 1997), in conjunction with the neuroblastoma 
cell line SK-N-SH, known to express IGF-II but not IGF-I mRNAs (Yee et al., 
1990). During the cell growth studies (Chapter 4), the four major IGF-I mRNAs as 
well as an IGF-IR mRNA were shown to be synthesised by SK-N-MC cells. As 
these cells reached confluency, each of the IGF-I mRNAs increased coordinately. 
However, when the SK-N-MC cells were induced to differentiate by the removal of 
serum (Chapter 4), only class 1 Eb mRNAs were detected, together with the IGF-IR 
and a potential variant IGF-IR mRNA. In contrast, SK-N-SH cells maintained in a 
serum-free environment failed to differentiate. Interestingly however, they switched 
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on the expression of class 1 Eb IGF-I mRNAs and a potential IGF-IR variant, while 
continuing to express IGF-ll, Ser-29 and IGF-IR mRNAs. The exclusive synthesis 
of class 1 Eb IGF-I mRNAs by both SK-N-MC and SK-N-SH cells in a serum-free 
environment suggests that the synthesis of the various IGF-I mRNAs is 
endogenously regulated. It has previously been shown in both of these cell lines that 
IGFs produced in an autocrine fashion activate the IGF-IR (Ota et al., 1988; Kiess et 
al., 1997). Therefore the present study suggests that tissue specific differentiation 
may involve the controlled upregulation of class 1 Eb mRNA, with the pro-IGF-I Eb 
or Eb peptides functioning in an autocrine fashion (Chapter 4). The absence of a 
differentiated phenotype in the SK-N-SH cells may be explained by the significantly 
lower levels of class 1 Eb expression, compared to those expressed by SK-N-MC 
cells. These cells may be density dependent. Further studies using an increased SK-
N-SH cell density would address this issue. 
A further finding of potential significance in the in vitro growth and differentiation 
studies, was the appearance of a potential variant IGF-IR in both SK-N-MC and SK-
N-SH cells following the removal of exogenous serum factors (Chapter 4). If 
translated, this IGF-IR variant may contribute to the autocrine actions of pro-IGF-I 
Eb. If confirmed, the presence, binding affinity and potential signal transducing 
capabilities of such a receptor would contribute significantly to the diverse biological 
effects of IGF-I and possibly IGF-II. 
The expression pattern of the variable IGF-I mRNAs was also examined during 
tumourigenesis, using the development and progression of breast cancer as the 
model system (Chapter 6). In this model, all four major IGF-I mRNAs as well as the 
IGF-IR were expressed in normal breast tissue, with increased expression in breast 
tumour samples. A significant finding in this study was the presence of a differential 
pattern of IGF-I expression during the development and progression of breast 
carcinogenesis. It was established that class 2 mRNAs increased significantly 
relative to class 1, and Eb mRNAs increased significantly relative toEa with disease 
progression, suggesting a role for the variant IGF-I mRNAs in tumourigenesis. 
Breast tissues of both normal and malignant origins are heterogenous in nature. 
Using in situ hybridisation histochemistry, the synthesis of IGF-I mRNAs was 
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localised primarily to the supportive stromal fibroblasts of both normal breast tissues 
and low grade ductal carcinomas. However, in contrast to other investigations (Yee 
et al., 1989a) it was found that with progression to more independent high grade 
carcinomas, IGF-I mRNAs were localised to the tumour epithelial cells as well as 
the stromal component of the tumour. IGF-IR mRNAs were also identified in the 
tumour epithelial cells of both low and high grade carcinomas. This study has 
shown that the breast tumour epithelial cells have the potential to turn on their own 
synthesis of IGF-I, which may in turn act in an autocrine manner to stimulate 
uncontrolled growth. 
The next question then posed was: Does the switch in the site of IGF-I synthesis 
associated with disease progression relate to the differential expression of the 
variable IGF-I mRNAs? So far I have only shown that Ea mRNAs localise primarily 
to stromal fibroblasts, while a preliminary investigation localised Eb synthesis to 
specific pockets of differentiating cells in normal breast tissue, due to the low 
expression and the relatively poor sensitivity of the in situ hybridisation 
experimental procedure. A further preliminary investigation using the highly 
sensitive in situ RT-PCR technology has also localised Eb specific mRNAs to both 
differentiating and de-differentiating cells. Therefore if we combine the in vitro data 
from the neuroblastoma cell lines with the breast data, it is tempting to speculate that 
the Eb mRNAs are key factors in the regulation of cellular differentiation. A fine 
balance may exist whereby the increase in Eb synthesis affects the state of cellular 
differentiation in a tissue specific manner, with an overexpression associated to a 
tumourigenic phenotype. Future studies using the more sensitive in situ RT -PCR 
technology in the present model, as well as an examination of variably expressing 
stably transfected pro-IGF-I Eb clones in a non-IGF-I expressing human cell line, 
will aid in further defining the role of Eb in growth, differentiation and 
tumourigenesis. The regulation of the two IGF-I promoter activities should also be 
studied further to address the priority of class 2 mRNAs over class 1 between normal 
cellular events and tumourigenesis. 
In contrast to the IGF-I variant mRNAs, there were no significant changes in the 
relative expression of IGF-II and its Ser-29 variant between SK-N-SH cells grown in 
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serum-containing and serum-free medium (Chapter 4). However, the synthesis of 
the Ser-29 variant of IGF-II increased significantly relative to IGF-II with the 
development and progression of breast tumourigenesis (Chapter 6). As for IGF-I, 
this differential expression may be associated to the cellular site of synthesis. An in 
situ hybridisation histochemical analysis to localise the sites of synthesis for the IGF-
II mRNAs, revealed that both tumour epithelial and stromal fibroblasts express 
possibly both forms of IGF-II mRNA throughout tumour development. Further 
studies using in situ PCR with one primer specific for the tetrapeptide substitution 
may reveal a differential pattern in the sites of synthesis for IGF-II and its Ser-29 
counterpart. Whether the differential expression of IGF-II and its Ser-29 variant are 
a result of, or a precursor to malignancy needs to be investigated further. A role for 
the Ser-29 variant of IGF-II has not previously been described, however this 
preliminary investigation suggests a potential role for the Ser-29 variant of IGF-II in 
tumourigenesis. 
Given the dramatic changes in the pattern of expression of the IGF mRNAs and the 
IGF-IR mRNA during cellular fate, this doctoral study was extended to investigate 
the pattern of IGFBP expression under the same conditions. Insufficient material 
prevented a full investigation of IGFBP expression during the in vitro growth and 
differentiation studies, however preliminary studies indicate significant differences 
in the expression of IGFBPs between the two states in the SK-N-MC neuroblastoma 
cell line. IGFBP-6 exhibited the most dramatic difference in expression between the 
two states, with IGFBP-6 mRNA absent in cells maintained in a serum-free 
environment, suggesting that its expression is regulated by specific factors within 
serum. Interestingly, a dramatic decrease in IGFBP-6 expression levels was also 
observed in both low and high grade ductal carcinomas of the breast compared to 
normal breast tissue. This was paralleled by a dramatic increase in IGFBP-4 
expression by the tumour epithelial cells of both low and high grade ductal 
carcinomas. IGFBP-6 has been reported to function primarily as a negative regulator 
of IGF-II (Manni et al., 1994; Babajko et al., 1997), while IGFBP-4 functions as a 
negative regulator of both IGF-I and -II (LaTour et al., 1990; Schiltz et al., 1993). 
Therefore, it can be proposed that a decrease in IGFBP-6 levels would increase the 
biological potency of IGF-II. IGFBP-4 is associated with a specific protease which 
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removes the inhibitory effects of IGFBP-4. This protease is activated by IGFs. The 
dramatic increase in IGFBP-4 expression observed with malignancy, may be a 
survival response to compete with an increase in the IGFBP-4 specific protease, 
activated by the increase in IGF ligands. If IGFBP-4 can out compete its protease, 
then it will be able to inhibit IGFs actions, contradictory to events in tumourigenesis 
complementary to normal cell physiology. Overall it may be that IGFBP-6 
expression is a precursor of malignancy and IGFBP-4 expression is a compensatory 
mechanism, set in place to prevent tumourigenesis. An important and fascinating 
future investigation would be to establish the expression pattern of the IGFBPs and 
to examine the exogenous serum factors which regulate the expression of IGFBP-6 
and IGFBP-4. Cell transfection studies examining the effect of deactivation and 
over-expression of IGFBP-6 and IGFBP-4 would be a useful tool for these 
hypotheses. Using the same model it would also be interesting to examine the 
effects of IGFBP-6 expression on IGF-ll, IGFBP-4 and the expression of the IGFBP-
4 protease. 
In summary, the results described in this doctoral study demonstrate that: 
• The four major IGF-I mRNAs are expressed during growth in SK-N-MC 
neuroblastoma cells, while class 1 Eb mRNAs are expressed exclusively m 
differentiating cells, by the absence an exogenous serum factor(s). 
• The variant IGF-I mRNAs are differentially expressed between cell growth and 
differentiation, as well as during the development and progression of 
tumourigenesis. 
• During development and progression of breast tumourigenesis, class 2 mRNAs 
increase more dramatically relative to class 1, and Eb increases more 
dramatically relative to Ea. 
• IGF-ll and its Ser-29 variant are differentially expressed during the development 
and progression of tumourigenesis. 
• A variant IGF-IR is expressed in SK-N-MC and SK-N-SH cells in response to 
serum-withdrawal. This requires confirmation. 
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• There is a differential pattern of IGFBP between cell growth and differentiation 
with the loss of IGFBP-6 expression with the removal of serum factors. 
• There is a differential pattern of IGFBP expression during the development and 
progression of breast tumourigenesis with IGFBP-6 expression lost and IGFBP-4 
expression increasing with tumourigenesis. 
• A splice variant of IGFBP-3 appears to be differentially expressed during the 
development and progression of breast tumourigenesis. 
confirmation. 
This requires 
The following hypothesis has emerged from this study. That Eb mRNA expression 
in combination with alternate promoter usage exist in a fine balance; whereby 
upregulation of class 1 Eb expression contributes to cellular differentiation, while 
overexpression of Eb mRNAs, using both Pl and P2 promoters, contributes to a 
tumourigenic phenotype. There appears to be a clear distinction in the expression of 
the 5' and 3' IGF-I variant ratios between normal and tumourigenic tissues, which is 
capable of distinguishing between the different grades of breast cancer. This may 
prove to be an important marker for the early detection of breast cancer and other 
forms of cancer. This thesis has provided evidence to show that the differential 
expression of IGF-I mRNAs provide an additional level of regulation for the 
biological actions of IGF-I. 
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